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A hexanucleotide repeat expansion (HRE) within the C9orf72 gene is the most prevalent 
cause of amyotrophic lateral sclerosis/fronto-temporal dementia (ALS/FTD).  Current 
evidence suggests that HREs induce neurodegeneration through the accumulation of RNA 
foci and/or dipeptide repeat proteins (DPRs), though there is also evidence for 
haploinsufficiency of the C9orf72 protein.   
Here, we modelled toxic gain of function disease mechanisms by generating and 
characterising two distinct transgenic zebrafish models.  Whilst both model systems express 
HREs that lead to RNA foci production, only one model expresses ATG-driven DPRs.  The 
two model systems were termed “RNA-only” and “RNA+DPR” zebrafish.  As a readout of 
cellular stress, we utilised a fluorescent-reporter construct that expresses DsRed under the 
control of a heat shock promoter, which we then used to screen for potential therapeutic 
compounds.  We also used immunoblotting techniques to characterise DPR, TDP-43 and 
SOD1 proteinopathies in human ALS post-mortem tissue.   
Our RNA-only zebrafish model did not display any evidence of reduced survival at 26 
months post-fertilisation.  In contrast, the RNA+DPR zebrafish model displayed muscle 
atrophy, motor neuron loss and reduced survival at 36 months post-fertilisation.  In line with 
increased toxicity, we identified that RNA+DPR zebrafish activate the heat shock response 
(HSR), which we also found to be true in C9orf72-ALS patient samples.  HSR activation 
correlated with disease progression in our RNA+DPR zebrafish model and, through drug 
screening, we found that this could be attenuated using the compounds ivermectin, 
selamectin and riluzole.  Finally, we report that SOD1 proteinopathy is detectable in disease 
relevant areas of C9orf72 patients CNS, and that this correlates with TDP-43 proteinopathy. 
We conclude that our RNA+DPR zebrafish model system shows motor neuron pathology, 
and the HSR readout in this zebrafish model may prove useful as a tool for evaluating 
potential neuroprotective compounds prior to mammalian testing.  Finally, our 
neuropathological findings suggest a potential link between C9orf72-HREs and SOD1 as 
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1. Chapter 1: General introduction 
1.1. Amyotrophic lateral sclerosis onset and symptoms 
Amyotrophic lateral sclerosis (ALS) or motor neuron disease (MND), is a progressive 
neurodegenerative disorder primarily causing loss of the motor neurons (MNs) supplying 
voluntary muscles.  ALS results in progressive muscle weakness which eventually leads to 
paralysis and death, usually due to respiratory failure.  A 2013 meta-analysis of ALS 
epidemiological studies showed that the median incidence of ALS in European populations 
is 2.08 per 100,000 persons per year, and that the median prevalence of ALS in the same 
population is 5.4 per 100,000 persons (Chio et al., 2013).  From onset of symptoms, the 
median survival time for ALS patients is 30 months, however this figure comes with the 
caveat that there is considerable variability in ALS patient survival rates (with some patients 
surviving for decades after diagnosis) (Logroscino et al., 2008).  Currently in the United 
Kingdom, riluzole is the only approved disease modifying treatment for ALS, which is thought 
to extend the lifespan of ALS patients by an average of 3-4 months (Bensimon et al., 1994).  
In both the United States and Japan, Edaravone (Radicava) has also been approved for the 
treatment of ALS patients (Hardiman and van den Berg, 2017).  At the time of writing, data 
on average lifespan extension for ALS patients being treated with Edaravone is not 
available.  However, Edaravone treated patients showed a significantly smaller decline on 
the revised ALS Functional Rating Scale (a measure of physical disability in ALS patients), 
when compared to placebo control patients (Cedarbaum et al., 1999, Abe et al., 2017). 
There are two types of MNs: the upper MNs (primary MNs or Betz cells) are located in the 
primary motor cortex and do not exit the central nervous system (CNS), whilst the lower MNs 
exit the CNS to innervate muscles.  Bulbar lower motor neurons supply the muscles of the 
face and throat and reside in the brainstem.  Spinal lower motor neurons supply the 
voluntary muscles of the rest of the body and reside in the ventral horn of the spinal cord.  In 
ALS it is common for the degeneration of one MN population to precede the degeneration of 
another (Gordon, 2013).  ALS onset in lower MNs typically presents as fasciculation, 
cramps, muscle atrophy and marked muscle weakness (Gordon, 2013).  Upper MN onset 
ALS typically presents as spasticity, hyperreflexia and modest weakness (Gordon, 2013).  
Additionally, ALS patients are commonly classified as having spinal or bulbar onset referring 
to whether muscle weakness is first observed in the limbs or the bulbar (speech and 
swallowing) muscles (Hardiman et al., 2017).  Despite the discovery of several causative 
genetic mutations, there is still no clear link between causative mutation and upper vs lower 
MN onset, nor spinal vs bulbar onset, in ALS patients. 
ALS remains a purely motor disorder in some patients, however approximately 40% of ALS 
patients exhibit some cognitive impairment throughout the disease course (Phukan et al., 
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2012).  Almost 60% of ALS patients with cognitive decline show impaired executive function, 
with the remaining 40% showing decline in other cognitive areas such as memory or 
language (Phukan et al., 2012).  Indeed, ALS and frontotemporal dementia (FTD) share 
many common causative genetic mutations and pathomechanisms, and for this reason the 
two disorders are now often considered to be at opposite ends of a continuous disease 
spectrum (Neumann et al., 2006, Kabashi et al., 2008, Sreedharan et al., 2008, Borroni et 
al., 2009, Ferrari et al., 2011). 
1.2. The genetic aetiology of ALS 
ALS cases are most commonly sporadic in origin (80-95% of all cases) and less frequently 
are familial in origin (5-20% of all cases), these numbers vary depending on the definitions of 
sporadic and familial used, and depending on geographic location (Byrne et al., 2011, Byrne 
et al., 2013).  Sporadic cases are thought to be caused by complex interactions between 
genetic and environmental risk factors, whereas familial cases have a direct heritable cause 
which typically affects multiple members of the same family (Byrne et al., 2013).   
The earliest identified genetic cause of ALS was mutations in the superoxide dismutase 1 
(SOD1) gene (Rosen et al., 1993).  SOD1 is the first in a family of three superoxide enzymes 
which are all involved in catalysing the conversion of superoxide anions into hydrogen 
peroxide, thus detoxifying free radicals generated from metabolism (Zelko et al., 2002).  
Despite sharing many functional similarities with SOD1, mutations in SOD2 or SOD3 genes 
are not linked with ALS.  On the other hand, over 170 mutations spanning almost every 
region of the SOD1 gene have been reported to cause ALS (Rotunno and Bosco, 2013, Wei 
et al., 2017).  Due to being discovered first, SOD1 is currently the most well studied ALS 
gene.  As DNA sequencing technologies improved, the discovery rate of novel ALS genes 
greatly increased.  Mutations in two genes coding for RNA-binding proteins were both 
identified as causing ALS.  The first gene in which mutations were identified was TAR DNA 
binding protein 43 (TARDBP) which codes for the RNA-binding protein TDP-43 (Sreedharan 
et al., 2008).  The second gene in which mutations were identified was fused in sarcoma 
(FUS), which encodes an RNA-binding protein of the same name (Kwiatkowski et al., 2009, 
Vance et al., 2009).  Both TDP-43 and FUS are predominately nuclear, and both have an 
array of functions which are mostly related to RNA processing (Kapeli et al., 2017).  Later, 
tandem studies identified the most commonly known cause of ALS to date, a hexanucleotide 
expansion in the chromosome 9 open reading frame 72 (C9orf72) gene (DeJesus-
Hernandez et al., 2011, Renton et al., 2011).  Since its discovery, C9orf72 and its’ 
hexanucleotide expansion have become the fastest growing area of ALS research.  C9orf72 
is the most common ALS gene by a wide margin and in the coming years will likely overtake 
SOD1 as the most well studied ALS gene (Chió et al., 2012).  Shortly thereafter, mutations in 
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the SQSTM1 gene, which encodes the p62 protein, were identified as causing ALS (Fecto et 
al., 2011).  p62 functions in the protein degradation pathway by binding to proteins and 
targeting them for degradation by the autophagosome, p62 positive inclusions are also often 
observed in ALS post-mortem tissues (Bjorkoy et al., 2006, Mizuno et al., 2006a).  Later, 
ALS causative mutations were identified in the genes encoding RNA binding proteins 
Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1), Heterogeneous nuclear 
ribonucleoprotein A2/B1 (hnRNPA2B1), TATA-Box Binding Protein Associated Factor 15 
(TAF15) and Ewing sarcoma breakpoint region 1 (EWSR1) (Ticozzi et al., 2011, Couthouis 
et al., 2012, Kim et al., 2013a).  Thus, further implicating RNA processing in the pathobiology 
of ALS.  Axonal transport defects have been reported in both mutant SOD1 and mutant 
TARDBP expressing mouse models (Magrane et al., 2014).  Later, ALS causative mutations 
were identified in the axonal transport associated genes TUBA4A and KIF5A (Smith et al., 
2014, Nicolas et al., 2018). 
The above section gives an outline of the ALS genetic discoveries which are relevant to data 
or discussion presented in later chapters of this thesis.  For a comprehensive list of ALS 
genes and their associated pathomechanisms see Table 1.1 below. 







(Hadano et al., 2001, 
Yang et al., 2001, Sato et 
al., 2018) 
ANG Angiogenin RNA processing 
(Greenway et al., 2006, 
Thiyagarajan et al., 2012) 
ATXN2 Ataxin-2 RNA processing 
(Elden et al., 2010, van 








al., 2011, Renton et al., 
2011, Zhang et al., 
2015b, Webster et al., 
2016a, Walker et al., 
2017) 
CCNF Cyclin F 
Ubiquitin/proteasome 
system 






containing protein 10 
Mitochondrial 
dysfunction 
(Bannwarth et al., 2014) 
CHMP2B 
Charged multivesicular 
body protein 2B 
Autophagy 
(Parkinson et al., 2006, 






(Takahashi et al., 2013) 
EWSR1 
Ewing sarcoma breakpoint 
region 1 






(Chow et al., 2009) 





(Kwiatkowski et al., 2009, 
Vance et al., 2009, Deng 




domain containing 1 
Unknown 









RNA processing (Kim et al., 2013a) 
NEK1 NIMA related kinase 1 DNA damage 
(Kenna et al., 2016, 
Higelin et al., 2018) 
KIF5A Kinesin family member 5A Cytoskeleton (Nicolas et al., 2018) 




(Maruyama et al., 2010, 
Markovinovic et al., 2017) 





(Chen et al., 2004, 
Bennett et al., 2018) 
SIGMAR1 
Sigma non-opioid 





(Luty et al., 2010, 
Fukunaga et al., 2015) 




(Rosen et al., 1993, Kraft 
et al., 2007) 
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1.3. Risk factors associated with ALS 
Risk factors may be broadly categorised as genetic or non-genetic (environmental) in nature.  
Genetic risk factors for ALS can be thought of as being on a continuous spectrum with the 
identified disease causing mutations, the location of the gene on the spectrum simply 
depends on the penetrance of the identified mutations.  Precise limits have not been well 
defined, but generally ALS gene mutations with a high penetrance are considered causative 
ALS genes, whereas those with low penetrance are considered risk factors. 
Well known general risk factors for ALS include increasing age, being male and having a 
family history of ALS (Armon, 2003).  Currently, there are many genes in which mutations 
have been identified as increasing the risk of developing ALS (low penetrance ALS genes), 
these include charged multi vesicular protein 2B (CHMP2B), ATXN2, SPG11, TAF15, 
OPTN, VAPB, UBQLN2 and NEK1 (Kenna et al., 2013, Kenna et al., 2016, Wang et al., 
2017).  As with causative ALS genes, the pathological molecular mechanisms of ALS 
genetic risk factors are not well understood.  As well as genetic risks factors, diverse non-
SPG11 Spastic paraplegia-11 
Lysosomal 
dysfunction 
(Orlacchio et al., 2010, 
Branchu et al., 2017) 
SQSTM1 p62 Autophagy (Fecto et al., 2011) 
TAF15 
TATA-Box Binding Protein 
Associated Factor 15 
RNA-processing (Ticozzi et al., 2011) 
TARDBP 





(Kabashi et al., 2008, 
Sreedharan et al., 2008) 
TBK1 TANK-binding kinase 1 
Autophagy, 
neuroinflammation 
(Cirulli et al., 2015, 
Freischmidt et al., 2015, 
Oakes et al., 2017) 
TUBA4A Tubulin alpha-4A Cytoskeleton (Smith et al., 2014) 




(Deng et al., 2011, Chen 





associated protein B/C 
Endoplasmic 
reticulum dysfunction 
(Nishimura et al., 2004, 
Fasana et al., 2010) 
VCP Valosin-containing protein 
Autophagy, DNA 
damage 
(Johnson et al., 2010, 
Meerang et al., 2011, Kim 
et al., 2013b) 
Table 1.1: Genetic discoveries and associated pathomechanisms in ALS 
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genetic risk factors have also been associated with ALS.  ALS is not one of the most 
common diseases caused by smoking, however a significant link between smoking and ALS 
has been reported in more than one study (Armon, 2003, Factor-Litvak et al., 2013).  Other 
lifestyle factors may also influence ALS, consumption of some antioxidants including vitamin 
E have been reported to associate with a lower risk of ALS (Ascherio et al., 2005, Veldink et 
al., 2007).  Conversely, treatment of ALS patients with riluzole supplemented with vitamin E 
failed to prolong survival in comparison to riluzole treatment alone (Graf et al., 2005).  Low 
BMI and frequent strenuous exercise have been reported to associate with an increased risk 
of ALS (Granieri et al., 1988, Turner, 2013).  Additionally, the incidence of ALS has been 
reported to be higher in populations of professional athletes and armed forces members 
(Beard and Kamel, 2015, Lacorte et al., 2016).  Exposure to pesticides and heavy metals 
have also been reported to increase the risk of developing ALS (Kamel et al., 2003, Kamel et 
al., 2012). 
 
1.4. Histopathology of ALS 
Histopathological characterisation of CNS tissues from ALS patients has revealed that large 
motor neurons are lost from the spinal cord, brainstem and motor cortex (Hammer et al., 
1979, Nihei et al., 1993).  In the ventral horn of the spinal cord, neuronal loss is observed 
across multiple types of morphologically distinct neurons, and is not limited to motor neurons 
(Stephens et al., 2006).  Loss of myelinated axons is also commonly observed in the ventral 
and lateral spinal cord of ALS patients (Saberi et al., 2015).  In patients with a pure ALS 
phenotype, degeneration is predominately confined to motor areas, but in patients with 
ALS/FTD neuronal and axonal loss in the frontal and temporal lobes also occurs (Brown and 
Al-Chalabi, 2017).  In both the brain and spinal cord of sALS patients, degenerating motor 
neurons are often surrounded by reactive astrocytes expressing glial fibrillary acidic protein 
(Kawamata et al., 1992, Schiffer et al., 1996).  Additionally, activated microglia are present in 
degenerating regions CNS regions of sALS patients (Troost et al., 1990, Kawamata et al., 
1992).  In sALS patients, mitochondria located in the ventral horn of the spinal cord often 
exhibit morphological abnormalities, such as appearing swollen with increased cristae or 
appearing stubby with short protrusions from the outer mitochondrial membrane (Sasaki and 
Iwata, 2007). 
CNS tissues from ALS patients frequently contain abnormal cellular inclusions.  
Approximately 85% of sALS cases show small round or oval eosinophillic inclusions termed 
Bunina bodies (Bunina, 1962). Bunina bodies are located in the cell bodies and dendrites of 
motor neurons of the spinal cord and brain stem nuclei (Piao et al., 2003, Okamoto et al., 
2008).  Bunina bodies are p62 and TDP-43 negative, but occasionally contain ubiquitin 
18 
 
(Lowe et al., 1988, Leigh et al., 1991, Mizuno et al., 2006a).  Furthermore, Bunina bodies are 
positive for proteins cytostatin c and transferrin (Okamoto et al., 1993, Mizuno et al., 2006b).  
It is currently unknown how Bunina bodies develop, or whether they actively contribute to 
ALS progression.  Ubiquitin positive inclusions are also observed in neurons (and less 
frequently in glial cells) of the majority of fALS and sALS cases (Leigh et al., 1988, Lowe et 
al., 1988).  These ubiquitin positive inclusions are frequently also positive for p62 and are 
primarily comprised of fragmented/aggregated TDP-43 protein (Arai et al., 2006, Mizuno et 
al., 2006a, Neumann et al., 2006).  p62 positive inclusions are also detected in the ventral 
horn of the spinal cord in the majority of ALS cases, and are frequently (but not always) 
ubiquitin positive (Arai et al., 2003, Mizuno et al., 2006a). 
Muscle tissue from ALS patients shows evidence of denervation, and attempted 
reinnervation by nerve sprouting of surviving motor neurons (Dadon-Nachum et al., 2011).  
Areas of type I or type II muscle fibre grouping due to reinnervation of muscle fibres is 
commonly observed in ALS patients (Soraru et al., 2008, Jensen et al., 2016).  Muscle fibres 
in ALS patients are frequently atrophic, although compensatory muscle hypertrophy as an 
attempt at muscle regeneration may also be observed (Soraru et al., 2008, Jensen et al., 
2016).  Similarly to ALS patient CNS tissue, muscle tissue from ALS patients also exhibits 
evidence of mitochondrial abnormalities and infiltration of immune cells (Wiedemann et al., 
1998, Al-Sarraj et al., 2014).  Also in line with CNS histopathology, p62 positive intracellular 
inclusions are also frequently detected in muscle fibres of ALS patients (Al-Sarraj et al., 
2014).  Conversely, no aggregation, fragmentation or cytoplasmic mislocalisation of TDP-43 
has been detected in muscle tissue from ALS patients, thus TDP-43 proteinopathy appears 
to be limited to CNS tissues of ALS patients (Soraru et al., 2010, Al-Sarraj et al., 2014). 
 
1.5. Common proteinopathies linking ALS sub-types 
Many causative ALS genes have now been identified.  The protein products of these genes 
have diverse ranging functions which are not always well understood.  An additional layer of 
complexity arises from the fact that mutations may not cause ALS by loss of endogenous 
function, but rather by an additional gained toxic function of the mutant protein product.  The 
lack of understanding of both the endogenous functions and possible gained toxic functions 
of ALS genes has made it difficult to identify whether different ALS genes share common 
pathological species.  Nevertheless, multiple previous studies have identified evidence for 
similar proteinopathies in different genetic variants of ALS which were previously thought to 
be unrelated, these studies are discussed in detail below. 
The SOD1 protein is essential in regulating the oxidation levels of the cell (Rosen et al., 
1993).  For this reason the first suspected mechanism of mutant SOD1 (mSOD1) toxicity 
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was due to a loss of dismutase enzymatic function leading to increased intracellular reactive 
oxygen species (Rosen et al., 1993).  However, evidence has since shown that many ALS 
causing variants of mSOD1 do not have reduced enzymatic activity (Borchelt et al., 1994, 
Ratovitski et al., 1999, Ramesh et al., 2010).  Additionally, a SOD1 knockout mouse model 
does not show a neurodegenerative phenotype (Reaume et al., 1996).  This evidence has 
led to a gain of toxic function mechanism being favoured for SOD1-ALS.  Many variants of 
mSOD1 are known to be less structurally stable than wildtype SOD1 (wtSOD1), and have 
been shown to form abnormal conformations which cause novel interactions between 
mSOD1 and proteins such as bcl2, among others (Pasinelli et al., 2004, Pedrini et al., 2010).  
Furthermore, the abnormal conformation, or misfolding, of mSOD1 makes the protein prone 
to oligomerisation, and formation of insoluble intracellular aggregates (Anzai et al., 2017).  
Although, recent evidence suggests that aggregation of SOD1 may be neuroprotective, and 
that soluble forms of misfolded mSOD1 are the more toxic species (Gill et al., 2019).  Thus, 
gain of toxic function through novel protein-protein interactions or aggregation of mSOD1 are 
both proposed mechanisms of mSOD1 mediated MN toxicity.  Other ALS genes cause a 
range of neurological phenotypes, for example C9orf72, VCP, FUS and TARDBP mutations 
result in a spectrum of ALS-fronto-temporal dementia (FTD) (Liscic, 2015).  Conversely, in 
>170 reported SOD1 mutations, a pure ALS phenotype predominates, this has led some 
researchers to hypothesise that SOD1 proteinopathy may be a crucial aspect of selective 
motor neuron toxicity and that SOD1 proteinopathy may also contribute to motor neuron 
pathology in non-SOD1 forms of ALS (Rotunno and Bosco, 2013, Wei et al., 2017).  To test 
the hypothesis that misfolded/aggregated SOD1 may underlie other forms of ALS, various 
antibodies which specifically recognise misfolded SOD1 have been generated.  Multiple 
studies have used several different misfolded SOD1 specific antibodies to detect 
misfolded/aggregated SOD1 in spinal cord tissue from patients with sporadic ALS (sALS) 
(Bosco et al., 2010, Forsberg et al., 2010, Pokrishevsky et al., 2012, Grad et al., 2014, Maier 
et al., 2018).  These data suggest that misfolded SOD1 may contribute to pathology in non-
SOD1 forms of ALS.  Moreover, a study using patient derived oligodendrocytes 
demonstrated that co-culture of oligodendrocytes derived from sALS and TARDBP mutation 
ALS patients conferred toxicity to wildtype mouse motor neurons upon co-culture (Ferraiuolo 
et al., 2016).  Interestingly, knockdown of the SOD1 protein in these oligodendrocytes prior 
to co-culture, ameliorated the toxicity usually conferred to the motor neurons.  These data 
suggest that within this in vitro system, the SOD1 protein directly or indirectly contributes to 
the motor neuron toxicity conferred by oligodendrocytes derived from non-SOD1 ALS 
patients.   
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In contrast however, there is also evidence that misfolded/aggregated wildtype SOD1 is not 
involved in non-SOD1 ALS.  Other studies using similar misfolded SOD1 specific antibodies 
to those discussed previously, have not been able to identify specific staining in the spinal 
cord from sALS patients (Kerman et al., 2010, Brotherton et al., 2012, Liu et al., 2012, Ayers 
et al., 2014).  The antibodies, staining techniques and sample numbers used vary from one 
study to another, and this may explain some of the observed discrepancies in the datasets.  
To address this issue, one recent study used 7 different misfolded SOD1 specific antibodies 
and stained a large cohort of over 40 ALS patient samples in total (Da Cruz et al., 2017).  
This comprehensive study did not identify any increase in misfolded SOD1 staining in sALS 
patients in comparison to non-neurological controls, despite the specificity of every antibody 
being validated in mSOD1 patient tissue.  Thus, whether SOD1 misregulation has a role in 
non-SOD1 ALS remains a highly controversial topic.   
The TARDBP gene codes for the ubiquitously expressed protein TDP-43 which has roles in 
mRNA splicing, RNA stability, gene transcription and many other functions (Lagier-Tourenne 
and Cleveland, 2009).  Mutations in the TARDBP gene are known to cause ALS 
(Sreedharan et al., 2008).  Additionally, nearly all sporadic and familial ALS cases (except 
SOD1 and FUS ALS cases) show ubiquitinated cytoplasmic TDP-43 positive aggregates 
which co-localise with disease affected areas (Arai et al., 2006, Neumann et al., 2006, 
Mackenzie et al., 2007, King et al., 2015).   TDP-43 is often mislocalised from the nucleus to 
the cytoplasm and aggregated, leading to the hypothesis that loss of nuclear function and 
aggregation mediated toxicity may be potential ALS causing mechanisms (Arai et al., 2006, 
Neumann et al., 2006).  In addition to TDP-43 many other RNA-binding proteins have been 
implicated in ALS pathogenesis.  Mutations in the genes which code for RNA-binding 
proteins FUS, hnRNPA1, hnRNPA2B1, TAF15 and EWSR1 are all known to cause ALS 
(Kwiatkowski et al., 2009, Vance et al., 2009, Ticozzi et al., 2011, Couthouis et al., 2012, 
Kim et al., 2013a).  All of the above mentioned RNA-binding proteins contain low-complexity 
prion-like domains, which allow for protein-protein interactions and self-assembly.  The 
majority of ALS causing mutations in RNA-binding protein genes are clustered in the regions 
coding for the low complexity prion-like domains of the protein (Kapeli et al., 2017).  Similarly 
to TDP-43 proteinopathy, all of the above mentioned RNA binding proteins have been shown 
to aggregate or mislocalise to the cytoplasm in a diverse range of ALS cases and models, 
albeit this is observed much less frequently than TDP-43 proteinopathy (Dormann et al., 
2010, Couthouis et al., 2011, Couthouis et al., 2012, Kato et al., 2012, Kim et al., 2013a).  
Notably, two studies from the same group have suggested that RNA-binding proteins (TDP-
43 and FUS) which are mislocalised to the cytoplasm can induce misfolding of wtSOD1 
(Pokrishevsky et al., 2012, Pokrishevsky et al., 2016).  Thus, dysregulation of multiple RNA 
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binding proteins and the SOD1 protein have been reported across diverse genetic subtypes 
of ALS, although evidence for SOD1 proteinopathy in non-SOD1 ALS remains a highly 
controversial topic at this point. 
 
1.6. C9orf72 expansions and potential routes of toxicity 
Tandem repeat disorders are caused by a microsatellite expansion located within the 
identified disease gene.  A microsatellite expansion is a short sequence of DNA (usually 3 to 
6 base pairs in length) which is repeated multiple times consecutively within a genome 
(Richard et al., 2008).  Huntington’s disease, fragile X tremor ataxia syndrome and myotonic 
dystrophy are all examples of neurodegenerative disorders caused by microsatellite 
expansions (Mirkin, 2007).  Recently, an intronic hexanucleotide expansion within the 
C9orf72 gene was identified as the most common known cause of ALS and frontotemporal 
dementia (FTD) (DeJesus-Hernandez et al., 2011, Renton et al., 2011).  In the case of the 
C9orf72 gene, the microsatellite expansion consists of repeats of the hexanucleotide 
sequence GGGGCC (G4C2), the number of these repeats can vary typically from 1-10 in 
healthy people and up to >1000 repeats in some ALS patients (DeJesus-Hernandez et al., 
2011).  The repeats are thought to become pathogenic from a length of approximately 30 
(Renton et al., 2011).  The microsatellite expansion is located in the first intron of the 
C9orf72 gene, and due to alternate splicing there are 3 possible mRNA transcripts which 
may be produced from C9orf72 (DeJesus-Hernandez et al., 2011, Renton et al., 2011).  
These mRNAs give rise to two distinct protein variants.  Both C9orf72 proteins contain a 
DENN (differential in normal and neoplastic cells) domain which led to the early hypothesis 
that C9orf72 may be a guanine exchange factor for Rab GTPases (Levine et al., 2013).  
Later, C9orf72 proteins were discovered to associate with Rab family proteins and regulate 
processes such as endocytosis and autophagy (Farg et al., 2014).  Most recently, the 
C9orf72 protein was shown to act as an effector for Rab proteins, ultimately involved in the 
initiation of autophagy (Sellier et al., 2016, Webster et al., 2016a).  In C9orf72 expansion 
bearing patients, expression of mRNA encoding endogenous C9orf72 gene products is 
reduced (DeJesus-Hernandez et al., 2011).  
Microsatellite expansions are transcribed bi-directionally (He et al., 2008).  Bidirectional 
transcription of the C9orf72 expansion results in the production of sense and antisense RNA 
transcripts very rich in bases G and C.  These GC rich RNA transcripts have a high 
propensity to form secondary structures such as hairpins and G-quadruplexes, as well RNA-
DNA hybrids termed r-loops (Fratta et al., 2012, Reddy et al., 2013, Zhou et al., 2018).  In 
C9orf72-ALS patients, the GC rich RNA transcripts produced from C9orf72 expansions are 
known to form insoluble, predominately intranuclear inclusions termed RNA foci (DeJesus-
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Hernandez et al., 2011) (Figure 1.1a+b).  Both sense and antisense transcribed RNA foci 
can be detected in neurons of multiple CNS regions including motor cortex, spinal cord, 
frontal cortex, cerebellum and hippocampus (Mizielinska et al., 2013, Zu et al., 2013, 
DeJesus-Hernandez et al., 2017).  Additionally, RNA foci frequently sequester RNA-binding 
proteins such as Pur-alpha, hnRNP-H and hnRNP-A1 (Lee et al., 2013, Sareen et al., 2013, 
Xu et al., 2013, Cooper-Knock et al., 2014). 
RNA transcripts produced from microsatellite expansions also undergo repeat associated 
non-ATG (RAN) translation (Zu et al., 2011).  RAN translation is the initiation of translation in 
the absence of the ordinarily necessary ATG start codon, and is triggered exclusively in 
microsatellite expansions.  As RAN translation is not bound by the requirement of an ATG 
codon, it is not limited to translation of a single frame of an mRNA transcript as in normal 
physiological translation.  Rather, RAN translation is capable of translating all frames of an 
mRNA transcript and can therefore produce several distinct proteins from a single transcript 
(Zu et al., 2011).  As microsatellite expansions are transcribed bi-directionally this will give 
rise to a (G4C2)n mRNA strand and a (C4G2)n mRNA strand.  From each of these mRNAs, 3 
different frames can be translated into proteins.  Thus, the C9orf72 hexanucleotide 
expansion will give rise to 2 mRNAs and 6 proteins.  However, in actuality one frame of G4C2 
and C4G2 RNA transcripts share a common base pair sequence, so only 5 distinct protein 
species are produced in total, these are poly glycine-alanine (GA), poly glycine-arginine 
(GR), poly glycine-proline (PA), poly proline-alanine (PA) and poly proline-arginine (PR), 
these are collectively termed dipeptide repeat proteins (Ash et al., 2013, Mori et al., 2013, Zu 
et al., 2013) (Figure 1.1c+d).  Dipeptide repeat proteins form p62/ubiquitin positive, TDP-43 
negative neuronal inclusions in multiple brain regions including the spinal cord, motor cortex, 
frontal cortex and temporal cortex, basal ganglia and cerebellum of ALS/FTD patients (Al-
Sarraj et al., 2011, Bigio et al., 2013, Mackenzie et al., 2013, Mann et al., 2013, Mori et al., 
2013, May et al., 2014, Baborie et al., 2015, Davidson et al., 2016). 
In summary, the three major, non-mutually exclusive, proposed mechanisms of C9orf72 
expansion mediated neurodegeneration are: 1) Toxicity derived from expansion mediated 
reduction of endogenous C9orf72 gene products, 2) Toxicity derived from RNA transcribed  
from the C9orf72 expansion and 3) Toxicity derived from the proteins translated from the 






Figure 1.1: Schematic of transcription and translation of the C9orf72 expansion 
(a)  An expanded GC rich DNA region is located within the C9orf72 gene of C9-ALS 
patients.  In addition to the endogenous transcription start site present in the 5’ promotor 
region of the C9orf72 gene, the presence of C9orf72 GC rich expansions also allows the 
transcription machinery to bind and transcribe RNA in the local expansion region (the 
exact binding site of the transcription machinery in the local expansion region is not 
known).  Additionally, expansion mediated initiation of transcription may occur in both 
sense and antisense directions.  (b)  Sense and antisense RNA transcripts produced from 
the GC rich expansion may form insoluble sense and antisense foci respectively.  These 
RNA foci are predominately nuclear, and less frequently also occur in the cytoplasm.  (c)  
In addition to forming intranuclear RNA foci, some RNA transcripts transcribed from the 
GC rich expansion are exported to the cytoplasm and then trafficked to the ribosome.  (d)   
Sense and antisense RNA transcripts transcribed from the GC rich expansion bind to the 
ribosome where peptides are produced in all 3 possible reading frames (the reason why 
canonical rules dictating reading frame are not respected in the case of these GC rich 




1.7. Evidence for loss or gain of function toxicity in C9orf72 models 
In addition to post-mortem tissue from C9orf72 expansion ALS patients, various in vitro and 
in vivo models have now been developed in order to help study different aspects of the role 
of C9orf72 in ALS pathogenesis.  In order to target therapeutic interventions and future 
research appropriately, it is important to ascertain which element(s) of the C9orf72 
expansion drive ALS pathogenesis.  Therefore the majority of ALS models to date have 
focussed on modelling one or a combination of RNA foci, DPRs and C9orf72 endogenous 
protein reduction.   
 
1.7.1. Evidence for loss of C9orf72 endogenous function causing toxicity 
Loss of function toxicity refers to a mutation which disrupts the endogenous functioning of 
the affected gene or its gene products.  Whether loss of function of the endogenous C9orf72 
protein products is neurotoxic has not been clearly defined.  In zebrafish, morpholino-
mediated knockdown of the zebrafish orthologue of C9orf72 caused a motor phenotype 
which could be rescued upon expression of human C9orf72 mRNA (Ciura et al., 2013).  
Furthermore, injection of C9orf72 RNA containing deletions in the DENN domain into 
zebrafish blastomeres resulted in locomotor defects and neuronal apoptosis (Yeh et al., 
2018).  Injection of a C9orf72 morpholino also phenocopied overexpression of the DENN 
deleted RNAs (Yeh et al., 2018).  Additionally, knockout of the C. elegans orthologue of 
C9orf72 resulted in motor neuron loss (Therrien et al., 2013).  These data suggest that 
haploinsufficiency may play a role in C9orf72-ALS pathogenesis.  Conversely, early reports 
from stable C9orf72 knockout zebrafish suggest that complete loss of C9orf72 protein 
expression does not induce any motor or neurodegenerative phenotype (Stepto et al., 2014).  
Additionally, 6 independently generated C9orf72 knockout mice, displayed no motor or 
behavioural abnormalities and no neurodegenerative phenotype (Koppers et al., 2015, 
Atanasio et al., 2016, Jiang et al., 2016, O'Rourke et al., 2016, Sudria-Lopez et al., 2016, Ji 
et al., 2017).  Further work is clearly needed to explain these directly contradictory datasets.   
 
1.7.2. Evidence for gain of function toxicity in C9orf72 expansion models 
Gain of function toxicity occurs when a genetic mutation results in the affected gene, or gene 
products, possessing new molecular functions. Toxicity related to RNA foci or DPR proteins 
are both examples of gain of function toxicity as RNA foci and DPR proteins are not 
expressed in people who possess a wildtype C9orf72 gene.  Modelling of gain of function 
mechanisms (RNA foci or DPRs) and loss of function mechanisms (C9orf72 protein levels) 
separately can be achieved with relative ease due to the independent nature of these 
pathways.  However, RNA foci and DPR pathology are intimately linked, therefore 
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expressing RNA without DPR or vice versa has proven to be a challenge in identifying the 
exact species which are responsible for driving ALS progression.  To overcome the difficulty 
of expressing RNA foci without DPRs being produced (or vice versa) researchers have 
developed various techniques.  One such technique involves introducing stop codons 
immediately prior to the expansion, which should therefore allow expression of RNA foci, but 
prevent translation of the RNA into DPR protein (Mizielinska et al., 2014).  Another technique 
involves expressing constructs which take advantage of codon degeneracy to avoid 
expressing 100% GC rich RNA transcripts, for example rather than being encoded by GGG-
GCC repeats (100% GC content), poly(GA) may be encoded by GGA-GCA repeats (66% 
GC content), thus allowing large DPR proteins to be encoded by RNA which has a more 
moderate GC content (Mizielinska et al., 2014, Wen et al., 2014).  Such constructs are 
henceforth referred to as DPR encoding constructs.   
Multiple cell lines expressing hexanucleotide expansions have now been generated, these 
cell lines show RNA foci and/or produce DPRs, which results in toxicity as measured by 
induction of apoptosis and direct reduction in cell viability.   (Lee et al., 2013, Kwon et al., 
2014, Stopford et al., 2017).  Certainly these studies demonstrate the potent toxicity of RNA 
foci and/or DPR species and therefore support gain of function mediated toxicity in ALS.  
However, due to RAN translation these models will likely not only express RNA foci but also 
some DPR proteins, indeed this was proven to be the case in one cell line but was not 
investigated in another (Lee et al., 2013, Stopford et al., 2017).   
Cell lines are often not representative of the complex biology of an entire organism, for this 
reason many in vivo models of C9orf72-ALS have also been generated (see Appendix A for 
a table summarising the in vivo C9orf72 models discussed in the section below).  These in 
vivo models have also been utilised in an attempt to unravel the contributions to 
pathogenicity of RNA foci and DPR toxicity.   
Transgenic drosophila expressing C9orf72 expansion containing constructs have helped to 
shed light on the relative toxicities of RNA and DPR species.  Drosophila expressing over 
200 G4C2 repeats showed RNA foci pathology, but RAN-translation of DPRs was prevented 
by the insertion of a bidirectional multi-frame stop codons throughout the C9-expansion 
(Mizielinska et al., 2014).  The drosophila expressing over 200 repeats with a stop codon did 
not show any DPR production or neurodegenerative phenotype.  However, in the same 
study drosophila expressing 103 repeats with no stop codons, displayed RAN translated 
poly(GR) peptides accompanied by a neurodegenerative phenotype and reduced survival 
(Mizielinska et al., 2014).  Additionally, treatment of the 103 repeat (no stop codon) 
drosophila with an agent which partially blocks protein synthesis ameliorated the decrease in 
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their survival (Mizielinska et al., 2014).  Similarly, another drosophila model demonstrated 
that expression of 160 G4C2 repeats (no stop codon) was sufficient to produce RNA foci, but 
again did not cause a neurodegenerative phenotype (Tran et al., 2015).  In the same study 
however, expression of 34 repeats in the context of a poly(A) tail allowed RNA to be 
exported to the cytoplasm and translated into DPR, and was potently neurotoxic.  Finally, 
Tran et al. demonstrated that growing the drosophila containing 160 repeats at a higher 
temperature (in order to increase the rate of protein synthesis) increased the amount of 
DPRs produced, and resulted in a corresponding increase in neurodegenerative phenotype 
(Tran et al., 2015).   
In addition to drosophila models, zebrafish models have also been utilised in attempting to 
unravel RNA and DPR toxicity.  Early data generated in zebrafish transiently expressing 
G4C2 RNA showed activation of apoptotic pathways (Lee et al., 2013).  Later, zebrafish 
stably expressing G4C2 expansions showed a modest toxic phenotype, whereas zebrafish 
expressing ATG-driven DPR proteins displayed a much more severe toxic phenotype (Ohki 
et al., 2017).  Additionally, injection of sense (35, 70 and 90 G4C2 repeats) and antisense (35 
and 70 C4G2 repeats) RNA at the 1-2 cell stage resulted in motor axonopathy in zebrafish 
(Swinnen et al., 2018).  In the same study, injection of an equimolar concentration (with 
respect to sense and antisense RNAs) of codon optimised (use of codon degeneracy to 
produce RNA transcripts with the lowest possible propensity to form secondary structures) 
DPR encoding RNA, resulted in motor axonopathy when 50 repeats of poly(PR) or poly(GR) 
encoding RNA was injected, but not when 50 repeats of poly(PA), poly(GA) or poly(GP) 
encoding RNA was injected.  Intriguingly, Swinnen and other authors confirmed that sense 
or antisense RNA injection did not result in the production of detectable levels of the toxic 
poly(GR) DPR or poly(PR) DPR respectively (Swinnen et al., 2018).  Furthermore, co-
injection of Pur-alpha mRNA resulted in rescue of the motor axonopathy observed with 
injection of sense and antisense repeats, but had no effect on poly(GR) or poly(PR) DPR 
mediated motor axonopathy.  Thus, Swinnen and other authors demonstrate that in this 
zebrafish model, C9orf72 expansion RNA and DPRs are both toxic to motor neurons, and 
may mediate their toxicity through independent mechanisms. 
Mammalian models have also offered insights into the debate over RNA and DPR toxicity.  
Viral mediated expression of 66 G4C2 repeats in the mouse central nervous system 
accurately recapitulated major aspects of human ALS (Chew et al., 2015).  The mice 
expressing 66 G4C2 repeats displayed RNA foci with the characteristic TDP-43 pathology 
frequently observed in ALS patients, the mice also showed intracellular inclusions of RAN 
translated proteins.  These mice also displayed mild motor impairment and neuronal cell loss 
(Chew et al., 2015).  Similarly, viral mediated expression of 102 G4C2 in the mouse CNS 
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resulted in expression of RNA foci, RAN-translated DPR species and caused gait and 
memory disturbances in these mice (Herranz-Martin et al., 2017).  A further mouse model 
virally expressed a DPR encoding construct (50 poly(GA) repeats), which resulted in mice 
showing anxiety-like behaviour and reduced latency to fall in the rotarod test (Zhang et al., 
2016).  Likewise, a similar mouse model which virally expressed a DPR encoding construct 
(69 poly(GA) repeats) showed motor impairment and neurodegeneration (Walker et al., 
2017).  Thus, virally driven mouse models of C9orf72 expansion ALS show a motor 
phenotype whether G4C2 expansions or DPR coding constructs are used.   
In addition to the mouse models described above, transgenic mouse models have also been 
generated from a bacterial artificial chromosome (BAC) containing a human ALS patient 
C9orf72 gene complete with G4C2 expansion and flanking regions.  Two BAC mouse models 
demonstrate the reduced survival, neuronal loss and motor deficits observed in human C9-
ALS/FTD (Jiang et al., 2016, Liu et al., 2016).  Liu and other authors, generated BAC mice 
expressing a maximum expansion size of 500 G4C2 repeats, within the full length human 
C9orf72 gene and flanked by 52 Kb of upstream sequence and 19 Kb of downstream 
sequence (Liu et al., 2016).  Whereas Jiang and other authors, generated BAC mice 
expressing a maximum of 450 G4C2 repeats, within exons 1-5 of the human C9orf72 gene 
and flanked by 140 Kb of upstream sequence (Jiang et al., 2016).  Unexpectedly, a further 
two independently generated BAC transgenic mouse models showed no signs of neuronal 
loss or reduced survival (O'Rourke et al., 2015, Peters et al., 2015).  O’Rourke and other 
authors, generated BAC mice with a maximum expansion size of 1000 G4C2 repeats within 
the full length C9orf72 gene (O'Rourke et al., 2015).   Whereas Peters and colleagues, 
generated BAC mice with a maximum expansion size of 500 G4C2 repeats (these mice 
contained an additional 300 repeat expansion) within exons 1-6 of the human C9orf72 gene, 
and flanked by 140.5 Kb of upstream sequence (Peters et al., 2015).  All 4 BAC transgenic 
mice showed expression of RNA foci and RAN translated DPR species.  While the two BAC 
mouse models which show an ALS/FTD like phenotype are consistent with the RNA foci 
and/or DPR mediated gain of function toxicity observed in cell, zebrafish, drosophila and 
previous viral expression mouse models.  It is still not known why two seemingly similar BAC 
mouse models expressed RNA foci and DPR proteins but did not develop any ALS/FTD 
symptoms (see Appendix A for a table of information on all 4 BAC mouse, and other in vivo 
C9orf72 models).  Taken together, current in vivo data show that both RNA foci and DPR 
species are toxic, with DPRs likely being the more potently cytotoxic species.  However, two 
of the 4 BAC mouse models generated, clearly demonstrate that expression of RNA foci and 
DPRs are not always sufficient to cause an ALS/FTD phenotype. 
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In summary, there is evidence suggesting that RNA foci, DPR species and 
haploinsufficiency of the C9orf72 protein products may all contribute to ALS pathogenesis.  
As these are none mutually exclusive pathways, it is possible that all three pathways may 
contribute to ALS pathology. 
 
1.8. Differential toxicity of DPR species 
Each DPR species is found to be differentially expressed in post-mortem CNS tissue from 
C9orf72-ALS patients (Mackenzie et al., 2013, Mackenzie et al., 2015, Schludi et al., 2015).  
For this reason it is important to determine what the relative toxicity of each DPR species is.  
Expression of DPR coding constructs in induced neuronal-like cells showed that poly(PA) 
was not cytotoxic but did cause electrophysiological abnormalities when expressed at over 
1000 repeats (Bennion Callister et al., 2016).  In the same study modest toxicity and 
electrophysiological changes were observed with similar repeat lengths of poly(GA).  
However, the most toxic DPRs were found to be the arginine rich poly(GR) and poly(PR) as 
these DPRs induced severe cytotoxicity at repeat lengths of ~1000 repeats, and caused 
electrophysiological changes from as few as 284 repeats (Bennion Callister et al., 2016).  
Similar results have also been obtained from drosophila expressing DPR encoding 
constructs.  Expression of DPR encoding constructs containing 100 repeats coding for either 
poly(PA) or poly(GA) had no effect, whereas expression of 100 repeats coding for either 
poly(GR) or poly(PR) resulted in reduced viability of the drosophila and the induction of a 
neurodegenerative phenotype (Mizielinska et al., 2014).  Additionally, independently 
generated drosophila expressing DPR encoding constructs also showed that poly(PR) DPRs 
induced a neurotoxic phenotype whereas poly(PA) and poly(GA) did not (Wen et al., 2014).  
Similarly, RNA injection of 50 repeats of codon optimised poly(PR) or poly(GR) resulted in 
motor axonopathy in zebrafish, however injection of equimolar concentrations of 50 repeats 
of poly(GA), poly(PA) or poly(GP) had no effect (Swinnen et al., 2018).  Independently, 
generated zebrafish models injected with DPR encoding DNA constructs identified that 200 
poly(GR) repeats more frequently induced death and swimming defects than constructs 
encoding 200 repeats of poly(GA, PA or PR) (Swaminathan et al., 2018).  In the same study, 
transgenic zebrafish expressing 100 poly(GR) encoding repeats showed reduced swimming 
distance at 7 dpf and reduced axonal length at 2 dpf, in comparison to non-poly(GR) 
expressing zebrafish (Swaminathan et al., 2018).  Importantly, induced motor neurons from 
C9orf72-ALS patients produce poly(PR) DPRs, and poly(PR) positive staining has also been 
identified in hippocampal neurons from C9orf72 patients (Mann et al., 2013, Wen et al., 
2014).  However, poly(PR) positive inclusions have not been identified in motor neurons in 
post-mortem tissue from C9orf72-ALS patients.  These data suggest that differential toxicity 
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exists between the various DPR species.  Although, there is evidence for direct cytotoxicity 
or a contribution to cell pathology in all DPR species. 
 
1.9. Pathways implicated in C9orf72 expansion pathology 
While it is important to ascertain which species resulting from the C9orf72 expansion is most 
toxic to cell and animal models, it is also important to identify the pathways through which 
these species mediate their toxicity.  Dysregulation of RNA processing, stress granule 
formation, nucleocytoplasmic transport, autophagy and DNA repair are among the most 
common pathways recurrently implicated in C9orf72 expansion pathology.  Data from post-
mortem C9orf72 patient tissue and cell/animal models of C9orf72 have all helped contribute 
to our understanding of how C9orf72 expansions affect these pathways.  
 
1.9.1. RNA processing 
Dysregulation of RNA processing in C9orf72 expansion pathology is thought to be caused by 
RNA foci mediated sequestration of RNA-binding proteins such as Pur-alpha, hnRNP-H and 
hnRNP-A1 (Lee et al., 2013, Sareen et al., 2013, Xu et al., 2013, Cooper-Knock et al., 2014) 
(Figure 1.2a).  Indeed, cell lines derived from C9orf72 expansion harbouring patients were 
shown to have an increased rate of splicing errors in comparison to non-C9orf72 expansion 
cells (Cooper-Knock et al., 2015a) (Figure 1.2b-c).  Overexpression of the RNA-binding 
protein Pur-alpha suppressed the toxic phenotype otherwise observed when expressing 
G4C2 repeat expansions in neuro-2a cells, drosophila or zebrafish (Xu et al., 2013, Swinnen 
et al., 2018).  Splicing errors in C9orf72-ALS patients may not be solely due to RNA foci 
sequestration of RNA-binding proteins, as nuclear extracts incubated with arginine rich DPR 
proteins showed defective spliceosome assembly and therefore impairment of normal 
splicing (Yin et al., 2017).  Moreover, expression of arginine-rich DPRs has been shown to 
impair splicing (Kwon et al., 2014).  As mentioned previously, cytoplasmic mislocalisation of 
RNA-binding factors such as TDP-43 and FUS among others, is a common theme occurring 
in the vast majority of ALS cases (Lagier-Tourenne and Cleveland, 2009, Kapeli et al., 
2017).  Additionally, loss of nuclear TDP-43 has been shown to cause widespread splicing 
dysregulation in motor neurons (Highley et al., 2014).  Thus suggesting that loss of TDP-43 
may cause splicing dysregulation across multiple ALS sub-types.  Whether RNA foci or 







Figure 1.2: Schematic of sequestration of RNA binding proteins by RNA foci and 
subsequent increase in splicing errors 
(a)  In C9orf72-ALS patients, nuclear sense and antisense RNA foci bind and sequester 
RNA binding proteins such as TDP-43, FUS and hnRNP-H among many others.  (b)  
During normal functioning, RNA binding proteins assemble with other splicing factors to 
form the spliceosome.  The spliceosome binds to pre-mRNA strands and removes the 
introns before then ligating the exons back together, thus forming a final mature mRNA 
strand which is then trafficked to the ribosome to begin translation.  (c)  In C9orf72-ALS 
patients, RNA binding proteins are sequestered by sense and antisense RNA foci and 
therefore are not available during spliceosome assembly.  An incomplete spliceosome is 
then formed in the absence of the RNA binding proteins, and splicing continues with the 
incomplete spliceosome, thus leading to an increase in the rate of splicing errors such as 





1.9.2. Formation and function of membraneless organelles 
Many RNA binding proteins, including TDP-43, FUS and hnRNP-A1, contain a low 
complexity prion-like domain (Kapeli et al., 2017).  Proteins containing a low complexity  
prion-like domain can undergo liquid-liquid phase separation to form membraneless 
organelles (Molliex et al., 2015).  Liquid-liquid phase separation refers to the process by 
which a single liquid undergoes demixing and transitions into two or more distinct liquid 
structures (Hyman et al., 2014).  Well known examples of liquid-liquid phase separation in  
 biology include the formation of liquid-like nucleoli from the liquid which comprises the 
nucleoplasm, and the formation of liquid-like stress granules from the  
cytoplasm/nucleoplasm (Hyman et al., 2014).  Stress granules are formed from a mixture of 
RNA-binding proteins, RNA and various protein/RNA modifying enzymes (Jain et al., 2016).  
The precise role of stress granules in the cell is not fully understood.  However, stress  
granules are thought to contribute to the activation of stress response related proteins, 
sequestration of specific signalling molecules in order to modulate signalling pathways and 
the metabolism of RNA (Protter and Parker, 2016).  Both poly(GR) and poly(PR) DPR 
proteins are known to interact with proteins containing low complexity prion like domains, 
and have been shown to interfere with the dynamics and function of stress granules both in 
vitro and in vivo (Lee et al., 2016, Lin et al., 2016, Boeynaems et al., 2017).  Additionally, 
stress granule assembly has been associated with defects in nucleocytoplasmic transport, 
due to stress granule mediated sequestration of key nucleocytoplasmic transport factors 
such as the Ran protein (Figure 1.3a) (Zhang et al., 2018). 
The nucleolus has functions including ribosome biogenesis and response to cell stress  
(Pederson, 2011).  Both RNA foci and poly(GR)/poly(PR) proteins co-localise with nucleolin 
protein, a principle component of the nucleolus (Haeusler et al., 2014, Lee et al., 2016).  In 
line with this, induced motor neurons from C9orf72-ALS patients, exhibit dispersed nucleolin 
immunostaining patterns, in comparison to the dense and well-defined immunostaining 
pattern observed in induced motor neurons from healthy controls (Haeusler et al., 2014).  
Furthermore, in C9orf72-ALS patient post-mortem tissue, neurons containing RNA foci or 
poly(GR) proteins exhibit enlarged nucleoli (Mizielinska et al., 2017).  Nucleolar localised 
poly(GR)/poly(PR) disrupt the normal functioning of the nucleolar protein nucleophosmin 1, 
which then disrupts the organisation of the nucleolus and impedes the normal maturation of 
ribosomal RNA transcripts,  (Kwon et al., 2014, Tao et al., 2015, White et al., 2019).  Thus, 
C9orf72 expansions disrupt both the structure and functioning of the nucleolus. 
 
1.9.3. Nucleocytoplasmic transport 
Disruptions in nucleocytoplasmic transports pathways are another recurrent theme in 
C9orf72 related ALS pathology.  Nucleocytoplasmic transport is the shuttling of protein and 
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RNA cargoes between the cytoplasm and the nucleoplasm.  Nucleocytoplasmic transport 
primarily occurs through large protein complexes known as nuclear pore complexes (NPCs).  
These complexes are formed from approximately 30 subunits which are individually known 
as nucleoporins (NUPs) (Cronshaw et al., 2002).  Molecules smaller than ~30kDa can freely 
diffuse through the NPC, molecules larger than this require specialised transporter proteins 
which are also associated with, and traverse through, the NPC (Cautain et al., 2015).   
Induced-neuronal cells derived from patients with C9orf72 expansions showed retention of 
nuclear RNA, suggesting dysregulation of the normal routes of RNA export through the NPC 
(Freibaum et al., 2015).  The same study also replicated this finding in drosophila models 
carrying C9orf72 expansions.  Using the same C9orf72 expansion drosophila model, a 
genetic modifier screen identified 18 genes which enhanced or suppressed the 
neurodegenerative phenotype, all of these genes coded for components of the NPC 
(Freibaum et al., 2015).  An additional and independently generated C9orf72 expansion 
drosophila model, also identified a key nucleocytoplasmic transport regulator as a potent 
suppressor of the neurodegenerative phenotype (Zhang et al., 2015b).  Furthermore, 
depletion of the nuclear export adapter protein SRSF1 suppressed the motor and rough eye 
phenotype observed in C9orf72 expansion drosophila (Hautbergue et al., 2017).  Also, 
depletion of SRSF1 in induced C9orf72 patient motor neurons resulted in reduced DPR 
production by the cells and increased motor neuron survival (Hautbergue et al., 2017).  
SRSF1 co-localised with sense RNA foci in spinal cord post-mortem tissue from C9orf72-
ALS patients, thus suggesting that SRSF1 mediates its effect on DPR production through 
processing of G4C2 RNA (Hautbergue et al., 2017).  RanGAP1 a regulator of 
nucleocytoplasmic transport has also been shown to co-localise with sense RNA foci in 
induced neurons derived from C9orf72-ALS patients (Zhang et al., 2015b).  Additionally, 
RanGAP1 and the nucleoporin Nup205 were shown to mislocalise into perinuclear puncta in 
induced neurons and brain tissue from C9orf72-ALS patients (Zhang et al., 2015b).   
However, DPR species may also interact with the nucleocytoplasmic transport system.  
Genetic modifier screens carried out in drosophila expressing DPR constructs encoding 
poly(PR) also identified genes coding for both components of the NPC and  
nucleocytoplasmic transport regulators as modifiers of the cytotoxic phenotype (Jovicic et al., 
2015).  Moreover, both poly(PR) and poly(GR) DPR proteins have been reported to bind with  
multiple nucleoporin proteins in two independent protein interaction assays (Lee et al., 2016, 
Lin et al., 2016).  Collectively, these data show that nucleocytoplasmic transport pathways 
are important disease modifiers of C9orf72 expansion pathology, and may interact with both 
RNA foci and DPR proteins (Figure 1.3b).  Deletion of genes relating to nucleocytoplasmic 
transport could either enhance or suppress the toxic phenotype, the reason why deleting 




Figure 1.3: Schematic of the C9orf72 expansion mediated stress granule formation 
and nucleocytoplasmic transport defects 
a) C9orf72 expansions drive increased stress granule formation.  Increased stress granule 
formation results in increased sequestration of nucleocytoplasmic transport factors such 
as the Ran protein.  b) Expression of C9orf72 expansions results in the sequestration of 
nucleocytoplasmic transport associated proteins nucleoporin 205 and RanGAP1 into 
perinuclear puncta. Poly(PR) DPRs translated from C9orf72 expansions bind with 
nucleoporin 205, and sense RNA foci sequester RanGAP1, it is not known whether the 
binding of these proteins by DPR/RNA foci is related to their formation of perinuclear 
puncta.  Expression of C9orf72 transcripts also results in nuclear retention of RNA 
transcripts, suggesting defects in RNA export.  Gain of function denotes that the pathway 




A final notable point about nucleocytoplasmic transport in ALS, is that it has been 
hypothesised that disrupted nucleocytoplasmic transport may be related to the pathological 
primarily cytoplasmic mislocalisation of many ALS associated RNA-binding proteins (Kim 
and Taylor, 2017). 
 
1.9.4. Autophagy 
Data obtained from human cell lines suggests that an important function of the C9orf72 
protein is in the initiation of autophagy.  Knockdown of the C9orf72 protein results in reduced 
autophagosome formation (Sellier et al., 2016, Webster et al., 2016a).  In a similar fashion, 
overexpression of the C9orf72 protein results in increased autophagosome formation 
(Webster et al., 2016a). Intriguingly, C9orf72 knockout mice are reported to have defective 
autophagy functioning (Ji et al., 2017).  Furthermore, induced neurons derived from C9orf72 
patients show defective autophagy and increased sensitivity to autophagy inhibition (Almeida 
et al., 2013, Webster et al., 2016a).  Additionally, reduced autophagy mediated clearance of 
DPR proteins has been identified as contributing to neurodegeneration in induced motor 
neurons derived from C9orf72 patients (Figure 1.4a) (Shi et al., 2018).  Defective autophagy 
has also been closely linked with Parkinson’s disease, and rare C9orf72 expansion 
harbouring patients have been reported to show parkinsonian symptoms (Zhang et al., 
2015a, Wilke et al., 2016).  Finally, accumulation of p62 positive intracellular inclusions have 
been hypothesised to be caused by defective autophagy mediated clearance of p62 tagged 
aggregates, thus suggesting a role for defective autophagy signalling across multiple ALS 
sub-types (Arai et al., 2003, Mizuno et al., 2006a). 
 
1.9.5. DNA damage and repair   
Damage to the DNA of a cell can arise from a myriad of chemical and physical sources 
which can induce single strand breaks or double strands breaks (DSBs) depending on the  
 nature of the interaction (Ciccia and Elledge, 2010).  Because of this, cells have evolved 
complex DNA repair mechanisms which are capable repairing these DNA breaks through 
various mechanisms which faithfully restore the DNA to its original base pair sequence  
(Ciccia and Elledge, 2010).  Chronic DNA damage or impairment of the machinery of the 
DNA repair response, can ultimately result in DNA damage induced cell death (Roos and 
Kaina, 2006).  Induced neurons derived from C9orf72 patients have increased expression of 
the DNA DSB marker yH2AX (phosphorylated histone 2AX) (Lopez-Gonzalez et al., 2016).  
Additionally, the same authors found that expression of poly(GR) repeats in control cell lines 
was also sufficient to induce DNA damage.  The number of DSBs detected in these cells 




Figure 1.4: Schematic of the C9orf72 expansion mediated defects in autophagy and 
DNA damage 
a)  Haploinsufficiency of the C9orf72 protein caused by the presence of C9orf72 
expansions results in decreased initiation of autophagy and therefore decreased 
clearance of p62 tagged cellular inclusions.  Additionally, autophagy dysfunction may be 
exacerbated by an increase in the number of p62 positive inclusions requiring degradation 
due to cytoplasmic inclusions of DPR proteins produced from the C9orf72 expansion.  b)  
Sense RNA foci, antisense RNA foci and DPR proteins (or a combination of these 
species) increase the frequency of double strand DNA breaks, resulting in increased 
expression of yH2AX (phosphorylated histone 2AX). Loss of function denotes that the 
pathway disruption is caused by the loss of function of C9orf72 endogenous gene 
products.  Gain of function denotes that the pathway disruption is caused by the gained 
function of the C9orf72 expansion or its gene products. 
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may be mediated in part by reactive oxygen species.  Furthermore, increased expression of 
key DNA repair proteins such as yH2AX, 53BP1 and phosphorylated ATM (pATM), have 
been reported in the spinal cords of C9orf72-ALS patients (Farg et al., 2017).  A more recent 
report however, supported the finding that increased yH2AX levels are induced by C9orf72 
expansions, but also reported that recruitment of 53BP1 and pATM to DNA repair foci was 
impaired by the C9orf72 expansion (Walker et al., 2017).  The same study showed that even 
upon treatment with camptothecin (a potent inducer of DNA breaks), 53BP1 and pATM 
would not be recruited to repair foci in the presence of C9orf72 expansions.  These findings 
suggest that, not only do C9orf72 expansions induce DNA damage, but that they may 
simultaneously impair critical aspects of the DNA damage response.  The precise reason 
why 53BP1 recruitment was increased in the presence of C9orf72 expansions in one study 
(Farg et al., 2017), and reported to be decreased in a later study (Walker et al., 2017), is not 
currently known.  Interestingly, mutation of the ALS/FTD causative genes VCP and FUS 
have also been shown to increase markers of DNA damage whilst simultaneously impairing 
the rate of DNA repair (Meerang et al., 2011, Wang et al., 2013, Naumann et al., 2018, 
Wang et al., 2018).  These data indicate that induction of DNA damage with simultaneous 
impairment of the DNA damage response may be involved in multiple ALS sub-types 
(Figure 1.4b). 
The precise molecular mechanism by which DNA damage is detected and repaired is 
dependent on the nature of the insult (Ciccia and Elledge, 2010).  Various forms of DNA 
damage can be detected by PARP1 and PARP2, these enzymes respond to DNA damage 
by attaching poly-ADP-ribose (PAR) polymers to the local DNA region (Dantzer et al., 2006).  
Subsequently, these PAR chains recruit proteins which are essential in the DNA repair 
process (Dantzer et al., 2000, Li and Yu, 2013).  PARP1 catalyses the formation of PAR 
chains, a process which consumes a single molecule of NAD+ for each PAR molecule added 
to the chain (Martire et al., 2015).  Hundreds of PAR molecules can be joined together in a 
single chain, therefore it is possible for over-activation of PARP1 to deplete cellular stores of 
NAD+ and induce cell death (Hoch et al., 2017).  Neurodegeneration induced by PARP1 
over-activation has been reported in patients suffering from cerebellar ataxia (Hoch et al., 
2017).  Additionally, mutations in the DNA repair factor tyrosyl phosphodiesterase 1 (TDP1) 
inhibit the ability of this protein to repair DNA single strand breaks and cause spinocerebellar 
ataxia with axonal neuropathy-1 (SCAN-1).  Despite their known roles in other forms of 
neurodegeneration, whether over activation of PARP1 or loss of function of TDP1 may 






Activated astrocytes and microglia have long been implicated in the pathology of sALS 
(Troost et al., 1990, Kawamata et al., 1992, Schiffer et al., 1996).  Recent evidence has also 
linked C9-ALS with neuroinflammation.  Rather than resulting in a neurodegenerative 
phenotype, knockout of C9orf72 in mice caused dysregulation of the immune system, 
including causing splenomegaly, lymphadenopathy, increased circulating levels of 
proinflammatory cytokines and abnormal immune cell functioning (Atanasio et al., 2016, 
Burberry et al., 2016, O'Rourke et al., 2016, Sudria-Lopez et al., 2016).  RNA-seq analysis 
revealed an upregulation of inflammatory related pathways in C9orf72 knockout mice in 
comparison to wildtype mice (O'Rourke et al., 2016).  Similarly, RNA-seq analysis carried 
out in ALS patient CNS tissue, identified a significant upregulation of inflammatory pathways 
in C9-ALS patients when compared to sALS patients (O'Rourke et al., 2016).  Furthermore, 
increased levels of activated microglia are observed in the white matter motor cortex of C9-
ALS patient’s brains when compared to the same regions in sALS patient’s brains 
(Brettschneider et al., 2012).  Thus, neuroinflammation may become dysregulated in 
C9orf72 expansion pathology. 
1.9.7. Axonal transport and mitochondrial dysfunction 
Mutations in the axonal transport related genes KIF5A and TUBA4A are causative of ALS 
(Smith et al., 2014, Nicolas et al., 2018).  Additionally, dysfunction in the axonal transport of 
cargoes such as mitochondria, have been reported in transgenic mouse models of ALS 
expressing mutant forms of either SOD1 or TDP-43 proteins (Magrane et al., 2014).  These 
data suggest a role of axonal transport in ALS pathobiology.  In line with this, impaired 
mitochondrial transport has also been reported in C9orf72 drosophila models expressing 
either 39 poly(PR) repeats or 39 G4C2 repeats (Baldwin et al., 2016).  However, drosophila 
expressing 39 RNA only G4C2 repeats did not exhibit significantly altered mitochondrial 
transport, suggesting that impaired axonal transport may be caused by DPR species in this 
model (Baldwin et al., 2016). 
In addition to defects in mitochondrial transport, defects in mitochondrial morphology have 
been observed in sALS post-mortem tissue, and defects in both mitochondrial structure and 
function have been observed in mouse models of SOD1-ALS (Higgins et al., 2003, Pasinelli 
et al., 2004, Sasaki and Iwata, 2007).  Increased production of reactive oxygen species by 
mitochondria is observed in induced motor neurons derived from C9orf72-ALS patients, 
when compared to induced neurons from healthy controls (Lopez-Gonzalez et al., 2016).  
This increase in reactive oxygen species production eventually lead to increased DNA 
damage in these motor neurons (Lopez-Gonzalez et al., 2016).  Furthermore, in a C9orf72 
mouse model expressing poly(GR) DPRs, morphological abnormalities in mitochondria were 
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observed at 3 months old (Choi et al., 2019).  Using the same mouse model, poly(GR) was 
discovered to interact with the mitochondrial protein Atp5a1, this interaction resulted in the 
ubiquitination and proteasomal degradation of Atp5a1 (Choi et al., 2019).  Moreover, Atp5a1 
protein expression was significantly reduced in the frontal cortex of both poly(GR) 
expressing mice and C9orf72-ALS patients, and overexpression of Atp5a1 rescued 
mitochondrial morphological abnormalities in cortical neurons derived from poly(GR) 
expressing mice (Choi et al., 2019).  Taken together these data highlight an emerging role 
for DPR mediated mitochondrial dysfunction in C9orf72 pathobiology.  Table 1.2 
summarises pathways which have been recurrently implicated in C9orf72 pathobiology. 
Dysregulated 
pathway 
Reported cause of 
defect 
Links to other 
pathways 
References 
RNA processing RNA foci sequester 
RNA binding proteins 
resulting in increased 
splicing errors 
Sequestered RNA 
binding proteins also 
function in stress 
granule formation  
(Lee et al., 
2013, Cooper-





DPR proteins/RNA foci 
expression alters stress 
granule dynamics 
Stress granules 
formation can cause 
nucleocytoplasmic 
transport defects by 
sequestering key 
proteins 








DPR proteins/RNA foci 
cause mislocalisation of 
nucleocytoplasmic 
transport proteins.  
DPR/RNA foci induced 
toxicity can be 
enhance/suppressed by 
the deletion of various 
nucleocytoplasmic 
transport genes 
Both RNA processing 
and DNA repair factors 
are frequently shuttled 
between the nucleus 
and the cytoplasm 
(Freibaum et 
al., 2015, 
Zhang et al., 
2015b) 
Autophagy Loss of C9orf72 gene 




associated protein p62 
co-localises with DPR 
aggregates 




Webster et al., 
2016a) 
DNA repair DPR proteins/RNA foci 
cause DNA damage 
and impair the normal 
recruitment and 
functioning of DNA 
repair factors 
Aggregation of the 
autophagy associated 
protein p62 has been 
reported to cause DNA 
repair defects 
(Farg et al., 
2017, Walker 
et al., 2017) 
Neuroinflammation Chronic activation of 
inflammatory pathways 
and microglia in the 
CNS 
Haploinsufficiency of 
C9orf72 protein may 
contribute to immune 
dysregulation 
(Brettschneider 
et al., 2012, 








Defects in mitochondrial 
transport, morphology 
and regulation of 
reactive oxygen species 
production 
Defects in axonal 
transport pathways 
result in impaired 
mitochondrial transport 
(Baldwin et al., 
2016, Lopez-
Gonzalez et 
al., 2016, Choi 
et al., 2019) 
Table 1.2 Summary of pathways implicated in C9orf72 pathobiology 
DPR: Dipeptide repeat protein 
 
 
1.10. Generation of genetic animal models 
There are many methods for generating transgenic or mutant animals, each method having 
advantages and disadvantages.  Due to the low efficiency of generating most transgenic 
animals, often one method will be used in conjunction with another in an attempt to increase 
efficiency.  Some of the most commonly used methods are DNA microinjection (with or 
without the use of transposons), transfection with lentiviral vectors and addition of transgenic 
pluripotent stem cells.  DNA microinjection involves injecting highly concentrated DNA in nl 
volumes, preferably at the one cell stage immediately following fertilisation (Ramesh et al., 
2010).  Following microinjection the exogenous DNA incorporates into the animal’s genome 
at an unknown location (Ramesh et al., 2010).  An advantage of microinjection is that its low 
efficiency means that the transgene construct incorporating multiple times in different genetic 
loci is less likely.  Likewise, the low efficiency of microinjection means that generating a 
transgenic animal by this method can be more time consuming.   
Homologous recombination is an endogenous DNA repair process during which a 
complementary DNA strand is synthesised and then used to replace a damaged genomic 
DNA sequence (Szostak et al., 1983).  By matching short sequences of transgenic DNA to a 
specific sequence present in the genomic DNA, the endogenous homologous recombination 
machinery can be exploited to accurately deliver exogenous DNA into a specific genetic 
locus (Thomason et al., 2007).  Homologous recombination of exogenous DNA into a 
specific locus has an extremely low efficiency (Garate et al., 2013). 
In order to increase efficiency of microinjections it is possible to add transposons to the DNA 
sequence being injected.  Transposons are short DNA sequences which are replicated and 
repeatedly incorporated into the same genome (McClintock, 1950).  By attaching the desired 
transgene to a transposon prior to microinjection, the efficiency by which the transgene 
incorporates into the host genome is increased (Largaespada, 2003).  Unfortunately due to 
the high efficiency of this process, the transgene will often incorporate into multiple genomic 
loci of a single organism (Ivics et al., 2014).  In the case of multiple transgene incorporations 
an additional outcrossing step is necessitated.  The transgenic animals are bred with 
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wildtype animals and screened for those offspring who possess the transgene at only one 
locus, this can be a very time consuming process (Ivics et al., 2014).    
Transfection with lentiviral vectors is another commonly used method of generating 
transgenic animals (Hofmann et al., 2003).  Lentiviruses have the ability to incorporate their 
own genes into the host’s genome (Goff and Berg, 1976).  This feature of lentiviruses is 
exploited in molecular biology, where genes of interest can be inserted into the lentivirus and 
then incorporated into the genome of the prospective animal model.  This method has 
previously been used to insert genes into early zebrafish embryos (Kawasaki et al., 2009). 
Clustered regularly interspaced short palindromic repeats (CRISPR) technology, is a 
recently developed tool which is used in the generation of model animals (Jinek et al., 2012).  
A synthetic guide RNA molecule is used to direct the endonuclease CRISPR associated 
protein 9 (cas9) to a specific genetic locus which is then cleaved by cas9 (Jinek et al., 2012).  
CRISPR therefore allows highly specific removal of short lengths of DNA and can be used to 
efficiently generate knockout mutations of specific genes (Auer and Del Bene, 2014, 
Lebedeva et al., 2017).  After cas9 cleavage, but before DNA ligation, additional genes can 
also be incorporated at the cleavage locus, as so CRISPR can be used to knockout or insert 
genes, allowing generation of both knockout and transgenic animal models with this 
technique (Kimura et al., 2014).  A disadvantage of the CRISPR-cas9 system is that off-
target cleavage events may occur, the frequency and loci of off-target cleavage events is 
unpredictable, thus making off target cleavages difficult to detect (Sander and Joung, 2014).  
CRISPR-cas9 has previously been used to modify the genome of zebrafish (Auer and Del 
Bene, 2014, Lebedeva et al., 2017). 
A further commonly used method of generating transgenic animals is by the use of 
pluripotent stem cells.  Genes of interest can first be inserted into the pluripotent cells using 
one of the aforementioned methods (e.g. homologous recombination).  The pluripotent cells 
can then be inserted into a developing wildtype embryo at the blastocyst stage (Doetschman 
et al., 1987, Thompson et al., 1989).  Pluripotent stem cells have a high capacity for self-
renewal and are capable of contributing to a large proportion of the developing embryo 
including contributing to cells in all three germ layers, and incorporating successfully into the 
germline (Bradley et al., 1984, Beddington and Robertson, 1989).  The chimeric animal is 
then bred, and if the pluripotent cells gave rise to a portion of the germ line this will result in a 
proportion of the offspring being full transgenic animals.   
Zebrafish are frequently used as model animals of multiple diseases (Bradford et al., 2017).  
The predominant method of generating transgenic zebrafish is by microinjection, which is 
likely due to the fact that the zebrafish offers several specific advantages with this technique 
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but fewer advantages with others.  The constantly improving efficiency and specificity of 
CRISPR-cas9 techniques indicates that in the near future a large proportion of zebrafish and 
other animal models may well be generated using CRISPR. 
 
1.11. Zebrafish as model organisms 
Zebrafish have been used as a research tool since the 1960s, and following their genetic 
characterisation have become a widely used in the modelling of human diseases (Streisinger 
et al., 1981, Howe et al., 2013, Bradford et al., 2017).  The following section describes the 
development of zebrafish post-fertilisation and identifies the advantages and disadvantages 
of their use as model organisms. 
Following fertilisation, zebrafish development begins rapidly and the yolk of the egg cell 
provides nourishment for the first five days (Fraher et al., 2016).  However, the yolk is an 
extraembryonic structure and will not form any of the developing zebrafish tissues (Kimmel 
et al., 1995).  All tissues of the zebrafish arise from the yolk free cytoplasm which begins to 
segregate immediately after fertilisation. At 24 hours post-fertilisation (hpf), early 
developmental versions of many organs are now visible and diverse cellular morphogenesis 
is occurring throughout the embryo (Kimmel et al., 1995).  Also, at this time,  spinal motor 
axons have grown into the myotomes and formed functional connections (Kimmel et al., 
1988). As functional motor neuron connections have been formed, it is possible to 
commence electrophysiological studies in the zebrafish motor system from 24hpf onwards.  
Thus early motor unit formation makes zebrafish amenable to studying motor pathologies.   
In comparison to zebrafish, functional neuromuscular junctions in rodents are not observed 
until approximately 12 days post-fertilisation (dpf) (Lin et al., 2000).  In addition to longer 
developmental periods, study of mammalian embryos is further complicated by the nature of 
in utero development, as embryos must be extracted from the uterus of the parent prior to 
any investigations being possible.  In the case of DNA micro injection when attempting to 
generate transgenic mice, the chimeric embryos must also be re-implanted into the uterus of 
the parent mouse.  As the zebrafish embryo develops externally, the simplicity of carrying 
out microinjections, and therefore generating transgenic animals, is greatly increased.  The 
minimum generation time in zebrafish is 2 months, this is similar to the generation times of 
both rats and mice, therefore transgenic zebrafish lines can be produced reasonably 
efficiently (Humphreys et al., 1976, Lambert, 2009, Lawrence et al., 2012).  Another 
advantage of using zebrafish as model animals is that the zebrafish genome has been fully 
sequenced and approximately 70% of human genes have at least one zebrafish orthologue 
(Howe et al., 2013).  Generation of transgenic animals often involves the addition of DNA 
(often a fluorescent reporter gene) which incorporates into the zebrafish genome.  In 
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zebrafish most tissues are optically clear which greatly aids in florescence, and other types 
of detailed microscopy.  A further benefit of using zebrafish as a model system stems from 
their relatively small size.  During the first few days of life zebrafish are only a few millimetres 
in length and can therefore be conveniently placed into multi-well plates.  This makes 
zebrafish very efficient when used in assays where a high throughput is required, such as 
during in vivo drug screening (McGown et al., 2013).  Owing to their rapid development, 
short generation time, externally developing embryos, well characterised genetics, optically 
clear tissues, small size and comparatively low maintenance costs, zebrafish offer unique 
advantages when used as animal models of disease.   
As expected, there are also disadvantages to the use of zebrafish in modelling human 
diseases.  Evolutionarily, zebrafish are further removed from humans than other typical 
mammalian lab animals such as mice and rats.  Therefore there is an expectation that a 
greater proportion of human disease genes may be lacking or have a modified function in 
the zebrafish genome.  Indeed, during evolutionary history zebrafish underwent a gene 
duplication event which did not occur in mammals (Meyer and Schartl, 1999, Taylor et al., 
2003).  Duplicate genes in the zebrafish may possess redundant functions which could 
potentially complicate the use of zebrafish in research, in particular the use of zebrafish in 
gene knockout studies (Force et al., 1999).  One example of the zebrafish genome 
duplication causing unexpected complications was in the study of the TARDBP gene.  
TARDBP is a human gene encoding the TDP-43 protein, mutations in TARDBP are linked 
with the eventual development of human motor neuron disease (Kabashi et al., 2008, 
Sreedharan et al., 2008).  Upon knockout of the zebrafish orthologue of TARDBP, it was 
discovered that no motor phenotype developed.  Later it was discovered this was due to a 
second gene in the zebrafish genome which coded for a truncated version of TDP-43, which 
upon knockout of TARDBP was able to produce a novel splice variant which functionally 
replaced TDP-43 (Hewamadduma et al., 2013).  This is one example of how variations 
between zebrafish and human genomes can cause unforeseen problems when attempting to 
generate models of disease.  Additional complications when using zebrafish as models of 
human disease may stem from fundamental anatomical and physiological differences 
between the two species.  For example, zebrafish muscle is polyneuronally innervated, 
whereas in humans each myotome receives innervation from a single motor neuron 
(Westerfield et al., 1986).  Additionally, zebrafish motor neurons exhibit a markedly higher 
capacity for regeneration in comparison with human motor neurons (Reimer et al., 2009).  
Clearly these two factors may cause unforeseen complications when using zebrafish to 
model human motor system disorders.  It is therefore vital to ensure that data generated in 




1.12. Zebrafish as models of neurodegenerative disorders 
Zebrafish are utilised in labs worldwide as model organisms of wide-ranging diseases.  The 
exact reasons for using zebrafish as a model animal vary depending on the disease being 
studied.  However, a common reason zebrafish are used is due to their remarkable ability to 
regenerate damaged tissues.  Zebrafish have a very high regenerative capacity, and unlike 
humans, retain their ability to activate regenerative pathways in all tissue types through to 
adulthood (Reimer et al., 2009).  To date, zebrafish have been used in the study of multiple 
diseases including heart disease, liver disease, vascular disease, cancer and many 
neurodegenerative disorders (Liu and Leach, 2011, Wilkins and Pack, 2013, Wilkinson et al., 
2014, Wilkinson and van Eeden, 2014).  Zebrafish are commonly used to model disorders of 
the central nervous system, among these are zebrafish models of Alzheimer’s disease, 
Parkinson’s disease and spinal muscular atrophy (Bretaud et al., 2007, Boon et al., 2009, Pu 
et al., 2017).   
Alzheimer’s disease results in progressive cognitive impairment and memory dysfunction, 
eventually leading to severe disturbances in speech, perception and normal social 
functioning (Forstl and Kurz, 1999).  In its most advanced stages, Alzheimer’s disease 
results in patients becoming bedridden and incapable of caring for themselves until 
eventually dying from an external cause, frequently due to infection (Forstl and Kurz, 1999).  
Alzheimer’s disease is caused by neurodegeneration in regions of the parietal, temporal and 
frontal lobes, as well as in sub-cortical regions such as the locus coeruleus (Wenk, 2003, 
Braak and Del Tredici, 2012).  Alzheimer’s disease molecular pathology is characterised by 
the presence of hallmark abnormal proteins, these are intracellular neurofibrillary tangles 
composed of hyper-phosphorylated tau protein (tau proteins are encoded by the MAPT 
gene) and extracellular aggregates of misfolded β-amyloid protein (β-amyloid proteins result 
from proteolytic cleavage of the APP protein) (Goedert et al., 1988, De Strooper et al., 1998, 
Blennow et al., 2006).  A small proportion of Alzheimer’s cases (<1%) are known to have a 
monogenic aetiology due to mutations in amyloid precursor protein (APP), presenilin 1 
(PSEN1) or presenilin 2 (PSEN2) genes, collectively these genes are responsible for the 
majority of familial Alzheimer’s disease (Scheuner et al., 1996, Robinson et al., 2017).  
However, the vast majority of Alzheimer’s cases are referred to as sporadic and are caused 
by complex interactions between disease genes and environmental factors (Robinson et al., 
2017).  In zebrafish, knockdown of the PSEN1 or PSEN2 genes causes abnormal brain 
development and deficits in neuronal functioning (Nornes et al., 2003, Nornes et al., 2009).  
Additionally, knockdown of PSEN1 in zebrafish larvae results in cognitive defects, increased 
β-amyloid deposition and reduced expression of synaptic marker protein PSD-95 (Nery et 
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al., 2017).  Transgenic zebrafish expressing a mutant human APP gene, displayed amyloid 
deposition and angiopathy in the brain, which eventually lead to neurodegeneration (Pu et 
al., 2017).  Similarly, transgenic zebrafish expressing a pathogenic human MAPT gene 
(MAPT-P301L) displayed the hyper-phosphorylated and aggregated tau protein 
characteristic of human Alzheimer’s disease (Paquet et al., 2009).  In the same study, the 
mutant human tau expressing zebrafish model was used to screen thousands of potentially 
therapeutic compounds, one of which one was found to powerfully inhibit a tau kinase which 
contributes to hyper-phosphorylation (Paquet et al., 2009).  Thus, zebrafish models of three 
major familial Alzheimer’s disease genes (APP, PSEN1 and PSEN2), recapitulate some 
aspects of human Alzheimer’s disease pathology including the hallmark deposition of β-
amyloid protein in the brain. 
Parkinson’s disease is primarily characterised by motor symptoms including bradykinesia, 
resting tremor, postural instability and muscle rigidity (Sveinbjornsdottir, 2016).  However, 
Parkinson’s disease can eventually result in non-motor symptoms such as cognitive decline, 
psychiatric symptoms, neuropathic pain and sleep disorders (Moreno et al., 2012, Kalia and 
Lang, 2015).  The primary molecular hallmark of Parkinson’s disease is the presence of 
intracellular inclusions of the α-synuclein protein, often termed Lewy bodies, or Lewy 
neurites, for cell body and neural process inclusions respectively (Spillantini et al., 1997, 
Goedert et al., 2013).  Notably, Parkinson’s disease patients possessing mutations in LRKK2 
or homozygous/compound heterozygous PRKN mutations frequently do not possess Lewy 
body pathology (Poulopoulos et al., 2012).  This has led some to hypothesise that soluble α-
synuclein oligomers, or other misfolded protein species may also be important in Parkinson’s 
disease pathogenesis (Kalia and Lang, 2015).  Parkinson’s disease can be caused by 
autosomal dominant mutations in the genes SNCA (encodes α-synuclein) and LRKK2, or by 
autosomal recessive mutations in genes such as PRKN, PINK1 and DJ-1 (Kalia and Lang, 
2015).  Zebrafish models of Parkinson’s disease most commonly involve silencing of one of 
the zebrafish orthologues of the above mentioned genes.  The ventral diencephalon of the 
zebrafish brain contains dopaminergic neurons which are analogous to the dopaminergic 
neurons of the mammalian nigrostriatal pathway (Rink and Wullimann, 2002).  LRKK2 
knockdown in zebrafish resulted in neurodegeneration which included dopaminergic neuron 
loss (Prabhudesai et al., 2016).  Similarly, knockdown of the PRKN orthologue in embryonic 
zebrafish caused substantial and selective loss of dopaminergic neurons, and reduced 
activity of complex I of the mitochondrial respiratory chain (Flinn et al., 2009).  Loss of 
dopaminergic neurons and reduced complex I activity, are both features typical of human 
Parkinson’s disease (Schapira et al., 1990, Haas et al., 1995, Kalia and Lang, 2015).  Two 
independently generated models in which the zebrafish orthologue of PINK1 was knocked-
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down, resulted in neurodevelopmental impairment (Anichtchik et al., 2008, Xi et al., 2010).  
Additionally, knockout of the PINK1 gene in zebrafish caused dopaminergic neuron loss and 
deficiencies in mitochondrial complex I and III activities (Flinn et al., 2013).  Furthermore, 
knockdown of TigarB (the zebrafish orthologue of human TIGAR) led to rescue of both 
mitochondrial dysfunction and dopaminergic neuron loss in PINK1 null zebrafish (Flinn et al., 
2013).  Intriguingly, the TIGAR protein has previously been identified as a component of 
Lewy bodies and Lewy neurites in human Parkinson’s disease patients (Lopez et al., 2019).  
Loss of PINK1 signalling has also been pharmacologically rescued in zebrafish models by 
utilising drugs which help restore mitochondrial calcium homeostasis or autophagy 
functioning (Soman et al., 2017, Zhang et al., 2017).  Finally, knockdown of DJ-1 in zebrafish 
did not result in dopaminergic neuron loss (Bretaud et al., 2007).  However, when DJ-1 
knockdown zebrafish were exposed to a second stressor, such as oxidative stress or 
proteasomal inhibition, significant loss of dopaminergic neurons was observed (Bretaud et 
al., 2007).  Taken together, these studies indicate that zebrafish models of multiple genetic 
sub-types of Parkinson’s disease recapitulate the dopaminergic neuron loss associated with 
human disease, and have aided in identifying potential therapeutic targets and compounds. 
The clinical presentation of spinal muscular atrophy (SMA) varies widely.  Type I SMA 
typically results in paralysis and death at under 2 years old, whilst type II SMA results in the 
inability to walk during childhood and typically causes death after 2 years old, whereas types 
III and IV SMA result in milder motor symptoms and death during adulthood (Lunn and 
Wang, 2008, Ibrahim et al., 2012).  Greater than 95% of SMA cases are caused by 
homozygous mutations of the SMN1 gene, while the remaining cases are caused by 
mutations of 32 other causative SMA genes (Brzustowicz et al., 1990, Farrar and Kiernan, 
2015).  In the case of SMN1 mutation related SMA, reduced expression of the SMN protein 
causes selective degeneration of spinal and cranial motor neurons (Lefebvre et al., 1997, 
Lunn and Wang, 2008).  Human SMN protein functions as an RNA binding protein (Fallini et 
al., 2012).  The zebrafish SMN protein shares 52% homology with the human SMN protein 
and also possesses RNA binding activity (Bertrandy et al., 1999).  Three independently 
generated SMN1 knockdown zebrafish models showed defects in axonal outgrowth and 
branching (McWhorter et al., 2003, Chitramuthu et al., 2010, Powis et al., 2016).  
Furthermore, the expression of the proteasome associated protein UBA1 was decreased in 
SMA-patient induced motor neurons, this reduced UBA1 expression was also mirrored in 
SMN1 knockdown zebrafish, and co-injection of UBA1 mRNA rescued the abnormal axonal 
outgrowth and axonal branching phenotype of these zebrafish (Powis et al., 2016).  
Zebrafish that are homozygous for knockout of the SMN1 gene display abnormal 
neuromuscular junction structure and die during the larval stage of development (Boon et al., 
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2009).  Using the same SMN1 knockout zebrafish, it was identified that loss of SMN protein 
expression caused a severe reduction in the expression of the plastin 3 protein, and that 
partial rescue of plastin 3 expression was sufficient to rescue the neuromuscular junction 
defects of SMN1 knockout zebrafish (Hao le et al., 2012).  Humans possess an additional 
SMN protein encoding gene named SMN2, this gene is capable of producing small amounts 
of functional SMN protein (Mailman et al., 2002).  Conversely, zebrafish do not possess an 
SMN2 gene, and consequently, homozygous knockout of the SMN1 gene in zebrafish 
ablates all SMN encoding genes from the genome, a genotype which is not representative of 
human SMA (Rochette et al., 2001).  In an attempt to rectify this inconsistency between 
human and zebrafish biology, the human SMN2 gene was expressed in the background of 
an SMN1 null zebrafish (Hao le et al., 2011).  Transgenic expression of human SMN2 in 
SMN1 null zebrafish delayed onset of neuromuscular junction defects and extended survival 
(Hao le et al., 2011).  Hence, expression of the SMN2 gene reduced disease severity 
caused by SMN1 gene loss in zebrafish, as is also the case in human SMA (Mailman et al., 
2002, Jedrzejowska et al., 2009).  Thus, the SMN protein plays an important role in motor 
neuron development and survival in both humans and zebrafish. 
In summary, these studies indicate that there is a disease relevant overlap between 
zebrafish and human neurobiology, which led to zebrafish models providing mechanistic 
insights, therapeutic targets and potential treatments for human diseases.  The disease 
relevant overlap applied to neurodegenerative disorders affecting multiple brain regions, 
motor specific brain regions and motor neuron specific disorders, as evidenced by the 
successful generation of zebrafish models of Alzheimer’s disease, Parkinson’s disease and 
SMA respectively. 
 
1.13. Zebrafish as models of amyotrophic lateral sclerosis 
Multiple models of known ALS causative disease genes have been generated in zebrafish 
using a variety of techniques.  ALS has been modelled in zebrafish by overexpression of 
ALS genes, by expression of physiological levels of mutant ALS genes, and by 
knockdown/knockout of ALS genes.  Current zebrafish models of ALS are outlined below.     
There are multiple mutations in Cu-Zn superoxide dismutase 1 (SOD1) that have been 
identified in ALS patients (Rosen et al., 1993, Elshafey et al., 1994).  Mutant SOD1 RNA 
injected into zebrafish at the 2-4 cell stage results in dose dependent defects in motor 
neuron outgrowth (Lemmens et al., 2007).  Motor axon outgrowth defects were consistently 
observed upon injection of RNA from G93A, G37A or A4V mutant SOD1 variants (Lemmens 
et al., 2007).  Intriguingly, co-expression of wildtype SOD1 and A4V mutant SOD1 caused 
more severe axonal outgrowth defects than expression of A4V mutant SOD1 alone 
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(Lemmens et al., 2007).  A further two independently generated mutant SOD1 RNA injection 
zebrafish models, also reported axonal outgrowth defects at 2 dpf (Sakowski et al., 2012, 
Robinson et al., 2018).  In addition to transient mutant SOD1 zebrafish, germline mutant 
SOD1 zebrafish have also been generated.  Overexpression of the G93A SOD1 mutation 
variant in transgenic zebrafish caused neuromuscular junction defects by 30 weeks post-
fertilisation and motor neuron loss at 40 weeks post-fertilisation (Sakowski et al., 2012).  
Similarly, transgenic overexpression of the human G93R mutant SOD1 gene in zebrafish 
caused defects in the structure of neuromuscular junctions, reduced swimming endurance, 
evidence of motor neuron loss and reduced life expectancy (Ramesh et al., 2010).  Using 
the same G93R model zebrafish, it was identified that a sub-populations of spinal 
interneurons begins to show stress response activation before any detectable motor neuron 
abnormalities were observed (McGown et al., 2013).  The discovery that interneuron 
dysfunction precedes motor neuron dysfunction led the authors to the hypothesis that both 
mutant SOD1 protein pathology and loss of interneuron innervation may contribute to motor 
neuron injury (McGown et al., 2013).  There are, however, potential drawbacks when 
overexpressing mutant SOD1 in zebrafish, firstly because the expression levels of mutant 
SOD1 may be significantly higher than would occur endogenously, and secondly because 
expression of both copies of wildtype zebrafish SOD1 may mask any potential loss of 
function caused by SOD1 mutations.  In order to address these potential drawbacks, an 
additional SOD1 zebrafish model was generated using the targeting induced local lesions in 
genomes (TILLING) genome editing technique to generate zebrafish expressing a 
pathological T70I mutation in the endogenous SOD1 zebrafish gene (Da Costa et al., 2014).  
Neither heterozygous nor homozygous T70I mutation of endogenous zebrafish SOD1 
affected overall SOD1 protein expression levels in comparison to wildtype zebrafish (Da 
Costa et al., 2014).  Physiological expression levels of T70I mutant SOD1 protein caused 
abnormal neuromuscular junction formation, spinal motor neuron loss and motor impairment 
in homozygous zebrafish (Da Costa et al., 2014).   
Mutations in the TARDBP gene (encoding TDP-43 protein) are a known cause of ALS 
(Kabashi et al., 2008).  Overexpression of mutant TARDBP transcripts, or TARDBP 
morpholino mediated knockdown in zebrafish, both resulted in motor axonopathies and 
defects in touch evoked escape response at 2 dpf (Kabashi et al., 2010).  Moreover, 
TARDBP knockdown induced motor axon and touched evoked escape response defects 
could be rescued by co-injection of wildtype but not mutant TARDBP transcripts (Kabashi et 
al., 2010).  A further independently generated zebrafish model, identified that overexpression 
of wildtype or mutant TARDBP caused defects in motor axon outgrowth and increased 
axonal branching, axonal defects caused by mutant TARDBP overexpression could be 
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rescued by co-expression of human progranulin (Laird et al., 2010).  In another 
independently generated zebrafish model, mutant TARDBP or mutant FUS expression 
induced motor axonopathies, which were again rescued by co-expression of human 
progranulin (Chitramuthu et al., 2017).  Mutations in the GRN gene which encodes 
progranulin are a known cause of frontotemporal dementia (Baker et al., 2006, Cruts et al., 
2006).  Progranulin has known functions in cell survival and immune signalling among 
various others functions (Ryan et al., 2009, Zhu et al., 2013).  Intriguingly, overexpression of 
human progranulin also rescued motor axon truncation and branching defects in SMN1 
knockdown zebrafish models of spinal muscular atrophy (Chitramuthu et al., 2010).  
Zebrafish homozygous for a TARDBP null mutation were viable to adulthood and did not 
show significant motor axonopathies when examined at 36 hpf (Hewamadduma et al., 2013).  
Zebrafish possess an additional gene named TARDBPL which encodes a truncated variant 
of the TDP-43 protein, TARDBP knockout precipitated alternative splicing of the TARDBPL 
pre-mRNA which led to the production of a novel mRNA transcript and novel TDP-43-like 
protein, this novel protein was termed TARDBPL-FL (Hewamadduma et al., 2013).  
Morpholino mediated knockdown of TARDBP-FL expression in TARDBP null zebrafish, 
caused axonal outgrowth defects at 36 hpf and death in the early larval stage of 
development, suggesting that TARDBP-FL was at least partially replacing TDP-43 
functionality (Hewamadduma et al., 2013).  Additionally, an independently generated 
TARDBP null zebrafish model confirmed that TARDBP knockout did not result in significant 
motor axonopathy at 30 hpf, and this was also confirmed to be due to at least partial 
functional replacement of TDP-43 by TARDBP-FL generated through a novel splicing event 
(Schmid et al., 2013).  Furthermore, knockout of both TARDBP and TARDBPL genes 
caused motor axon outgrowth defects at 28 hpf, muscle degeneration at 2 dpf and death in 
the early larval stage of development (Schmid et al., 2013). 
Mutations in the RNA-binding protein FUS also cause ALS (Kwiatkowski et al., 2009, Vance 
et al., 2009).  Both knockdown of the ALS associated gene FUS, and over expression of 
mutant FUS in zebrafish, resulted in deficits in the touch evoked escape response and 
impaired motor axon outgrowth (Kabashi et al., 2011).  Importantly in FUS knockdown 
zebrafish, defects in escape response and motor axon outgrowth were rescued by co-
injection of wildtype human FUS mRNA, but not with co-injection of mutant human FUS 
mRNA (Kabashi et al., 2011).  Moreover, knockdown of TARDBP expression also resulted in 
defects in touch evoked escape response and motor axon outgrowth, and these deficits 
were rescued upon co-injection of wildtype FUS RNA (Kabashi et al., 2011).  Conversely 
deficits caused by FUS knockdown could not be rescued by wildtype TARDBP expression, 
suggesting that FUS may act downstream of TDP-43 (Kabashi et al., 2011).  Similarly, 
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expression of mutant FUS, or FUS knockdown in zebrafish, caused early swimming defects 
and defects in transmission across neuromuscular junctions (Armstrong and Drapeau, 
2013).  FUS knockdown phenotype in these zebrafish could be partially rescued by co-
injection of wildtype FUS, but not by co-injection of mutant FUS (Armstrong and Drapeau, 
2013).  Despite FUS knockdown in zebrafish causing an early motor phenotype, stable 
CRISPR mediated ablation of FUS in zebrafish did not result in defects in motor axon 
formation or touch evoked escape responses at 2-3 dpf (Lebedeva et al., 2017). 
ALS causative mutations have also been identified in the SQSTM1 gene which encodes the 
autophagy associated p62 protein (Fecto et al., 2011).  Morpholino-mediated knockdown of 
the zebrafish orthologue of SQSTM1 resulted in defective axonal outgrowth and reduced 
total swimming distance when measured at 2 dpf (Lattante et al., 2015).  Co-injection of 
wildtype SQSTM1 RNA, but not mutant SQSTM1 RNA, was sufficient to partially rescue both 
axonal outgrowth and swimming defects observed upon SQSTM1 knockdown (Lattante et 
al., 2015). 
To date, multiple gain of function and loss of function zebrafish models of C9orf72-ALS have 
been generated.  Loss of function of endogenous zebrafish C9orf72 gene products was 
sufficient to induce a motor phenotype in two out of three reported models (Ciura et al., 
2013).  See section 1.7.1 for a full outline of evidence supporting loss of function toxicity in 
C9orf72-ALS, including the contributions of zebrafish models.  Zebrafish models of gain of 
function toxicity have identified that C9orf72 expansion expression is sufficient to induce 
apoptosis and result in reduced survival of zebrafish (Lee et al., 2013, Ohki et al., 2017).  
Additionally, gain of function C9orf72 zebrafish models have shown that although DPR 
species are likely more toxic than RNA species, both RNA and DPR species may contribute 
to toxicity via independent mechanisms (Ohki et al., 2017, Swinnen et al., 2018).  See 
sections 1.7.2 and 1.8 for a full outline of evidence supporting gain of function toxicity in 
C9orf72-ALS, including the contributions of zebrafish models.  In summary, zebrafish models 
of multiple ALS disease genes have successfully recapitulated features of human ALS.  
Although, current C9orf72 zebrafish models have mainly focussed on elucidating the 
pathomechanisms or specific toxic species which underlie C9orf72-ALS, rather than utilising 
zebrafish as screening tools for potential therapeutic compounds. 
 
1.14. Aims 
Zebrafish models represent an excellent tool for studying neurodegenerative diseases.  At 
the time of the initiation of this project, no stable genetic C9orf72 zebrafish models had been 
created.  We proposed to take full advantage of the unique characteristics of the zebrafish 
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which make it useful as a vertebrate drug screening tool.  Additionally, investigation of 
common proteinopathies in ALS (outlined in section 1.5) has identified abnormal protein 
species which are observed across multiple ALS sub-types, therefore representing a 
potential therapeutic target which could benefit multiple ALS sub-types simultaneously.  
Taking the above points into consideration, the primary aims of the current study are detailed 
below: 
1. To generate stable transgenic C9orf72 expansion model zebrafish lines, and to 
characterise their molecular and phenotypic hallmarks in order to assess whether 
they recapitulate features of human C9orf72-ALS. 
2. To develop C9orf72 expansion model zebrafish lines into a validated drug screening 
paradigm. 
3. To discover common pathological species between C9orf72-ALS and sALS by 
examining neuropathological tissue. 
 




2. Chapter 2: Materials and methods 
2.1. Materials 
2.1.1. Antibodies 
The antibodies used in the work throughout this thesis are listed in table 2.1. 
IHC: immunohistochemistry, AR: antigen retrieval 
 
2.1.2. RNA probes 
To detect sense foci (in 5.3 zebrafish lines) RNA probes with sequence (CCCCGG)3 were 
utilised.  To detect antisense foci (2.2 zebrafish lines) RNA probes with sequence 
(GGGGCC)3 were utilised.  Both RNA probes have a 5’ conjugation to the fluorophore 
TYE563 and are locked nucleic acids.  Both probes were obtained custom made from 
Exiqon, and were used at a final concentration of 40nM. 
 
2.1.3. Home office approval and zebrafish husbandry 
Project license approval was obtained from the home office under the title “Aquatic models 
of human neurological disease” (PPL No. 70/8058).  A zebrafish specific personal license 
was also obtained from the home office (PIL No. ICCB97EFC).  Adult, larval and embryonic 
zebrafish were maintained at the University of Sheffield zebrafish facility at 28°C and bred 
according to established procedures (Westerfield, 2000).  All animal experiments were 
conducted in accordance with the Animals (Scientific Procedures) Act 1986. 
 
Table 2.1: List of antibody information 
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2.1.4. Human samples 
Ethical approval for use of human frozen brain samples and human fixed brain samples was 
reviewed by the Sheffield Brain Tissue Bank Management Board, and approval to release 
tissue under REC 08/MRE00/103 was granted.  See table 2.2 for a summary of patient 
information from frozen and fixed human samples used.  In C9-ALS patients, the presence 
of >30 G4C2 expansions was confirmed by repeat primed PCR as part of the clinical 
protocol.  However, the clinical protocol did not include estimation of expansion length by 
southern blotting, therefore expansion length data was not available for patients listed in 
table 2.2. 
Diagnosis Gender Age Use 
Post mortem 
interval 
Cause of death 
Patient 
code 
C9-ALS M 48 IB 23 ALS 6 
C9-ALS F 69 PC/IB 55 ALS 7 
C9-ALS M 72 PC/IB 96 ALS 8 
C9-ALS F 62 PC/IB 63 ALS 9 
C9-ALS F 64 PC/IB 24 ALS 10 
C9-ALS F 67 PC/IB 24 ALS 17 
C9-ALS F 53 PC 48 ALS n/a 
C9-ALS F 58 PC 2 ALS n/a 
C9-ALS F 59 PC 28 ALS n/a 
C9-ALS F 64 PC 7 ALS n/a 
C9-ALS F 66 PC 10 ALS n/a 
C9-ALS M 46 PC 4 ALS n/a 
C9-ALS M 57 PC - ALS n/a 
C9-ALS M 59 PC 72 ALS n/a 
C9-ALS M 64 PC 48 ALS n/a 
C9-ALS M 67 PC 38 ALS n/a 
C9-ALS M 68 PC 31 ALS n/a 
Control M 84 IB 72 wm damage 1 
Control F 63 PC/IB 22 - 2 








Control M 58 IB 24 pontine haemorrhage 5 
Control F 59 PC/IB 5 Pneumonia 15 
Control M 47 IB 15 - 16 




Control F 61 PC - - n/a 
Control F 76 PC - - n/a 
Control F 82 PC - - n/a 
Control F 87 PC 14 myocardial infarct n/a 
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Control M 40 PC - - n/a 
Control M 51 PC - - n/a 
Control M 70 PC - - n/a 
Control M 72 PC 31 - n/a 
sALS F 64 IB 27 ALS 11 
sALS M 79 IB 48 ALS 12 
sALS F 69 IB 12 ALS 13 
sALS M 40 IB 96 ALS 14 
sALS M 60 IB 9 ALS 18 
sALS F 46 IB 20 ALS 19 
Table 2.2: Human CNS tissue sample information 
Patient codes are also listed next to the relevant sample in western blot and dot blot figures 
so that sample pathology may be linked with patient information.  Patient codes are not listed 
for samples only used in Purkinje cell counts.  F: female, M: male, PC: Purkinje cell counting, 
IB: immuno blotting, - indicates unknown information 
2.2. Methods 
2.2.1. Generation and sequencing of GC rich DNA constructs (performed by Adrian 
Higginbottom and Tennore Ramesh respectively) 
The GGGGCC hexanucleotide repeat gene was generated by first annealing two primers 
with sequence: forward, 5’-TCGAC(GGGGCC)10-3’ and reverse 5’-TCGA(CCCCGG)10-3’.  
Due to the high propensity of GC rich DNA to form secondary structures, a long annealing  
protocol was required in which the annealing temperature is reduced from 95°C to 40°C, in a 
stepwise manner at 5°C/hour.  The annealed primers were then ligated overnight at 16°C 
with standard T4 DNA ligase (New England Biolabs).  The ligation mix was then run on a 1% 
agarose gel and multiple bands representing varying lengths of polymerised primers were 
cut out and purified.  The maximum hexanucleotide repeat length obtained by this method 
was 99 repeats.  The 99 hexanucleotide repeats were then ligated, at both 5’ and 3’ ends, to 
adaptors containing a BsrGI restriction endonuclease site.  BsrGI sites were then 
endonuclease cleaved using the BsrGI restriction enzyme (New England Biolabs) and 
ligated into a construct containing the remaining transgene sequence.  As BsrGI sites were 
present at both 5’ and 3’ DNA ends, this would allow the GC rich insert to ligate in either 
sense (G4C2) or antisense (C4G2) orientations.  DNA constructs were then transformed in 
chemically competent E.coli cells (5-Alpha Competent E. coli, New England Biolabs) by 
incubating for 30 seconds at 32°C.  Bacterial colonies were then grown overnight on 
carbenicillin treated agar plates at 37°C.  A few colonies were picked for each DNA construct 
and grown overnight in 3ml of LB broth at 37°C.  Plasmid DNA constructs were then purified 
from the E. coli using a Miniprep Kit (Qiagen).  GC rich DNA expansions are known to be 
unstable in E. coli so both sense and antisense constructs were sequenced to confirm the 
presence of the hexanucleotide expansion.  In the construct containing the sense 
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orientation, the full 99 G4C2 repeats were confirmed to be present by DNA sequencing 
(Figure 3.1a; see Appendix B for full transgene sequence).  However, in the antisense 
orientation DNA sequencing was not able to read through the entire GC rich region, 
therefore only 89 C4G2 repeats were confirmed to be present (Figure 4.1a; see Appendix C 
for full transgene sequence). 
 
 
2.2.2. Transgene construct 
The expression of GFP, a hexanucleotide repeat expansion (HRE) and an auxin inducible 
degron (AID) gene was driven by a zebrafish ubiquitin promoter (Mosimann et al., 2011), a 
kind gift from Henry Roehl.  In the case of the sense orientation HRE (5.3 zebrafish lines) a 
stop codon was formed after GFP and before the hexanucleotide repeats (Figure 3.1a).  In 
the case of the antisense orientation HRE (2.2 zebrafish lines) a stop codon was formed 
after the HRE but before the AID gene (Figure 4.1a).  The protein product of the AID gene 
becomes ubiquitinated and therefore targeted for proteasomal degradation selectively in the 
presence of auxin.  We planned to exploit this system to selectively degrade the GFP-DPR 
fusion protein, however due to technical difficulties of working with an HRE, the AID gene 
could not be cloned in frame with the GFP and HRE in any of our constructs.  Further 3’ of 
the AID gene, is a DsRed gene driven by a heat shock protein 70 (HSP70) promoter, 
functioning as a fluorescent reporter of generalised cellular stress (Ramesh et al., 2010).  
Flanking both 5’ and 3’ of the transgene regions described above, are I-SceI meganuclease 
restriction sites. 
 
2.2.3. Zebrafish strains used 
All transgenic zebrafish used in the present study, and all non-transgenic zebrafish used as 
controls, were from the AB zebrafish strain.  All subsequent generations of transgenic 
zebrafish were generated by breeding with zebrafish from the AB strain. 
 
2.2.4. Generating transgenic zebrafish (performed by Tennore Ramesh) 
DNA plasmid was digested with ISceI and the transgene containing fragment was purified 
and placed in solution with 1X concentration digestion buffer, 1 U/ml of ISceI, Phenol Red 
and 1X injection buffer (10 mM Tris-HCl, pH 7.5, 0.1 mM EDTA, 100 mM NaCl, 30 µM 
spermine and 70 µM spermidine) to a final concentration of DNA ranging from 80-100 ng/µl.  
DNA solution was then injected into early one-cell stage embryos in a 1nl volume (within 5 
minutes of fertilisation).  At 48 hpf the injected embryos were placed into 96 well PCR plates 
and heat shocked (30 minutes at 37°C followed by 30 minutes at 28°C, for three cycles) in a 
standard thermocycler.  Heat shocking robustly increases hsp70 promoter mediated 
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production of DsRed, thus allowing easy identification of transgenic zebrafish.  Heat shocked 
embryos were examined for DsRed florescence at 72 hpf under a fluorescence microscope 
and highly chimeric embryos showing DsRed expression in a large proportion of their tissues 
were kept and grown to adulthood.  Chimerism was determined by visually examining which 
tissue types expressed the transgene according to visible DsRed fluorescence (GFP 
florescence was also used if visible), zebrafish which showed transgene expression in at 
least muscle, heart and eye tissue were considered to be highly chimeric.  The chimeric 
adult zebrafish (F0s) were outcrossed with AB zebrafish and their resulting offspring were 
screened for transgene expression using the same heat shocking-DsRed expression method 
described above.  Any full transgenic offspring (F1s) identified during the screens were 
separated from their siblings and grown to adulthood.  F1 zebrafish could then be 
outcrossed to AB zebrafish to give rise to an individual transgenic line. 
 
2.2.5. In Situ Hybridisation (with assistance from Adrian Higginbottom) 
At 10 dpf, zebrafish were terminally anaesthetised and then fixed in 4% paraformaldehyde in 
phosphate buffered saline (PBS) overnight at 4°C.  Fixed zebrafish were then washed three 
times in PBS for 5 minutes per wash.  Zebrafish were processed for paraffin embedding in a 
tissue processor and then embedded for longitudinal sectioning in paraffin.  Paraffin 
embedded tissue blocks were sectioned at 10µm and dewaxed by 5 minute sequential 
immersions in each of the following solutions - xylene 100%, xylene 100%, ethanol 100%, 
ethanol 95%, ethanol 70% and dH2O.  Dewaxed sections were then incubated in 150µl of 
pre-hyb buffer (50% formamide, 300mM NaCl, 30mM trisodium citrate dihydrate, 10% 
dextran sulphate, 20mM monobasic sodium phosphate and 30mM dibasic sodium 
phosphate) for 1 hour at 66°C.  A 5’TYE563 conjugated oligonucleotide-probe (for antisense 
foci: 5’-GGGGCCGGGGCCGGGG-3’; for sense foci: 5’-CCCCGGCCCCGGCCCC-3’, 
Exiqon) was diluted in pre-hyb buffer (40nM probe) and the sections were incubated with 
150µl of the probe-hyb buffer over night at 66°C.  Sections were then washed for 10 minutes 
at room temperature with the first wash buffer (300mM NaCl, 30mM trisodium citrate 
dihydrate and 0.1% Tween20), then washed three times for 10 minutes each at 66°C in the 
second wash buffer (15mM NaCl and 1.5mM trisodium citrate dihydrate).  Slides were then 
nuclei stained with Hoechst, mounted in Vectashield and imaged using confocal microscopy 
(TCS SP5II, Leica Microsystems) as described previously (Cooper-Knock et al., 2014). 
 
2.2.6. Immunohistochemistry 
Zebrafish were terminally anaesthetised in 4% tricaine solution and fixed in 4% 
paraformaldehyde at 4°C ON.  Tissue was then embedded in paraffin blocks and sectioned 
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at 5µm using a microtome (RM2245, Leica Microsystems).  Antigen retrieval was carried out 
by gradually heating the sections in a pressure cooker to 125°C while immersed in either 
Access Revelation buffer (pH 6.4, A.Menarini diagnostics) or Access Super RTU buffer (pH 
9.5, A.Menarini diagnostics).  Sections were then washed three times in PBDT (1% dimethyl 
sulfoxide, 0.5% triton X100, 1% bovine serum albumin in phosphate buffered saline) for 15 
minutes per wash, at RT.  Following this, normal goat serum (NGS) was added to PBDT 
(final concentration 0.1% NGS) and the tissue sections were blocked in this solution for one 
hour.  Sections were then incubated in primary antibody at 4°C ON (see materials section for 
antibody manufacturers and dilutions).  The following day, embryos were washed six times 
in PBDT for 15 minutes per wash and incubated in secondary antibody at 4°C ON.  The next 
day, embryos were washed six times in PBDT for 15 minutes per wash, nuclei stained with 
Hoechst and mounted in Vectashield.  Sections were then imaged by confocal microscopy 
(TCS SP5II, Leica Microsystems).  
 
2.2.7. Western blots  
Human cerebellum or motor cortex samples were ground to powder in liquid nitrogen prior to 
lysing.  For adult zebrafish tissue, brain and spinal cord were dissected from deeply 
anaesthetised and decapitated zebrafish and flash frozen in liquid nitrogen.  Laemmli buffer 
(4% SDS, 10% 2-mercaptoethanol, 20% glycerol, 0.00004% bromophenol blue and 0.125M 
Tris-HCl pH6.8) was added to either human or zebrafish tissue at a ratio of 10µl:1mg of 
tissue.  The samples were then sonicated at 25% power for three rounds of 10s each, with 
30s cooling on ice between each round (Vibra-Cell, Sonics).  Samples were then boiled at 
95°C for 10 minutes, no centrifugation was performed. 
To obtain protein lysates from embryonic (<5.2 dpf) zebrafish, embryos were first terminally 
anaesthetized in 4% tricaine solution, then all media was carefully removed and Laemmli 
buffer was added at a volume of 2µL per embryo.  Samples were then lysed and stored as 
described above. 
The equivalent of 1mg tissue (frozen tissue mass) of protein lysate was separated on a 10% 
tris SDS-polyacrylamide gel for one hour at 110V, protein was then transferred to a poly-
vinylidene difluoride membrane at 110V for 1.5 hours.  The membrane was then blocked for 
one hour using 5% milk in tris buffered saline with 0.1% Tween20 (TBST), before primary 
antibody diluted in blocking buffer was added overnight at 4°C (see Table 2.1 for antibody 
manufacturers and dilutions).  Following this, the membranes were washed three times in 
TBST for 10 minutes per wash, before a secondary HRP conjugated antibody diluted in 
blocking buffer was added for 90 minutes.  Membranes were now washed a further three 
times in TBST for 10 minutes per wash.  Membranes were imaged by incubating with 2ml of 
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EZ-ECL chemiluminescent HRP enzyme substrate (biological industries) for one minute 
before being captured as a sub-saturating image using a G:box imaging system (Syngene).  
Membranes were re-probed using a different species primary antibody by first incubating in 
0.01% sodium azide in blocking buffer for 1 hour, and then proceeding with addition of 
primary antibody as described above. 
 
2.2.8. Embryonic spontaneous locomotor behaviour 
At 5 dpf zebrafish were placed into individual wells of a 96well plate in 200µl aquarium 
water.  The zebrafish were then habituated in in the dark for 10 minutes before a light 
stimulus was turned on for a duration of 10 minutes.  Following this, the light stimulus was 
turned off and zebrafish activity was recorded for 10 minutes under dark conditions, this light 
–dark cycle was repeated once more for 2.2-7 zebrafish experiments, and twice more for 5.3 
zebrafish experiments.  Only activity under dark conditions was used in the analysis.  All 
dark activity periods were combined together before calculating average speed and total 
distance moved values.  Time spent swimming at different speeds was also calculated using 
the flowing speed thresholds: slow (0<x<5mm/sec), intermediate (5<x<15mm/sec) and fast 
(x>15mm/sec).  Recordings were carried out using ZebraBox software (ViewPoint Behaviour 
Technologies). 
 
2.2.9. Embryonic centre avoidance behaviour 
At 5 dpf zebrafish were placed into a 6 well plate at a density of 30 zebrafish per well, in a 
volume of 3ml aquarium water.  After a 30 minute habituation period with the lights on, the 
lights were turned off the moment recording began.  Lights were off for 5 minutes then on for 
5 minutes for 6 cycles.  Beginning at 30 seconds after the lights were turned on, a frame was 
pulled out every minute using the Imagegrab tool, and this was repeated for each of the 6 
lights on periods.  Using ImageJ, circles of the same size were placed around the outside of 
every well so that only the centre of the well was visible, the % of zebrafish present in the 
centre of the well was then blind counted for every image and the average per well was 
calculated. 
 
2.2.10. Developmental analysis of transgenic zebrafish 
To obtain fertilised zebrafish eggs, adult zebrafish pair mates were placed into breeding 
tanks separated by a divider and left overnight.  The following morning the dividers were 
removed and the eggs were collected 2-3 hours later, thus ensuring that all of the zebrafish 
included in the assay were of a similar developmental stage.  In order to standardise water 
quality conditions a water change was performed in the morning immediately following 
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collection of eggs, another water change was performed in the afternoon and again the 
following morning.  At 5 dpf zebrafish were placed into 2L of fresh water and a partial water 
change of roughly 350ml was carried out every day until 13 dpf at which point a constant 
flow of fresh water was applied to the tank.  The zebrafish were genotyped and counted at 
24hpf.  Any zebrafish embryos which were malformed or had died before this point were not 
included in the assay.  The zebrafish were again genotyped and counted at 5 dpf and 15 
dpf. 
 
2.2.11. Weighing zebrafish 
Adult zebrafish were deeply anaesthetised in 4% tricaine solution, before being gently dried 
using a paper towel, zebrafish were then weighed in groups of 5 using a fine lab balance. 
 
2.2.12. Swim tunnel and adult spontaneous locomotor behaviour 
Zebrafish were not fed the day of the swim tunnel test and were allowed to acclimatise to the 
testing room for one hour.  Zebrafish were individually placed into a 1” diameter swim tunnel 
chamber initially with no water flow.  The water flow was then increased in 2L/min 
increments every 5 minutes (for 2-3 month old 5.3-9 zebrafish flow was increased at 1L/min 
every 10 minutes) until the maximum flow rate of 11.6L/min was achieved.  For experiments 
using 2.2 zebrafish a wider 1.5” swimming chamber was used due to a lack of availability of 
the swimming chamber used in 5.3 zebrafish experiments.  Zebrafish that stopped swimming 
during the test were allowed to briefly recover at 4L/min with the timer paused.  Once the 
zebrafish began to swim again the flow was again increased to the rate at which the 
zebrafish previously failed, and the timer was started again once the flow rate had returned.  
Once a zebrafish either stopped swimming twice or successfully swam at 11.6L/min for 5 
minutes, it was removed from the chamber and placed into a recovery tank.  After 5 minutes 
in the recovery tank each zebrafish was placed into a behaviour monitoring tank and 
spontaneous swimming behaviour was monitored for 30 minutes using a camera linked to 
ZebraLab software (ViewPoint Behaviour Technologies).  Average speed and total distance 
moved were then calculated for each individual zebrafish.  Time spent swimming at different 
speeds was also calculated using the following speed thresholds: slow (x<60mm/sec), 
intermediate (60<x<120mm/sec) and fast (x>120mm/sec). 
 
2.2.13. Motor neuron counts and myotome measurements 
Zebrafish body segments just anterior to the pelvic fin were first fixed in 4% 
paraformaldehyde in PBS overnight at 4°C.  Body segments were then washed three times 
in PBS for 5 minutes per wash.  Zebrafish body segments were then decalcified by 
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incubating in 0.5M EDTA solution for 1 week. Body segments were then processed for 
paraffin embedding before being embedded for transverse sectioning in paraffin.  Body 
segments were cut at 10µm thickness and dewaxed by 5 minute sequential immersions in 
each of the following solutions - xylene 100%, xylene 100%, ethanol 100%, ethanol 95%, 
ethanol 70% and dH2O.  Following this, sections were stained with haematoxylin and eosin 
(H&E) by immersion in haematoxylin (1 minute), tap water rinse, 1% acid alcohol (1 minute), 
tap water rinse, Scott’s tap water (30 seconds), tap water rinse, eosin (5 minutes) and a final 
tap water rinse.  Sections were then dehydrated by short immersions in ethanol 70%, 
ethanol 95% and ethanol 100% before being cleared in xylene and mounted in DPX.  Cells 
with a soma size >75µm2 and within 25,000µm2 proximity of the central canal were 
designated as motor neurons.  Three sections were counted per animal, by two independent 
blinded investigators.  The two independent scores were averaged to give the final score for 
each animal. 
The area of each individual body muscle myotome was measured by a blinded investigator 
from 6 images per animal.  All muscle images were obtained from the epaxial muscle region 
just lateral from the dorsal spinal bone.  Any myotome which was incomplete due to being 
partially out of frame was not included in the analysis. 
 
2.2.14. Heat shock cell stress drug screening assay 
At 2 dpf, transgenic zebrafish were removed from the chorion and placed into a 96 well plate 
in 200µl of drug or DMSO containing E3 zebrafish media.  No water changes or additional 
dosing was performed.  At 5 dpf zebrafish embryos were individually placed into the well of a 
V-bottom 96 well plate in 50µl of 4% tricaine solution.  Each well was sonicated for 10s at 
25% power, before the plate was centrifuged at 3000rpm for 10 minutes, 20µl of supernatant 
was then added to a 384 well plate.  The 384 well plate was measured in a microplate 
reader (PHERAstar FSX, BMG Labtech), and both DsRed fluorescence (540nm 
excitation/590nm emission; 1399 gain) and GFP fluorescence (485nm excitation/520nm 
emission; 1865 gain) were quantified.  This method was also used in 5 dpf zebrafish to 
obtain GFP and DsRed levels for comparison.  
 
2.2.15. Embryonic drug injections 
Immediately following fertilisation zebrafish embryos were placed into an injection mould in a 
small volume of E3 zebrafish media.  Injections were carried out using a thinly pulled hollow 
glass pipette (make) attached to a Pneumatic PicoPump (World Precision Instruments).  
Approximately 1-2nl of drug or DMSO (diluted to appropriate concentration in E3 zebrafish 




2.2.16. Dot blots 
Human motor cortex or cerebellum tissue was ground to powder in liquid nitrogen, and lysis 
buffer (4% SDS, 10% 2-mercaptoethanol, 20% glycerol, 0.00004% bromophenol blue and 
0.125M Tris-HCl pH6.8) was added at a ratio of 10µl:1mg of tissue before the samples were 
briefly homogenised with an electric homogeniser.  20µl of each sample was vacuum drawn 
onto a PVDF membrane and immunoblotted for tubulin as a loading control.   A second dot 
blot was then prepared using the previous tubulin loading control to adjust the required 
volume of each sample to ensure equal loading.  Each sample was diluted to a total volume 
of 400µl in PBS, before being divided into two 200µl aliquots immediately before being 
vacuum drawn onto a PVDF membrane.  By splitting samples into two aliquots, duplicate 
membranes were generated to allow immunoblotting with two different sets of antibodies.  
Immunoblotting was carried out according to the same protocol descried for western blotting 
in section 2.2.7.  The first duplicate membrane was immunoblotted with an anti-tubulin 
antibody and after treatment with sodium azide (to avoid signal cross over between 
antibodies of different species), was then immunoblotted for poly(PR).  The second duplicate 
membrane was immunoblotted with an anti-poly(GA) antibody followed by sodium azide 
treatment and immunoblotting for anti-poly(GP).  Sub-saturating images were captured using 
a G:box imaging system (Syngene).  As the membranes used were duplicates (derived from 
the same sample preparation), the same tubulin image was used as a loading control for 
poly(PR), poly(GA) and poly(GP) images. 
 
2.2.17. Larval drug dosing 
At 1 dpf zebrafish were genotyped and placed into a 6 well plate containing either drug or 
DMSO in E3 zebrafish medium (30 zebrafish per well).  Daily changes of 50% drug or 
DMSO containing E3 media were carried out.  At 5 dpf, zebrafish were transferred to a 1.2L 
tank in 100ml of drug/DMSO media.  An equal volume of drug/DMSO media was added to 
the tank daily.  Once the water level in the tank had reached 800ml, the media was strained 
until 200ml was remaining and then equal volumes were added daily again.  At 15 dpf 
zebrafish were removed from the tank and terminally anaesthetised in 4% tricaine solution, 
and then frozen at -80°C to later be used for western blotting.  Any zebrafish which became 
sick during the course of the experiment were removed from the tank and terminally 




2.2.18. Purkinje cell counts 
Human cerebellum was formalin fixed and processed for paraffin embedding before being 
sectioned coronally at a thickness of 5µm.  To ensure a similar anatomical region was used 
in each patient, only sections containing a portion of the dentate gyrus were used.  Dentate 
sections were then dewaxed by 5 minute sequential immersions in each of the following 
solutions - xylene 100%, xylene 100%, ethanol 100%, ethanol 95%, ethanol 70% and dH2O.  
Following this, sections were stained with haematoxylin and eosin (H&E) by immersion in 
haematoxylin (1 minute), tap water rinse, 1% acid alcohol (1 minute), tap water rinse, Scott’s 
tap water (30 seconds), tap water rinse, eosin (5 minutes) and a final tap water rinse.  
Sections were then dehydrated by short immersions in ethanol 70%, ethanol 95% and 
ethanol 100% before being cleared in xylene and mounted in DPX.  Whole mounted H&E 
stained slides were then automatically imaged at 40X zoom using a NanoZoomer Digital 
slide scanner (Hamamatsu).  Images were visualised using the NDP view software 
(Hamamatsu), where the Purkinje cell layer was traced until either 200 Purkinje cells or 1 
entire slide had been counted.  The number of cells counted was then divided by the 
distance of Purkinje layer over which the cells were distributed, to give an average value of 
Purkinje cells per mm for each patient.  Only Purkinje cells where the nucleolus was visible 
were counted, to ensure that cell would not influence the dataset. 
 
2.2.19. Statistical analysis and definition of n number used 
For adult and embryonic zebrafish behaviour experiments, each individual zebrafish was 
considered as one n number.  Zebrafish in each group were derived from a minimum of 
three independent clutches unless otherwise stated. 
For continuous datasets comparing two groups, normality was assessed using the Shapiro-
Wilk test.  Non-normally distributed data were compared using the Mann-Whitney U test.  
Normally distributed data were further assessed for homogeneity of variance using the F 
test.  When variance was equal, datasets were compared using the unpaired t test.  
However, when variance was not equal unpaired t test with Welch’s correction was used. 
For continuous datasets comparing a single factor across more than two groups, normality 
was assessed using the Shapiro-Wilk test.  Normally distributed data were compared using a 
one-way ANOVA.  Non-normally distributed data were compared using the Kruskal-Wallace 
test.  For continuous datasets comparing two factors across two or more groups a two-way 
ANOVA was used.  Correlation between two datasets was analysed using Pearson 
correlation coefficient.  Survival type data was analysed using the log-rank test. 
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Discrete data were analysed using a Chi-squared test for trend.  For all figures in this 




3. Chapter 3: RNA-only zebrafish exhibit no ALS phenotype 
3.1. Introduction 
Although previous studies in zebrafish and drosophila have convincingly demonstrated that 
DPR proteins are generally more toxic than RNA foci, the contribution of each to cellular 
stress has thus far only been determined by generic readouts such as neurodegeneration 
and reduced viability (Lee et al., 2013, Mizielinska et al., 2014, Tran et al., 2015, Ohki et al., 
2017).  It is also important to accurately quantify the amount of cellular stress through simple 
molecular readouts, as this can allow early detection of the cell stress which precedes 
neurodegeneration or death (McGown et al., 2013).  Furthermore, although 
neurodegeneration and loss of viability are good quality readouts, simple molecular readouts 




In order to address the above points, we aimed to generate two sets of transgenic zebrafish.  
One set of zebrafish would express only RNA foci (without ATG-driven DPRs) and the other 
set of fish would express both RNA foci and ATG-driven DPR proteins.  Both sets of 
zebrafish would also have a tandem drug screening fluorescence reporter readout as used 
previously to successfully screen drugs in a SOD1-ALS zebrafish model (McGown et al., 
2013).  The two sets of zebrafish could therefore be used to identify the relative toxicity of 
RNA foci and DPR, and also screen for drugs which aid in alleviating this toxicity.  Chapter 3 
focuses on the generation and characterisation of RNA-only zebrafish. 
 
3.3. C9orf72 expansion RNA-only transgenic zebrafish express hallmark RNA foci 
At the single cell stage wildtype zebrafish of the AB strain were nuclear injected with a 
C9orf72 expansion containing construct (figure 3.1a).  Expression of GFP and C9orf72 
expansion RNA is driven by a zebrafish ubiquitin promoter.  The C9orf72 expansions used in 
this construct were interrupted (GGGGCC)99 hexanucleotides (strings of G4C2 repeats 
interrupted by TCGAC linkers).  Specifically, the C9orf72 expansion sequence used was: 
(G4C2)12-TCGAC-(G4C2)17-TCGAC-(G4C2)10-TCGAC-(G4C2)22-TCGAC-(G4C2)17-TCGAC-
(G4C2)9-TCGAC-(G4C2)12 (see Appendix B for the full transgene sequence).  The presence 
and size of the expansion was confirmed by DNA sequencing prior to injection.  Further 3’ of 
the C9orf72 expansion is the sequence of an auxin inducible degron (AID) gene.  The AID 
gene was initially included in this construct as a control for its expression in DPR producing 
transgene constructs discussed later (see section 4.3 for a full explanation of the uses of the 




Figure 3.1: RNA-only 5.3 model zebrafish display RNA foci 
(a) Schematic representation of the transgene inserted into 5.3 zebrafish.  A zebrafish 
ubiquitin promotor drives GFP expression, but a stop codon prevents translation of all 
sequence downstream from GFP.  A hsp70 promotor then drives DsRed production as a 
read out of cellular stress.  (b) In situ hybridisation of paraffin embedded sections of 10dpf 
5.3-9 zebrafish using a Cy3-conjugated (red) GC probe (CCCCGG)x4 showed that RNA 
foci are present in the nuclei of muscle cells. Yellow arrow heads denote RNA foci. Images 
are representative of 3 sections assessed from 3 individual zebrafish per group (not 
quantified). Scale bar = 10µm. 
 
beginning of the GFP gene and a stop codon was placed at the end of the GFP gene, thus 
ensuring that no ATG-driven DPRs are produced (all potential frames are not amenable to 
RAN-translation in this construct due to the presence of stop codons or lack of ATG-like 
initiation codons).  Thus, the ubiquitin promoter drives expression of GFP-C9orf72 
expansions-AID RNA, but only GFP is translated into protein, this is the disease gene 
component of the transgene construct.  Further 3’ of the disease gene is a hsp70 promoter 
driving expression of a DsRed gene, forming the drug screening portion of the DNA 
construct. NTG clutchmate zebrafish were used as controls for transgenics in all 
experiments as they provide the closest possible match for tank conditions, age and 
background genetics.  NTG zebrafish do not express non-disease gene elements of the 
transgene expressed in transgenic zebrafish (e.g. GFP and DsRed).  However, these genes 
have been widely used in zebrafish research and no toxicity has been reported through to 
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adult expression (Ju et al., 1999, Zhu and Zon, 2004, Ramesh et al., 2010, Blackburn et al., 
2011). 
In total approximately 500 zebrafish were injected with the RNA-only transgene construct.  
These zebrafish were referred to by the arbitrary term ‘5.3’ - these zebrafish will be 
henceforth be referred to as 5.3 zebrafish lines.  From those injected, 25 highly chimeric 5.3 
zebrafish were identified.  Chimerism was determined by visually examining which tissue 
types expressed the transgene (according to visible GFP or DsRed fluorescence).  Zebrafish 
which showed transgene expression in at least muscle, heart and eye tissue (indicative of 
early transgene integration into embryos) were considered to be highly chimeric.  These 
highly chimeric 5.3 zebrafish were grown to adulthood, then bred, and their offspring were 
screened for transgene expression by first heat shocking (see section 2.2.4 for details) and 
then examined for DsRed and GFP fluorescence under a fluorescence microscope.  Of the 
25 highly chimeric zebrafish, 7 gave rise to a proportion of full transgenic offspring.  
However, 2/7 exhibited extremely high transgene expression levels, and the offspring died 
within 5-7 dpf, thus preventing the establishment of a full transgenic line.  The remaining 5/7 
highly chimeric zebrafish gave rise to full transgenic offspring which were grown to adulthood 
and used to establish a full transgenic line.  From each of the 5 full transgenic 5.3 zebrafish 
lines, a few embryos were examined by eye under a fluorescence microscope to judge the 
strength of their fluorescence relative to one another.  High, middle and low expressing lines 
were selected for further examination, these lines were named 5.3-9, 5.3-5 and 5.3-6 
respectively.  As 5.3-9 demonstrated the highest transgene expression, this line was used 
for further characterisation.  Transgenic 5.3-9 embryos and their NTG clutchmates were 
grown to 10 dpf and then processed for in situ hybridisation to test whether RNA foci from 
the C9orf72 expansion could be observed.  Numerous GGGGCC orientation RNA foci were 
observed in muscle cells of the 5.3-9 zebrafish, but not in their NTG clutchmates (Figure 
3.1b).  A limitation of the RNA foci data is that zebrafish were obtained from a single clutch, 
ideally 3 or more zebrafish clutches should be studied so that variation in background 
genetics may be accounted for and statistical comparison may be applied.   
 
3.4. 5.3 zebrafish lines express GFP and DsRed 
It is important to determine how strongly the transgene is expressed in each line of 
transgenic fish as it is likely that the highest expressing zebrafish would be most likely to 
develop a phenotype, if indeed the transgene is conferring toxicity to the zebrafish.  The 
lines 5.3-9, 5.3-5 and 5.3-6 had already been identified as high, middle and low transgene 
expressers by eye.  However, a more quantitative measure of this was required.  For this 
reason, 5 dpf embryos from each of the aforementioned lines were lysed and individual GFP 
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and DsRed fluorescence values of each lysate were determined using a fluorescence plate 
reader.  GFP fluorescence was significantly higher in the 5.3-9 line as compared to both 5.3-
5 and 5.3-6 zebrafish lines (1.7x105 vs. 1.3x105 and 1.7x105 vs. 0.5x105 A.U. respectively; 
Figure 3.2a).  Additionally, 5.3-5 GFP fluorescence was significantly higher than that of 5.3-
6.  GFP fluorescence was used as a convenient readout for transgene expression at the 
protein level.  However, expression of the transgene was not examined at the DNA level 
(transgene copy number analysis) or RNA level (mRNA expression level analysis).  Similar 
patterns were observed when DsRed florescence was measured.  5.3-9 DsRed fluorescence 
was significantly higher than both 5.3-5 and 5.3-6 (1.3x105 vs. 1.2x105 and 1.3x105 vs. 
0.1x105 A.U. respectively; Figure 3.2b).  Additionally, 5.3-5 DsRed fluorescence was 
significantly higher than that of 5.3-6.  Although raw fluorescence values are an important 
measure of transgene expression levels, a better readout of average cell stress levels is 
given by the ratio of DsRed:GFP.  This is because DsRed protein levels can be influenced 
by the number of copies of the transgene present in each individual line, as well as by cell 
stress driving the hsp70 promoter.  Therefore, by normalising DsRed fluorescence levels to 
the GFP florescence levels of the same zebrafish, the influence of transgene copy number 
on DsRed fluorescence will be diminished, giving a more accurate representation of cell 
stress levels.  The DsRed:GFP ratio of 5.3-9 zebrafish was significantly higher than both 5.3-
5 and 5.3-6 zebrafish (0.78 vs. 0.23 and 0.78 vs. 0.12 respectively; Figure 3.2c).  
Interestingly, despite higher raw fluorescence values, the DsRed:GFP ratio of 5.3-5 
zebrafish was not significantly higher than that of 5.3-6 zebrafish. 
As 5.3-9 zebrafish showed significantly higher GFP, DsRed and DsRed:GFP ratio than the 
other 5.3 lines, it was considered that 5.3-9 zebrafish would be the most likely to develop a 
phenotype.  Therefore, the majority of subsequent phenotypic characterisation was 
conducted in the 5.3-9 zebrafish line.  In order to confirm that 5.3-9 zebrafish were producing 
GFP protein alone (i.e. no DPR species were being translated from the C9orf72 expansion), 
5 dpf embryos from the 5.3-9 zebrafish were lysed and western blotted.  Immunoblotting of 
5.3-9 embryonic lysates with an antibody against GFP revealed a single band at 25KDa, the 
exact expected size of the GFP protein (Figure 3.2d).  Both GFP and DsRed were also 
detectable by confocal imaging of endogenous fluorescence in 15dpf cryosectioned 5.3-9 
zebrafish (Figure 3.2e).  Although transgene driven expression of GFP was observed in 
muscle tissue of 15dpf cryosectioned 5.3-9 zebrafish, it was not clear whether GFP 





Figure 3.2: RNA-only 5.3 zebrafish lines express GFP and DsRed 
(a) At 5dpf, 5.3-9 zebrafish have significantly higher GFP fluorescence than both 5.3-5 and 5.3-6 
lines.  Additionally, 5.3-5 zebrafish have significantly higher GFP fluorescence than 5.3-6 zebrafish.  
N=9 5.3-9, 10 5.3-5 and 9 5.3-6 zebrafish, derived from a single clutch.  Statistical comparisons 
were carried out using a one-way ANOVA with Tukey’s post-hoc test.  (b) At 5dpf, 5.3-9 zebrafish 
have significantly higher DsRed fluorescence than both 5.3-5 and 5.3-6 lines.  Additionally, 5.3-5 
zebrafish have significantly higher DsRed fluorescence than 5.3-6 zebrafish.  N=9 5.3-9, 10 5.3-5 




3.5. GFP but not DPR proteins are expressed in adult 5.3-9 zebrafish brains 
ALS is primarily a neurological disease, it is therefore critical to determine whether 
expression of the RNA-only transgene is present in the zebrafish CNS.  For this reason, we 
lysed adult 5.3-9 zebrafish brains and western blotted them for GFP.  A GFP 
immunoreactive band was detected at the predicted molecular weight of GFP in the 5.3-9 
adult brain lysates, but not in those of NTG controls brain lysates (Figure 3.3a, top panel).  
GFP levels detected in the 5.3-9 zebrafish brain lysates were statistically significantly higher 
than those detected in the NTG controls (Figure 3.3b).  This demonstrates that the C9orf72 
expansion containing transgene is expressed in the CNS, despite the lack of an ALS-like 
phenotype being observed.  As shown previously at 5 dpf, GFP was detected at 25KDa, the 
expected size of the GFP protein, thus demonstrating that translation of the C9orf72 
expansion is prevented by the stop codon placed at the end of the GFP gene.  However, 
DPR species can be produced from C9orf72 expansions even in the absence of a start 
codon due to the phenomenon of RAN-translation.  Additionally, translation of RAN-
translated DPR species would be initiated in close proximity to the C9orf72 expansion and 
therefore would not allow for translation of GFP.  This means that RAN-translated DPRs 
would not be likely to be detected using a GFP antibody.  In order to assess whether RAN-
translated DPR proteins were being produced from the C9orf72 expansion, we probed 5.3-9 
adult brain lysates with antibodies against poly(GA) and poly(PA) DPRs.  Neither poly(GA) 
nor poly(PA) antibodies detected any specific protein bands in the 5.3-9 zebrafish brain 
lysates (Figure 3.3a, middle two panels).   
Previous validation of the poly(GA) antibody used here, identified that the poly(GA) antibody 
binds both human and recombinant poly(GA) protein, and showed minimal cross reactivity 
with all other DPR species (Gendron et al., 2015).  Similarly, the binding specificity of the  
was not normally distributed according to the Shapiro-Wilk test for normality, and was therefore 
statistically compared with the Kruskal-Wallis test with Dunn’s post-hoc test.  (c) At 5dpf, 5.3-9 
zebrafish have significantly higher DsRed:GFP ratio than both 5.3-5 and 5.3-6 lines.  N=9 5.3-9, 10 
5.3-5 and 9 5.3-6 zebrafish, derived from a single clutch.  This dataset was not normally distributed 
according to the Shapiro-Wilk test for normality, and was therefore statistically compared with the 
Kruskal-Wallis test with Dunn’s post-hoc test.  (d) At 5dpf, whole 5.3-9 zebrafish protein lysates 
produce a single GFP immunoreactive band at 25KDa (the exact size of the GFP protein).  (e) At 
15 dpf, 5.3-9 zebrafish produce GFP and DsRed.  The NTG zebrafish shown for comparison is 5 
dpf.  Transverse body sections.  Scale bar = 100µm.  Images are representative of 9 zebrafish 
imaged (not quantified).  All data are shown as mean +/- standard deviation; *P < 0.05 and ****P < 







 poly(PA) antibody used here has been validated previously in a western blot which showed 
that poly(PA) immunoreactive bands were detected only in lysates from poly(PA) expressing 
cells, and not in lysates of cells expressing any other DPR species (May et al., 2014).  
Hence, a lack of poly(GA) or poly(PA) antibody specificity is not likely to be the cause of the 
absence of 5.3-9 specific bands detected in adult brain lysates.  Thus, despite transgene 
expression being detectable in adult 5.3-9 brain tissue as shown by GFP production, no 
poly(PA) or poly(GA) containing DPRs are produced at detectable levels through 
conventional translation or RAN-translation.  Furthermore, muscle tissue from the  
same zebrafish was also western blotted and probed for GFP.  A GFP immunoreactive band 
was also detected at the predicted molecular weight of GFP protein in 5.3-9 adult zebrafish 
muscle tissue, but not in NTG controls (Figure 3.3c).  GFP levels in adult muscle tissue of 
5.3-9 zebrafish were statistically significantly higher than those in NTG control adult muscle 
tissue (Figure 3.3d).  No other GFP immunoreactive bands were detected in adult muscle 
zebrafish tissue, indicating that only GFP protein, and not GFP tagged DPRs are produced 
in this tissue.   
 
3.6. Embryonic 5.3-9 zebrafish show a mild hyperactivity phenotype 
In order to determine whether ALS-like locomotor defects were present in 5.3-9 embryonic 
zebrafish, spontaneous locomotor activity was monitored in 5 dpf embryos.  Swimming 
activity was monitored under dark conditions for 30 minutes, and average speed and total 
distance swam was calculated for each individual zebrafish.  Despite average speed being 
46% higher in 5.3-9 compared with NTG zebrafish, this increase did not reach statistical 
significance (Figure 3.4a).  Similarly, 5.3-9 zebrafish swam on average 45% further than  
Figure 3.3: Adult 5.3-9 zebrafish produce GFP, but not poly(GA) or poly(PA) DPRs 
(a) Adult 26 month old 5.3-9 zebrafish brains produced an immunoreactive band at 25KDa 
that is not present in any NTG lane, this is the predicted weight of the GFP protein. No 
5.3-9 specific bands could be detected with either poly(GA) or poly(PA) antibodies, all the 
bands shown for these antibodies are non-specific bands and are not DPRs. Poly(GA) and 
poly(PA) blots underwent long exposures to help identify any DPR proteins which may 
have been expressed at low levels.  (b) Quantification of GFP/tubulin levels in adult 5.3-9 
zebrafish brains.  Statistical comparison was carried out with an unpaired t-test.  (c) Adult 
26 month old 5.3-9 zebrafish muscle produces an immunoreactive band at 25KDa that is 
not present in any NTG lane, this is the predicted weight of the GFP protein.  (d) 
Quantification of GFP/tubulin levels in adult 5.3-9 zebrafish muscle.  Statistical comparison 





Figure 3.4: 5.3-9 zebrafish spend more time swimming at fast speeds 
(a) No difference is observed in the average speed of the 5.3-9 and NTG zebrafish over a 
30 minute recording period.  Statistical comparison was carried out using an unpaired t-
test.  (b) No difference is observed in the average speed of the 5.3-9 and NTG zebrafish 
over a 30 minute recording period. Statistical comparison was carried out using an 
unpaired t-test.  (c) No difference was observed in the time spent swimming at slow speed 
between 5.3-9 and NTG zebrafish over a 30 minute recording period. This dataset was not 
normally distributed according to the Shapiro-Wilk test for normality and was therefore 
statistically compared using the Mann-Whitney U test. (d) No difference was observed in 
the time spent swimming at intermediate speed between 5.3-9 and NTG zebrafish over a 
30 minute recording period. This dataset was not normally distributed according to the 
Shapiro-Wilk test for normality and was therefore statistically compared using the Mann-
Whitney U test. (e) 5.3-9 zebrafish spent significantly more time swimming at fast speeds 
in comparison to NTG zebrafish over a 30 minute recording period. This dataset was not 
normally distributed according to the Shapiro-Wilk test for normality and was therefore 
statistically compared using the Mann-Whitney U test. N=16 individual fish per genotype 
for all comparisons, zebrafish were derived from a single clutch. Speed thresholds used 
were slow (0<x<5mm/sec), intermediate (5<x<15mm/sec) and fast (x>15mm/sec).  All 
data were recorded under dark conditions and are shown as mean +/- standard deviation; 
ns: not significant and *P < 0.05. 
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 NTG zebrafish, however this difference also did not reach statistical significance (Figure 
3.4b).   
In order to analyse swimming behaviour in more detail, zebrafish swimming data were 
subdivided into time spent swimming at slow, intermediate and fast speeds.  No significant 
difference was observed in the amount of time 5.3-9 and NTG zebrafish spent swimming at 
slow or intermediate speeds (Figure 3.4c+d).  However, 5.3-9 zebrafish spent significantly 
more time swimming at fast speeds in comparison to NTG zebrafish (3.6 vs 1.7 seconds for 
5.3-9 and NTG zebrafish respectively; Figure 3.4e). 
Behavioural studies in embryonic zebrafish are known to generate highly variable data, this 
is at least in part due to the propensity of some embryonic zebrafish to not move for long 
periods of time (Liu et al., 2017).  For this reason, large numbers of zebrafish from multiple 
clutches are typically favoured in embryonic zebrafish behavioural experiments.  An 
important limitation of the behavioural data shown in figure 3.4, is that the zebrafish used 
were derived from a single clutch. 
 
3.7. Survival of 5.3-9 zebrafish is normal through to adulthood 
Production of DsRed in 5.3-9 zebrafish indicates activation of the hsp70 promoter.  
Activation of the hsp70 promoter suggests that RNA foci may be driving low level toxicity in 
5.3-9 zebrafish.  To assess whether the C9orf72 expansion and/or RNA foci were impacting 
upon the viability of zebrafish, we monitored survival of 5.3-9 zebrafish up to the early larval 
stage.  At both 5 dpf and 15 dpf no significant difference in survival was observed between 
5.3-9 zebrafish (mix of heterozygous and homozygous resulting from a 5.3-9 X 5.3-9 cross) 
and their NTG clutchmates (84 vs. 86% survival at 15dpf for 5.3-9 and NTG respectively; 
Figure 3.5a).  In order to assess whether toxicity derived from RNA foci may manifest over a 
long period of time, heterozygous 5.3-9 zebrafish survival was monitored into adulthood.    At 
26 months old, the survival of 5.3-9 zebrafish was slightly higher than that of their NTG 
clutchmates (55 vs. 53% survival for heterozygous 5.3-9 and NTG adults respectively; 
Figure 3.5b).  A limitation of these data is that all 3 clutches of fish were maintained in the 
same tank from 1dpf until 26 months old.  Therefore, rather than 3 separate values for 26 
months survival (1 value from each clutch), only a single survival value could be calculated 
(1 value from all three clutches combined).  For this reason statistical comparison of 5.3-9 
and NTG survival at 26 months was not possible.  Although there is no overt loss of viability 
in RNA foci expressing zebrafish up to 26 months, it is important to assess whether RNA foci 
may cause a sub-lethal ALS-like phenotype such as impairments in neuromuscular 





3.8.  Adult 5.3-9 zebrafish exhibit normal swimming endurance 
 Of the 5.3 zebrafish, the highest transgene expressing zebrafish (5.3-9) exhibit RNA foci 
pathology but do not show any overt reduction in survival when monitored well into 
adulthood.  It is therefore important to determine whether the 5.3-9 zebrafish exhibit a more 
subtle ALS-like phenotype such as impaired motor function.  To assess this, the swimming 
endurance of 5.3-9 zebrafish was measured using a swim tunnel setup.  At 2-3 months old, 
the swimming endurance of 5.3-9 zebrafish showed a small but non-significant reduction 
compared with their NTG clutchmates (98 vs. 100 minutes median swimming time for 5.3-9  
and NTG respectively; Figure 3.6a).  Only 4 fish of each genotype were tested at 2-3 
months old, before it was decided to wait until the 5.3-9 zebrafish were older and were more 
likely to display a clear phenotype.  During this time the protocol used in the swim tunnel was 
optimised to allow faster exhaustion of the zebrafish being tested.  For this reason the swim 
tunnel performance of the two age groups of 5.3-9 zebrafish tested are not directly 
comparable.  At 26 months old, 5.3-9 zebrafish were re-tested using the new swim tunnel  
 
Figure 3.5: 5.3-9 zebrafish have normal survival at 26 months old 
(a) Survival of 5.3-9 zebrafish is not significantly different from NTG clutch mates at 5dpf 
or 15 dpf.  N=4 clutches for each group.  Data were statistically compared using a two-way 
ANOVA with Sidak’s post hoc test.  (b) Survival of 5.3-9 zebrafish is similar to that of NTG 
clutchmates at 26 months old.  N=60 fish of each genotype at 1 dpf.  Data could not be 
compared statistically as survival was only assessed at a single time point, i.e. of the 60 
fish in each group at 1dpf, how many were still alive at 26 months old. All data are shown 





Figure 3.6: 5.3-9 zebrafish have normal swimming ability at 26 months olds 
(a) At 2-3 months old, swimming ability of 5.3-9 zebrafish was not significantly different 
from that of NTG clutchmates. N=4 fish per genotype.  Statistical comparison was carried 
out using the log-rank test.  (b) At 26 months old, swimming ability of 5.3-9 zebrafish was 
not significantly different from that of NTG clutchmates. N=11 fish per genotype. Statistical 
comparison was carried out using the log-rank test.  (c) At 26 months old, body mass of 
5.3-9 zebrafish was not significantly different compared to their NTG clutchmates.  N=11 
fish per genotype.  Statistical comparison was carried out using an unpaired t-test.  (d) At 
26 months old, body length of 5.3-9 zebrafish was not significantly different compared to 
their NTG clutchmates.  N=11 fish per genotype. Statistical comparison was carried out 










 protocol, but still showed no significant difference in swimming performance as compared 
with their NTG clutchmates (25 vs. 25 minutes median swimming time; Figure 3.6b).  To 
ensure that the swimming ability of zebrafish was not being influenced by body mass or body 
length, these factors were measured after removal from the swim tunnel.  Neither body mass 
nor body length was significantly different between 5.3-9 zebrafish and their NTG 
clutchmates (Figure 3.6c+d).   
 
 
3.9. The G-quadruplex unfolding drug TMPYP4 does not influence heat shock 
response activation 
Despite a lack of detectable DPR species, 5.3-9 zebrafish exhibit DsRed production as early 
as 5 dpf, as seen in figure 3.2.  One potential explanation for this is that RNA foci may 
directly or indirectly activate the hsp70 promoter and therefore drive DsRed production.  The 
expression of RNA foci was confirmed in 10 dpf 5.3-9 zebrafish (see figure 3.1), but not in 
adult 5.3-9 zebrafish.  GGGGCC RNA foci are formed by the GC-rich RNA molecules 
adopting G-quadruplex structures (Reddy et al., 2013).  To test whether G-quadruplex RNA 
foci formation can drive the heat shock response, we injected zebrafish with TMPYP4 which 
has previously been demonstrated to unfold G-quadruplex structures (Morris et al., 2012).  
First, preliminary injections were performed in NTG zebrafish immediately after fertilisation, 
in order to identify an appropriate injection dose.  Although some degree of toxicity was 
observed with every dose of TMPYP4 injected, 730 µM was selected as the dose to use in 
the injections of 5.3-9 zebrafish embryos, as it was the maximum dose which did not cause 
substantial death and abnormalities (30% death with 730µM injection vs 70% death with 
7300µM injection; Figure 3.7a).  Injections were then carried out in 5.3-9 zebrafish, where 
immediately after fertilisation embryos were injected with ultra-pure water (1nl), 730µM 
TMPYP4 (single dose, 1nl), 730µM TMPYP4 (double dose, 2nl) or left uninjected.  No 
significant difference was observed between any of the groups (Figure 3.7b).  It is important 
to note that we did not test whether TMPYP4 injection was sufficient to prevent RNA foci 
formation or block typical RNA foci interactions, in the 5.3-9 zebrafish. 
 
3.10. Discussion 
RNA-only zebrafish were generated through nuclear microinjection of transgenic DNA 
constructs.  The DNA constructs used did not contain transposable elements.  
Microinjections of this kind are often considered to be very laborious due to their predicted 
low rate of transgenesis.  However, a combination of spermine and spermidine containing 
injection buffer (keeps DNA in compact conformation) and pre-screening (by eye under a 
fluorescence microscope) for highly chimeric embryos, led to 28% (7/25) of chimeric  
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 zebrafish grown to adulthood giving rise to full transgenic offspring.  Not only does this 
method offer reasonable rates of transgenesis without the need to clone transposons into 
DNA constructs, but it also obviates the lengthy process of backcrossing zebrafish which is 
necessitated when transposable elements have caused transgene integration in more than 
one locus.  2/7 highly chimeric zebrafish showed severely reduced fertility and the few 
fertilised offspring died within the first few days.  The reason why these offspring show an 
embryonic lethal phenotype whereas 5.3-9 zebrafish have no detectable phenotype even 
during adulthood is not fully understood.  It has however, been reported previously that  
injection of C9orf72 expansion containing RNA can lead to toxicity even in the absence of 
DPR proteins (Swinnen et al., 2018).  Therefore there may be a threshold at which C9-
 
Figure 3.7: The G-quadruplex unfolding drug TMPYP4 does not influence heat 
shock response activation 
(a) When a 1nl volume was injected into the yolk sac of NTG zebrafish immediately after 
fertilisation, every concentration of TMPYP4 caused an increase in death compared with 
uninjected zebrafish.  The increase in death rates was markedly higher when 7300µM 
TMPYP4 was injected. 730µM was the highest dose which did not induce high death rates, 
so this was selected to be used in future injections with 5.3-9 zebrafish.  (b) No significant 
change in DsRed fluorescence was observed in 5.3-9 zebrafish when injected with H2O, or 
a single or double injection of 730µM TMPYP4, as compared to uninjected 5.3-9 zebrafish.  





expansion RNA will trigger an early lethal phenotype, but RNA levels below this threshold 
may be manageable over the long term. 
The 5.3-9 zebrafish line showed higher expression levels of GFP and DsRed, as compared 
to 5.3-6 and 5.3-5.  If GFP and DsRed expression levels were solely determined by 
transgene copy number then GFP and DsRed expression should increase in linear 
proportion to one another, and therefore GFP:DsRed ratios should be comparable across all 
5.3 zebrafish lines.  However, the DsRed:GFP ratio was higher in 5.3-9 zebrafish, indicating 
that DsRed production may be influenced by C9orf72 expansion expression levels.  
Additionally, 5.3-5 zebrafish showed significantly higher GFP and DsRed levels as compared 
to 5.3-6, though no significant difference was detected in the DsRed:GFP ratio.  This 
suggests that there may be an expression threshold required before C9orf72 expansions will 
result in hsp70 promoter activation and production of additional DsRed protein. 
No significant locomotor phenotype could be detected in embryonic zebrafish as measured 
by average speed or total distance covered, despite an approximate 45% increase in both 
measurements in 5.3-9 zebrafish.  However, a mild hyperactivity phenotype was detected in 
5.3-9 zebrafish when swimming at fast speeds.  All locomotor data obtained were highly 
variable, this is likely due to a combination of the relatively small sample size used and 
innate variability in zebrafish behaviour at this developmental stage (Liu et al., 2017).   A 
further limitation of these data is that the zebrafish used were obtained from a single clutch.  
Therefore, future experiments should repeat locomotor analysis with a further 2 clutches of 
zebrafish, ideally using a larger sample size, which may help reduce variation in the data. 
The 5.3-9 zebrafish did not show any early or late onset reduction in viability/survival.  
Additionally, 5.3-9 zebrafish did not show any underlying motor impairment as measured by 
swim tunnel testing during adulthood.  These 5.3-9 zebrafish showed GFP expression in 
CNS and muscle tissues during adulthood, but no detectable DPR species.  This is 
consistent with previous reports suggesting that a stop codon in close proximity to the 
C9orf72 expansion, combined with a lack of ATG-like codons upstream of the repeats, will 
effectively prevent the formation of RAN-translation products (Todd et al., 2013, Mizielinska 
et al., 2014, Green et al., 2017).  This suggests that expression of C9orf72 expansion RNA 
alone is not sufficient to induce toxicity at this age.  However, age is a known risk factor for 
ALS (Armon, 2003).  Survival, swim tunnel and DPR expression data were obtained from 
5.3-9 zebrafish at 26 months old.  Zebrafish mean life span typically ranges between 36 and 
42 months old depending on the strain (Gerhard et al., 2002).  Therefore, on average 5.3-9 
zebrafish may be expected to live 10-16 months longer, and should continue to be monitored 
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during this time to assess the role of aging on C9orf72 expansion pathogenicity in this 
zebrafish model.   
Early injection of 5.3-9 zebrafish with the proposed G-quadruplex unfolding molecule 
TMPyP4 (Morris et al., 2012), did not result in amelioration of the heat shock stress 
response.  It is important to note that it was not assessed whether TMPyP4 was able to 
enter the cell/nucleus, or whether indeed the molecule was able to unfold the secondary 
structure of RNA foci.  Accurately measuring these two factors in future experiments will be 
important to determine whether TMPyP4 can unfold the G-quadruplex structures formed by 
RNA foci and whether this may help reduce cellular stress. 
It will also be important to re-analyse tissue from any 5.3-9 zebrafish which develops a 
phenotype in the future, to test for the presence of DPR proteins so that the relative 
contribution of toxicity from RNA and DPR may be further assessed.  Finally, determining 
whether RNA foci or perhaps minute undetectable levels of DPRs are causing the heat 
shock mediated production of DsRed in the 5.3-9 zebrafish will help provide clues to the 
relative contributions to toxicity from these two species.
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4. Chapter 4: RNA+DPR zebrafish show ALS/FTD features 
4.1. Introduction 
Reports from drosophila models indicate that RNA foci expression in isolation results in no 
neurodegenerative phenotype (Mizielinska et al., 2014, Tran et al., 2015).  Zebrafish models 
expressing RNA foci have been reported to show a mild phenotype which is not indicative of 
ALS (cardiac oedema) (Ohki et al., 2017).  These findings are somewhat corroborated by 
data presented in chapter 3 of this thesis, showing that zebrafish expressing RNA foci do not 
develop any measurable ALS-like phenotype when studied well into adulthood.   
On the other hand, when DPR proteins are expressed, a previously reported zebrafish 
model shows a more severe form of the cardiac oedema phenotype and are no longer viable 
(Ohki et al., 2017).  Additionally, drosophila models expressing DPR proteins show a 
neurodegenerative phenotype (Mizielinska et al., 2014, Tran et al., 2015).  Whilst these 
studies are informative about the relative toxicities of RNA foci and DPR species, they do not 
accurately recapitulate an ALS phenotype.  Furthermore, stable BAC mouse models which 
do recapitulate an ALS-like phenotype are not amenable to high throughput drug screening 
(Jiang et al., 2016, Liu et al., 2016).  Therefore, there is currently a need for an in vivo model 
which can accurately recapitulate the ALS symptoms observed in human C9orf72 patients, 
and which can be used to efficiently test potential therapeutic compounds. 
 
4.2. Aims 
In order to address the above points, we aimed to generate C9orf72 expansion zebrafish 
expressing both RNA foci and DPR proteins.  These RNA+DPR zebrafish could then be 
used to both study the molecular pathology generated by DPR species, and identify 
therapeutic compounds which may alleviate DPR toxicity.  This chapter describes the 
generation and characterisation of RNA+DPR expressing zebrafish.   
 
4.3. C9orf72 expansion RNA+DPR transgenic zebrafish express hallmark RNA foci 
At the single cell stage wildtype zebrafish of the AB strain were nuclear injected with a 
C9orf72 expansion containing construct (figure 4.1a).  The constructs begins with a ubiquitin 
promotor which drives expression of a GFP gene and C9orf72 expansions (encoding a GFP-
DPR fusion protein).  The C9orf72 expansions used in this construct were interrupted 
(CCCCGG)89 hexanucleotides (strings of C4G2 repeats interrupted by GTCGA linkers).  89 
hexanucleotide repeats were counted, however more may be present as sequencing reads 
were not able to traverse the entire C9orf72 expansion.  Specifically, the C9orf72 expansion 




Figure 4.1: RNA+DPR 2.2 model zebrafish display RNA foci 
(a) Schematic representation of the transgene inserted into 2.2 zebrafish.  A zebrafish 
ubiquitin promotor drives GFP-DPR expression.  The AID gene is out of frame and a stop 
codon prevents it from being translated into protein.  A hsp70 promotor then drives DsRed 
production as a read out of cellular stress.  (b) In situ hybridisation of paraffin embedded 
sections of 10dpf 2.2-7 zebrafish using a Cy3-conjugated (red) GC probe (GGGGCC)x4 
showed that RNA foci are present in the nuclei of muscle cells. Yellow arrow heads denote 
RNA foci.  Scale bar = 5µm.  Images are representative of 6 body muscle sections 
assessed from 3 individual zebrafish per group.  (c) Blinded quantification of RNA foci in 
2.2 lines and NTG zebrafish muscle.  Quantified images were taken from 3 zebrafish (6 
sections were assessed for each group) from a single clutch per condition. 
 
GTCGA-( C4G2)12 (see Appendix C for full transgene sequence).  The presence of the 
C9orf72 expansion was confirmed by DNA sequencing prior to injection.  Further 3’ of the 
C9orf72 expansion is an AID gene.  Upon co-expression of the TIR1 protein and exposure to 
the plant hormone auxin, the AID protein can be utilised to target itself, and other proteins 
with which it is fused, for proteasomal degradation (Nishimura et al., 2009).  The AID gene 
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had been planned to encode the final portion of a GFP-DPR-AID fusion protein, which we 
hypothesised may allow for efficient proteasomal degradation of DPR species.  However, 
due to unforeseen cloning difficulties, the AID gene was out of frame with respect to the start 
codon for GFP in this construct, this generated a premature stop codon, which resulted in 
the entire AID gene not being translated into protein.  Thus, only a GFP-DPR fusion protein 
was encoded by this construct.  As the C9orf72 expansion prevents polymerase 
processivity, frame correction of the AID gene with standard cloning techniques was not 
possible.  It is possible that due to RAN-translation of all frames, some RAN-translated DPR-
AID fusion protein may be produced, however this is likely a small percentage of the total 
DPR protein, due to RAN-translation being significantly less efficient than ATG-mediated 
translation (Kearse et al., 2016).  Hence, AID mediated degradation of RAN-translated DPR-
AID proteins was not considered a worthwhile avenue to pursue further.  A start codon was 
placed at the beginning of the GFP gene and a stop codon was present at the end of the 
C9orf72 expansion.  Thus, from this construct GFP and the C9orf72 expansion will be 
translated into a GFP-DPR fusion protein.  The ubiquitin promoter driving GFP, C9orf72 
expansions and AID (not translated) is the disease gene component of the construct.  
Further 3’ of the disease gene is a hsp70 promoter driving expression of a DsRed gene, this 
forms the drug screening portion of the DNA construct.  For clarity, the 3 differences 
between the RNA-only construct used to generate the zebrafish described in chapter 3 and 
the RNA+DPR construct described here are: 1) C9orf72 expansions are of opposite 
orientation, G4C2 for RNA-only and C4G2 for RNA+DPR; 2) C9orf72 expansion length, 99 
confirmed repeats for RNA-only and 89 confirmed repeats for RNA+DPR; 3) The position of 
disease gene stop codon, after GFP for RNA-only (codes for GFP protein only) and after 
C9orf72 expansion for RNA+DPR (codes for GFP-DPR fusion protein).  The orientation of 
the repeats was reversed in RNA+DPR constructs due to the G4C2 expansions being too 
unstable in this context.  NTG clutchmate zebrafish were used as controls for transgenics in 
all experiments as they provide the closest possible match for tank conditions, age and 
background genetics.  NTG zebrafish do not express non-disease gene elements of the 
transgene expressed in transgenic zebrafish (e.g. GFP and DsRed) however these genes 
have been widely used in zebrafish research and no toxicity has been reported even when 
expressed throughout adulthood (Ju et al., 1999, Zhu and Zon, 2004, Ramesh et al., 2010, 
Blackburn et al., 2011).  Furthermore, 5.3 zebrafish also express transgene elements such 
as GFP and DsRed and do not exhibit ALS-like phenotypic alterations.  We therefore reason 
that it is highly unlikely that non-disease gene elements of the transgene contribute to the 




In total, approximately 500 zebrafish were injected with this RNA+DPR transgene construct.  
These zebrafish were referred to by the arbitrary term ‘2.2’.  These zebrafish will be 
henceforth be referred to as 2.2 zebrafish lines.  From those injected, 7 highly chimeric 2.2 
zebrafish were identified.  Chimerism was determined by visually examining which tissue 
types expressed the transgene (according to visible GFP or DsRed fluorescence).  Zebrafish 
which showed transgene expression in at least muscle, heart and eye tissue (indicative of 
early transgene integration into embryos) were considered to be highly chimeric.  These 
highly chimeric 2.2 zebrafish were grown to adulthood, then bred, and their offspring were 
screened for transgene expression by first heat shocking (see methods section for details) 
and then examined for DsRed and GFP fluorescence under a fluorescence microscope.  Of 
the 7 highly chimeric zebrafish, 3 gave rise to a proportion of full transgenic offspring.  
However, 1/3 exhibited extremely high transgene expression levels, and the offspring died 
within 5 dpf, thus preventing the establishment of a full transgenic line.  The remaining 2/3 
highly chimeric zebrafish gave rise to full transgenic offspring which were grown to adulthood 
and used to establish a full transgenic line.  The 2 separate zebrafish lines generated using 
the RNA+DPR transgene were arbitrarily named 2.2-2 and 2.2-7.  A few embryos from 2.2-2 
and 2.2-7 zebrafish lines were grown to 10 dpf and then processed for in situ hybridisation to 
test whether RNA foci from the C9orf72 expansion could be observed.  In a blinded analysis, 
50% (11/22) of muscle nuclei from 2.2-7 zebrafish contained foci, 30% (6/20) of 2.2-2 
zebrafish nuclei contained foci and only 4% (1/25) of NTG zebrafish nuclei contained foci 
(Figure 4.1b+c).  It is presumed, that the single focus observed in the NTG zebrafish was 
due to non-specific binding of the in situ probe.  For 2.2-2 and 2.2-7 zebrafish all foci 
observed were localised to the nucleus and only a single focus per nucleus was observed.  
A limitation of the RNA foci data is that zebrafish were obtained from a single clutch, ideally 
3 or more zebrafish clutches should be studied so that variation in background genetics may 
be accounted for and statistical comparison may be applied.  As it had now been confirmed 
that 2.2 zebrafish express RNA foci, the next step was to test whether these zebrafish also 
produced DPR species. 
 
4.4. Multiple DPR species and stress response activation can be detected in 
embryonic 2.2 zebrafish 
The various DPR species are known to have differential toxicity, with arginine rich species 
being considered the most toxic.  To investigate whether there is a relationship between 
molecular weight (MW) and species toxicity, western blot was performed on 5 dpf 2.2-2 and 
2.2-7 zebrafish lysates.  The transgene construct expressed in both 2.2-zebrafish lines 
causes the production of GFP tagged DPR proteins via canonical ATG (start codon) 
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dependent translation, these GFP tagged DPRs are produced from C4G2 transcripts and can 
be detected at 5 dpf (Figure 4.2a, top panel).  Interestingly, multiple GFP bands are 
detected in both the 2.2-2 and 2.2-7 zebrafish lines, and these bands were often unique to 
specific zebrafish lines.  It was noted that, across multiple clutches of 5 dpf zebrafish 
embryos (>10 different clutches) that 2.2-2 zebrafish express 5 major GFP tagged DPR 
bands with 3 being common (3 lowest MW) and 2 being unique (2 highest MW), and 2.2-7 
zebrafish express 6 major GFP tagged DPR bands with 3 being common and 3 unique (3 
highest MW).  The differential expression of DPRs between 2.2-2 and 2.2-7 zebrafish also 
holds true when probing for the DPR proteins directly (i.e. using antibodies which directly 
bind the dipeptide motifs).  Poly(PA), poly(PR) and poly(GP) bands are each detectable at 5 
dpf and are differentially expressed between 2.2-2 and 2.2-7 zebrafish lines (Figure 4.2a, 
middle three panels).  Probing with poly(PA), poly(PR) and poly(GP) antibodies also 
revealed that some DPR bands detected did not co-localise with any of the ATG-dependent 
translation bands detected when using the GFP antibody, thus suggesting that these bands 
are likely to be produced via non-canonical RAN translation (Figure 4.2a, middle panels 
marked with asterix).  Poly(GP) and poly(PR) antibodies were both purified from rabbit 
serum, however specific bands could be distinguished based on molecular weight. 
In addition to the poly-PA, PR and GP DPRs produced from the antisense (C4G2) RNA 
transcripts, we were also able to detect poly(GA) DPR produced from the sense (G4C2) RNA 
transcript, however poly(GA) was only detected in the 2.2-7 zebrafish line (Figure 4.2b, top 
panel).  Poly(GA) immunoblotting was carried on a separate PVDF membrane to GFP 
immunoblotting, in order to avoid cross reactivity (both poly(GA) and GFP antibodies are 
purified from mouse serum).  The detection of poly(GA) indicates that bidirectional 
transcription of the C9orf72 expansion is occurring from our transgene.  As the transcription 
of the RNA transcript containing the sense (G4C2) expansion is not driven by a conventional 
promoter region, this strongly suggests that poly(GA) protein is indeed produced via RAN 
translation.   
The binding specificity of the poly(PR) and poly(GP) antibodies used here has previously 
been validated using an enzyme-linked immunosorbent assay to demonstrate that each 
antibody binds its target DPR antigen, and exhibits minimal cross-reactivity to all other DPR 
species (Davidson et al., 2016).  Additionally, both poly(PR) and poly(GP) antibodies have 
been previously used to detect DPR species in C9orf72-ALS post mortem tissue samples 
(Davidson et al., 2016).  Validation of the binding specificities of both poly(GA) and poly(PA) 







Figure 4.2: Both 2.2 zebrafish lines produce multiple DPR species and 2.2-7 
zebrafish produces more DsRed 
(a) Anti-sense DPRs (predominately ATG-driven) detected in 5dpf embryonic lysates. 
Asterix (*) denotes protein bands which are proposed to have been produced via RAN-
translation. (b) Sense Poly(GA) DPRs (exclusively RAN-translation driven) detected in 
5dpf embryonic lysate of 2.2-7 zebrafish. Asterix (*) denotes protein bands which are 
proposed to have been produced via RAN-translation.  (c) GFP fluorescence at 5dpf does 
not differ between 2.2-2 and 2.2-7 zebrafish.  Statistical comparison carried out using an 
unpaired t-test.  (d) DsRed fluorescence at 5dpf is higher in 2.2-7 zebrafish compared with 
2.2-2 zebrafish.  This dataset was not normally distributed according to the Shapiro-Wilk 
test for normality, and was therefore statistically compared using the Mann-Whitney U 
test.  (e) The ratio of DsRed/GFP at 5dpf is higher in 2.2-7 zebrafish compared with 2.2-2 
zebrafish. This dataset was not normally distributed according to the Shapiro-Wilk test for 
normality, and was therefore statistically compared using the Mann-Whitney U test. N=75 
2.2-2 and 76 2.2-7 individual zebrafish for all comparisons. All data are shown as mean +/- 
standard deviation; ****P < 0.0001 and ns: not significant. 
 
 
Due to the presence of multiple bands of variable strength, quantifying transgene expression 
in each 2.2 zebrafish line by immunoblotting for GFP would have proven difficult.  Instead 
individual embryos of each 2.2 zebrafish line were lysed and GFP and DsRed fluorescence 
were measured using a plate reader.  The GFP fluorescence of 2.2-7 and 2.2-2 zebrafish 
was not significantly different (4.2x104 vs. 3.9x104 A.U. respectively; Figure 4.2c), 
suggesting similar transgene expression levels in both 2.2 zebrafish lines.  However, despite 
similar GFP expression levels in both 2.2 zebrafish, DsRed fluorescence of 2.2-7 zebrafish 
was significantly higher than that of the 2.2-2 zebrafish (1.1x105 vs. 0.71x105 A.U. 
respectively; Figure 4.2d). Furthermore, the DsRed:GFP ratio of 2.2-7 zebrafish was 
significantly higher than that of 2.2-2 zebrafish (2.8 vs. 2.0 respectively; Figure 4.2e).   
Embryonic expression of GFP and DsRed in 2.2 zebrafish, was also confirmed by confocal 
imaging of endogenous fluorescence in 5 dpf cryosections (Figure 4.3).  GFP expression 
appeared to mainly localise to the nucleus of cells, although GFP and DAPI co-localisation 
was not quantified.  In order to assess whether DPR/RNA foci expression leads to toxicity in 





Figure 4.3: 2.2 zebrafish produce GFP and DsRed at 5dpf 
At 5 dpf, both 2.2-7 and 2.2-2 zebrafish produce predominately nuclear localised GFP and 
diffusely expressed DsRed.  Scale bar = 100µm.  Transverse body sections.  Images are 
representative of 9 zebrafish imaged (not quantified).  
 
 
4.5. Embryonic 2.2-7 zebrafish show increased spontaneous locomotor activity 
Neither 2.2-zebrafish lines showed any overt morphological abnormalities during embryonic 
development (0- 5 dpf).  To assess whether RNA foci and DPR pathology was causing any 
underlying motor deficits, the spontaneous locomotor activity of 2.2 zebrafish was monitored 
at 5 dpf.  Embryonic 2.2 zebrafish were monitored in 96 well plates using the Viewpoint 
behaviour monitoring setup.  Under dark conditions, the average speed of movement of 2.2-
7 zebrafish was significantly higher than that of both 2.2-2 and NTG zebrafish, over the 20 
minute recording period (2.1 vs 1.7 and 1.8 mm/s average speed for 2.2-7, 2.2-2 and NTG 
zebrafish respectively; Figure 4.4a).  Similarly, under dark conditions the total distance 
moved by 2.2-7 zebrafish was significantly higher than that of both 2.2-2 and NTG zebrafish, 
over the 20 minute recording period (2440 vs 1950 and 1940 millimetres moved for 2.2-7, 




Figure 4.4: 2.2-7 zebrafish show increased average speed and total distance moved 
at 5dpf 
(a) The average speed of 2.2-7 zebrafish is significantly higher than that of both 2.2-2 and 
NTG zebrafish.  (b) The total distance moved over a 20 minute recording period is 
significantly higher in 2.2-7 zebrafish as compared to both 2.2-2 and NTG zebrafish.  (c) 
There is no significant difference in the time spent swimming at slow speed between NTG, 
2.2-2 and 2.2-7 zebrafish over a 20 minute recording period.  (d) 2.2-7 zebrafish spent 
significantly more time swimming at intermediate speeds in comparison to both 2.2-2 and 
NTG zebrafish over a 20 minute recording period.  (e) There is no significant difference in 
the time spent swimming at fast speed between NTG, 2.2-2 and 2.2-7 zebrafish over a 20 
minute recording period.  N=144 NTG, 71 2.2-2 and 60 2.2-7 individual fish per genotype 
for all comparisons, zebrafish were derived from three separate clutches.  All datasets 
were not normally distributed according to the Shapiro-Wilk test for normality, and were 
therefore statistically compared using the Kruskal-Wallis test with Dunn’s post-hoc test. 
Speed thresholds used were slow (0<x<5mm/sec), intermediate (5<x<15mm/sec) and fast 
(x>15mm/sec).  All data were recorded under dark conditions and are shown as mean +/- 





In order to analyse swimming behaviour in more detail, zebrafish swimming data were 
subdivided into time spent swimming at slow, intermediate and fast speeds.  No significant 
difference was detected in the time spent swimming at slow speed between NTG, 2.2-2 and 
2.2-7 zebrafish (Figure 4.4c).  However, 2.2-7 zebrafish spent significantly more time 
swimming at intermediate speeds in comparison to 2.2-2 and NTG zebrafish (53 vs 32 and 
32 seconds for 2.2-7, 2.2-2 and NTG zebrafish respectively; Figure 4.4d).  No significant 
difference was observed in the time spent swimming at fast speeds between 2.2-7, 2.2-2 
and NTG zebrafish (Figure 4.4e).  Thus, at the embryonic stage (5dpf) 2.2-7 zebrafish show 
signs of hyperactivity.  We next set out to determine whether other behavioural or 
developmental abnormalities were present in either of the 2.2 zebrafish lines during 
embryonic and larval development. 
 
4.6. Early behavioural abnormalities, reduced viability and reduced body mass are 
detected in 2.2-7 zebrafish 
As expansions in human ALS cause a spectrum of both motor and cognitive deficits, we 
examined whether normal zebrafish behaviour was affected in 2.2-7 zebrafish at 5 dpf.  
Centre avoidance behaviour assays are a validated means of measuring willingness to 
explore in zebrafish (Schnorr et al., 2012), and are comparable to the open field test 
performed in mice.  It was determined that 2.2-7 zebrafish were significantly less likely to 
venture into the centre of the well when compared to their NTG clutchmates (27% of 2.2-7 in 
centre vs. 34% of NTG zebrafish in centre; Figure 4.5a+b). 
To determine if the early embryonic expression of RNA foci and DPR impacted upon the 
viability of the zebrafish, we carried out early (1-15 dpf) survival analysis.  Heterozygous 2.2-
2 zebrafish did not show any change in survival within 15 dpf as compared to NTG zebrafish 
(data from NTG clutchmates of all genotypes are pooled; Figure 4.5c).  In contrast, 
heterozygous 2.2-7 zebrafish did show a significant decrease in survival within 15 dpf as 
compared to NTG zebrafish (79% vs. 92% survival for 2.2-7 and NTG respectively at 15dpf; 
Figure 4.5c). 
It was noted that during early development, the 2.2-7 zebrafish appeared smaller than their 
NTG clutchmates.  At 30 dpf there was a significant decrease in total body mass of 2.2-7 
zebrafish compared to their NTG clutchmates (1.7mg (21%) vs. 9.9mg (100%) mean body 
mass for 2.2-7 and NTG respectively; Figure 4.6a).  However, 2.2-2 zebrafish did not show 
a significant difference in body mass as compared to their own clutchmates at the same age 
(Figure 4.6b).  In summary, 2.2-7 zebrafish but not 2.2-2 zebrafish, showed significant 
reduction in survival at 15 dpf, and reduction in body mass at 30 dpf.  At 5 dpf, 2.2-7 




Figure 4.5: 2.2-7 zebrafish show early behavioural defects and reduced viability 
(a) Representative images of the plate set-up used to monitor centre avoidance behaviour 
in zebrafish.  30 fish were placed in each well and one image every minute was analysed.  
Image shown as recorded (top) and then following removal of the region around the edge 
of the plate for analysis (bottom). In these representative images 2.2-7 zebrafish are 
placed across the top 3 wells and NTG zebrafish across the bottom 3 wells. (b) 
Quantification of centre avoidance behaviour showing 2.2-7 zebrafish are significantly less 
often found in the plate centre.  N=6 clutches per genotype. Datasets were found to have 
unequal variance according to the F test, and were therefore statistically compared using 
a t-test with Welch’s correction.  (c) Survival of zebrafish did not change by 5dpf, however 
by 15dpf survival of the 2.2-7 line was significantly reduced compared to NTG and 2.2-2.  
N=4 clutches per genotype. Datasets were statistically compared using a two-way ANOVA 
with Sidak’s post hoc test.  All data are shown as mean +/- standard deviation; ns: not 






Figure 4.6: 2.2-7 zebrafish have reduced body mass at 30dpf 
(a) At 30dpf 2.2-7 zebrafish have reduced average body mass in comparison to their NTG 
clutch mates.  N=3 clutches per genotype (48 x 2.2-7 and 79 x NTG zebrafish in total).  
Statistical comparison was carried out using an unpaired t-test.  (b) At 30dpf there was no 
difference in average body mass between 2.2-2 zebrafish and their NTG clutch mates.  
N=3 clutches per genotype (82 x 2.2-2 and 79 x NTG zebrafish in total). Statistical 
comparison was carried out using an unpaired t-test. All data are shown as mean +/- 
standard deviation; ns: not significant and ***P < 0.001. 
 
The increased phenotypic severity of 2.2-7 zebrafish is consistent with their increased hsp70 
promoter mediated DsRed production, as compared with 2.2-2 zebrafish.  Transgene 
expression, DPR pathology and the motor/behavioural phenotype have now been 
characterised in developing zebrafish.  The next step was therefore to characterise the 
expression of the transgene and associated phenotype in adult 2.2 zebrafish.   
 
4.7. Adult 2.2 zebrafish express nuclear localised DPR proteins 
Previous reports indicate that DPR species often localise to the nucleus.  This is particularly 
true for the arginine rich DPRs poly(PR) and poly(GR) (Mizielinska et al., 2014).  To examine 
the cellular localisation of the DPR species produced in 2.2 zebrafish, immunofluorescence 
with DPR antibodies was carried out in adult zebrafish muscle.  The majority of poly(GP), 
poly(PA) and poly(PR) DPR signal was found to be localised to the nucleus (Figure 4.7, 
Figure 4.8 and Figure 4.9).  The 2.2 zebrafish express interrupted C9orf72 expansions, 
meaning that runs of pure C4G2 are linked together with 5 non-GC base pairs.  As there are 
5 non-GC base pairs, this effectively shifts the reading frame for subsequent C4G2 
expansions.  Therefore, most individual DPR species produced in the 2.2 zebrafish will likely 
contain a mixture of multiple DPR species, as can be seen in figure 4.2a, in which the same 




Figure 4.7: Both 2.2 model zebrafish express nuclear localised poly(GP) DPRs 
GFP and poly(GP) immunostaining of adult (12 months old) zebrafish muscle tissue 
shows that GFP tagged DPRs and poly(GP) containing DPRs localise to the nucleus in 
2.2-2 and 2.2-7 zebrafish.  For all DPR images nuclei are stained with Hoechst (blue), 
GFP is stained with GFP antibody (green) and DPR proteins are stained with the poly(GP) 






Figure 4.8: Both 2.2 model zebrafish express nuclear localised poly(PA) DPRs 
GFP and poly(PA) immunostaining of adult (12 months old) zebrafish muscle tissue shows 
that GFP tagged DPRs and poly(PA) containing DPRs localise to the nucleus in 2.2-2 and 
2.2-7 zebrafish.  For all DPR images nuclei are stained with Hoechst (blue), GFP is 
stained with GFP antibody (green) and DPR proteins are stained with the poly(PA) 






Figure 4.9: Both 2.2 model zebrafish express nuclear localised poly(PR) DPRs 
GFP and poly(PR) immunostaining of adult (12 months old) zebrafish muscle tissue shows 
that GFP tagged DPRs and poly(PR) containing DPRs localise to the nucleus in 2.2-2 and 
2.2-7 zebrafish.  For all DPR images nuclei are stained with Hoechst (blue), GFP is 
stained with GFP antibody (green) and DPR proteins are stained with the poly(PR) 




signal for multiple DPR species are all localised to the nucleus in 2.2 zebrafish.  Based on 
previous reports, the nuclear localisation is most likely mediated by poly(PR) DPR proteins 
(Wen et al., 2014).  DPR expression in muscle tissue from 2.2 zebrafish had now been 
confirmed.  However, in ALS expression of C9orf72 expansions is primarily associated with 
neurodegeneration.  Therefore, we next planned to test whether transgene expression in 2.2 
zebrafish was also present in central nervous system tissues. 
 
4.8. DPR species are produced in 2.2 zebrafish CNS tissues 
In human ALS, toxicity occurs primarily in cells of the central nervous system (CNS), and so 
it is essential to ascertain whether DPR species are also produced within the CNS of this 
zebrafish model.  In adult spinal cord and brain of both 2.2-zebrafish lines, GFP-tagged DPR 
species and DPR species which were not immunoreactive with GFP antibodies, could be 
detected (Figure 4.10a+b).  This suggests that both ATG-dependent translation and RAN 
translation of DPR species occurs within the CNS of the 2.2-zebrafish.  DPR bands which 
are not immunoreactive for GFP and are therefore proposed to be produced via RAN-
translation are marked with an asterix.  In both 2.2-zebrafish lines, the band pattern of DPRs 
detected largely remains constant from 5 dpf until adulthood, although higher molecular 
weight (>50KDa) poly(PR) positive bands are more abundant in adult tissue.  Of all the DPR 
species examined here, poly(PR) generally has the highest propensity to form high MW 
RAN-translation mediated bands.  Poly(GP) and poly(GA) immunoblotting was not carried 
out due to the presence of multiple specific and non-specific bands already produced by 
antibodies derived from the same species.  Poly(GP) and poly(PR) were both purified from 
rabbit serum, and poly(GA) and GFP antibodies were both purified from mouse serum.  As 
multiple DPR species are produced in the CNS of adult 2.2 zebrafish, we next planned to 


















Figure 4.10: Both 2.2 zebrafish lines produce multiple DPR species in brain and 
spinal cord 
(a) Anti-sense DPRs (predominately ATG-driven) detected in adult spinal cord lysates. 
Asterix (*) denotes protein bands which are proposed to have been produced via RAN-
translation.  (b) Anti-sense DPRs (predominately ATG-driven) detected in adult brain 




4.9. Reduced swimming endurance is observed in adult 2.2-7 zebrafish 
To assess the neuro-muscular integrity of the 2.2-7 transgenic zebrafish, swimming 
endurance was tested using a swim tunnel, the aquatic equivalent to a treadmill.  Due to 
equipment availability, the swim tunnel setup used previously to test the 5.3 zebrafish was 
not available when testing 2.2 zebrafish.  Instead, this swim tunnel setup had a wider 
swimming chamber and so was not able to fully exhaust every zebrafish tested.  Flow into 
the swimming chamber began at 2L/min and then was increased in 2L/min increments every 
5 minutes until 11.6L/min (maximum flow rate for this setup) had been reached, at which 
point the experiment was halted.  For this reason, direct comparisons cannot be drawn 
between 5.3 zebrafish and 2.2 zebrafish swim tunnel performance.  Despite the swim tunnel  
not being able to fully exhaust every zebrafish, at 9 months of age 2.2-7 zebrafish showed 
significantly reduced swimming endurance as compared to their NTG clutchmates (38% vs. 
77% still swimming at maximum flow rate for 2.2-7 and NTG respectively; Figure 4.11a).  
Zebrafish size can affect swimming ability, therefore the body length and body mass of each 
zebrafish used in the swim tunnel was measured.  Despite decreased body mass during 
early development, neither variable was significantly different between 2.2-7 and NTG clutch 
mates at 9 months of age (Figure 4.11b+c).  The swim tunnel test was repeated using the 
same experimental setup and the same cohort of zebrafish three months later (zebrafish 
were now 12 months old).  Again, 2.2-7 zebrafish showed significantly reduced swimming 
endurance compared to their NTG clutchmates (23% vs. 85% still swimming at maximum 
flow rate for 2.2-7 and NTG respectively; Figure 4.11d).  Furthermore, neither body length 
nor body mass was significantly different between transgenic and NTG groups at 12 months 
old (Figure 4.11e+f).  Immediately, following removal from the swim tunnel zebrafish were 








Figure 4.11: 2.2-7 zebrafish show adult onset swimming endurance deficits 
(a) At nine months old, 2.2-7 transgenic zebrafish failed to continue swimming at earlier 
time points than their NTG clutch mates. N=13 fish per genotype.  Statistical comparison 
was carried out using the Log-rank test.  (b) At nine months old there was no difference in 
body mass between 2.2-7 zebrafish and their NTG clutchmates. N=13 fish per genotype. 
Statistical comparison was carried out using an unpaired t-test.  (c) At nine months old 
there was no difference in body length between 2.2-7 zebrafish and their NTG 
clutchmates. N=13 fish per genotype. Statistical comparison was carried out using an 
unpaired t-test. (d) At twelve months old, 2.2-7 transgenic zebrafish failed to continue 
swimming at earlier time points than their NTG clutch (legend continues on next page) 
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mates. N=13 fish per genotype.  Statistical comparison was carried out using the Log-rank 
test. (e) At twelve months old there was no difference in body mass between 2.2-7 
zebrafish and their NTG clutchmates. N=13 fish per genotype. Statistical comparison was 
carried out using an unpaired t-test. (f) At twelve months old there is no difference in body 
length between 2.2-7 zebrafish and their NTG clutchmates. N=13 fish per genotype. 
Statistical comparison was carried out using an unpaired t-test. All body mass and body 
length data are shown as mean +/- standard deviation; ns: not significant and *P < 0.05. 
 
 
4.10. 2.2-7 zebrafish show normal locomotor activity following swim tunnel testing 
Zebrafish were removed from the swim tunnel after testing, placed into a recovery tank and 
allowed 5 minutes to recover before spontaneous locomotor activity recordings began.  At 9 
months of age there was no difference in average speed of movements made or the total 
distance moved by the zebrafish over a 30 minute recording period (Figure 4.12a+b).  
Similarly, at 12 months old there was no difference in average speed of movements made or 
the total distance moved by the zebrafish over a 30 minute recording period (Figure 
4.12c+d).   
In order to analyse swimming behaviour in more detail, zebrafish swimming data were 
subdivided into time spent swimming at slow, intermediate and fast speeds.  No significant 
difference was observed in the time spent swimming at slow, intermediate or fast speed 
between 9 month old 2.2-7 and NTG zebrafish (Figure 4.13a-c).  Similarly, no significant 
difference was observed in the time spent swimming at slow, intermediate or fast speeds 
between 12 month old 2.2-7 and NTG zebrafish (Figure 4.13d-f).  Following the swim 
tunnel/locomotor testing of the 2.2-7 zebrafish, it was noted that some of the 2.2-7 zebrafish 
were rapidly losing body muscle (no zebrafish displaying this phenotype were included in the 














Figure 4.12: After swim tunnel, 2.2-7 zebrafish show normal swimming activity 
(a) After being removed from the swim tunnel, 9 month old 2.2-7 fish did not show any 
significant difference in average speed of movements made over a 30 minute recording 
period in comparison to NTG zebrafish. N=12 fish per genotype. (b) After being removed 
from the swim tunnel, 9 month old 2.2-7 fish did not show any significant difference in total 
distance moved over a 30 minute recording period in comparison to NTG zebrafish. N=12 
fish per genotype.  (c) After being removed from the swim tunnel, 12 month old 2.2-7 fish 
did not show any significant difference in average speed of movements made over a 30 
minute recording period in comparison to NTG zebrafish. N=13 fish per genotype.  (d) 
After being removed from the swim tunnel, 12 month old 2.2-7 fish did not show any 
significant difference in total distance moved over a 30 minute recording period in 
comparison to NTG zebrafish. N=13 fish per genotype.  All statistical comparisons were 
carried out using an unpaired t-test.  All data are shown as mean +/- standard deviation; 







Figure 4.13: After swim tunnel, the time spent swimming at different speeds is not 
significantly different between 2.2-7 and NTG zebrafish 
(a) There is no significant difference in the time spent swimming at slow speeds between 
2.2-7 and NTG zebrafish at 9 months old. Statistical comparison was carried out using an 
unpaired t-test.  N=12 fish per genotype. (b) There is no significant difference in the time 
spent swimming at intermediate speeds between 2.2-7 and NTG zebrafish at 9 months 
old. Statistical comparison was carried out using an unpaired t-test.  N=12 fish per 
genotype. (c) There is no significant difference in the time spent swimming at fast speeds 
between 2.2-7 and NTG zebrafish at 9 months old. This dataset was not normally 
distributed according to the Shapiro-Wilk test for normality and was therefore statistically 
compared using the Mann-Whitney U test. N=12 fish per genotype. (d) There is no 
significant difference in the time spent swimming at slow speeds between 2.2-7 and NTG 
zebrafish at 12 months old. Statistical comparison was carried out using an unpaired t-
test.  N=13 fish per genotype. (e) There is no significant difference in the time spent 
swimming at intermediate speeds between 2.2-7 and NTG zebrafish at 12 months old. 
Statistical comparison was carried out using an unpaired t-test.  N=13 fish per genotype. 
(f) There is no significant difference in the time spent swimming at fast speeds between 
2.2-7 and NTG zebrafish at 12 months old. This dataset was not normally distributed 
according to the Shapiro-Wilk test for normality and was therefore statistically compared 
using the Mann-Whitney U test. N=13 fish per genotype. All data were recorded over a 30 
minute period after zebrafish had been removed from the swim tunnel and allowed to rest 
for 5 minutes. Speed thresholds used were slow (x<60mm/sec), intermediate 
(60<x<120mm/sec) and fast (x>120mm/sec).Data are shown as mean +/- standard 





4.11. Early mortality is observed in 2.2-7 zebrafish 
While visually inspecting tanks containing 12 month old 2.2-7 zebrafish, it was noted that a 
small proportion of the 2.2-7 zebrafish showed marked loss of body muscle.  These 2.2-7 
zebrafish were then closely monitored, and it became clear that the loss of body mass was 
progressive and was beginning to interfere with the normal tank swimming behaviour of the 
2.2-7 zebrafish.  At this point specific criteria were decided upon in order to determine when 
a zebrafish had reached end-stage, and would need to be culled to prevent unnecessary 
suffering.  A zebrafish was defined as having reached end-stage once it had lost the ability 
to maintain normal swimming (showing signs of paralysis) to the extent where it was no 
longer able to obtain food.  End-stage 2.2-7 zebrafish displayed  severe wasting in the body 
muscle region, had very poor locomotor skills and would often rest at the bottom of tank 
completely still (this is very abnormal for zebrafish who typically maintain almost constant 
swimming whilst awake).  Over time more 2.2-7 zebrafish developed this progressive muscle 
wasting phenotype, and by 36 months there was a significant reduction in survival of the 2.2-
7 zebrafish compared with that of NTG zebrafish (22% vs. 86% survival for 2.2-7 and NTG 
respectively at 36 months old; Figure 4.14).  In contrast to 2.2-7, no NTG zebrafish 
displayed this muscle wasting phenotype.  We next planned to assess adult muscle integrity 
of the 2.2 zebrafish using histological techniques. 
 
Figure 4.14: 2.2-7 zebrafish have reduced survival 
Adult transgenic 2.2-7 zebrafish have reduced survival from 8-36 months in comparison to 
their NTG clutch mates which are housed in the same tank.  N=17 2.2-7 and 27 NTG at 8 





4.12. Both 2.2 zebrafish show abnormal muscle histology 
Progressive muscle atrophy is observed in all ALS patients and similar muscle atrophy was 
observed in end-stage 2.2-7 zebrafish.  In order to investigate the nature and severity of this 
muscle atrophy, we H&E stained epaxial muscle sections from NTG, 2.2-2 and end-stage 
2.2-7 zebrafish to examine their muscle structure.   End-stage 2.2-7 zebrafish muscle 
displayed widespread severe atrophy, muscle fibres were sparse and disorganised (Figure 
4.15a).  The muscle of 2.2-2 zebrafish displayed more subtle changes.  To assess 2.2-2 
zebrafish, muscle integrity myotome size and number was counted from 2.2-2 and NTG 
epaxial muscle sections in a blinded analysis.  Myotomes of 2.2-2 zebrafish muscle were 
significantly smaller and more numerous compared to NTG muscle myotomes (1.1 vs. 
1.7mm2 median myotome size for 2.2-2 and NTG respectively; Figure 4.15a+b).  End-stage 
2.2-7 zebrafish muscle fibre size and number was not quantified, as 2.2-7 myofibres were so 
severely disorganised that it was not possible to discern individual myotomes.  It was now 
clear that end-stage 2.2-7 zebrafish have severely atrophied muscle tissue.  We next 
planned to examine what the cause of muscle atrophy in these fish may have been.   
 
4.13. 2.2-7 zebrafish show motor neuron loss 
In ALS patients, the underlying molecular pathology ultimately leads to motor neuron death, 
which in turn leads to atrophy of denervated muscle.  To investigate whether motor neuron 
loss underlies the muscle atrophy observed in 2.2-7 zebrafish, we counted motor neurons 
from the ventral spinal cord of NTG, 2.2-2 and end-stage 2.2-7 H&E stained zebrafish 
sections.  Significant loss of motor neurons was observed in end-stage 2.2-7 zebrafish as 
compared with NTG controls (1.0 vs. 3.2 mean number of motor neurons per body section of 
2.2-7 and NTG respectively; Figure 4.16a+b).  A small, non-significant reduction in motor 
neurons was observed in 2.2-2 zebrafish as compared with NTG controls (Figure 4.16a+b). 
As mentioned previously the 2.2 zebrafish lines were generated with the aim of producing an 
in vivo model which recapitulates key aspects of the ALS/FTD phenotype and can be used 
to screen potential neuroprotective compounds using hsp70 promoter driven DsRed as a 
cellular stress readout.  As already described, the 2.2 zebrafish show behavioural and motor 
defects.  Additionally, we have already shown that embryonic DsRed is higher in the 
phenotypically severe 2.2-7 zebrafish, compared with the phenotypically less severe 2.2-2 
zebrafish.  We next aimed to characterise how DsRed levels change over time in the CNS of 








Figure 4.15: Both 2.2 zebrafish lines display abnormal muscle histology 
(a) Representative H&E staining of zebrafish epaxial muscle (body muscle) myotomes.  
Scale bar = 50µm.  (b) Frequency distribution of 2.2-2 and NTG myotome sizes.  N=6 
individual zebrafish per genotype, 6 sections were analysed for each individual zebrafish 
(36 sections per genotype in total). 2.2-7 zebrafish were culled once they had reached 
phenotypic end stage (age matched NTG zebrafish were culled alongside end stage 2.2-7 
zebrafish), average age of culling was 12.6 months (8, 11, 13, 14, 15 and 15 months 
individually for both 2.2-7 and NTG zebrafish).  2.2-2 zebrafish were all culled at 12 
months old.  Statistical comparison was carried out using the Chi-squared test for trend.  
Myotome size data are shown as the frequency of myotome sizes binned into defined 







Figure 4.16: 2.2-7 zebrafish display motor neuron loss 
(a) Representative H&E staining of zebrafish spinal cord sections in which motor neurons 
are denoted by yellow arrowheads.  Scale bar = 25µm. (b) 2.2-7 zebrafish have significant 
motor neuron loss compared to NTG. N=6 individual fish per genotype, 3 sections were 
analysed for each individual zebrafish (18 sections per genotype in total). 2.2-7 zebrafish 
were culled once they had reached phenotypic end stage (age matched NTG zebrafish 
were culled alongside end stage 2.2-7 zebrafish), average age of culling was 12.6 months 
(8, 11, 13, 14, 15 and 15 months individually for both 2.2-7 and NTG zebrafish).  2.2-2 
zebrafish were all culled at 12 months old.  Statistical comparison was carried out using a 
one-way ANOVA with Tukey’s post hoc test.  Data are shown as mean +/- standard 





4.14. DsRed production correlates with disease severity in 2.2-7 zebrafish and heat 
shock activation occurs in human C9orf72-ALS 
To examine whether CNS DsRed production changes as disease severity is increasing in 
2.2-7 zebrafish, brains of end-stage 2.2-7 zebrafish (ages 15, 15 and 19 months), pre-
symptomatic 2.2-7 zebrafish (all aged 7 months) and NTG zebrafish (age matched to end-
stage) were lysed and western blotted.  Pre-symptomatic was defined as fish which did not 
show any overt swimming or musculature abnormalities, and were of a younger age than the 
age at which the earliest swim tunnel abnormalities had been detected.  GFP tagged DPRs 
were increased in the brains of end-stage zebrafish in comparison to the brains of pre-
symptomatic zebrafish (1.0 vs. 0.17 A.U. for end-stage and pre-symptomatic respectively; 
Figure 4.17a+b).  Similarly, DsRed was also increased in the brains of end-stage zebrafish 
in comparison to the brains of pre-symptomatic zebrafish (1.0 vs. 0.43 A.U. for end-stage 
and pre-symptomatic respectively; Figure 4.17a+c), suggesting that there is a correlation 
between DPR production, phenotypic severity and hsp70 promoter driven DsRed production.   
Activation of the heat shock response due to cellular stress driven by aberrant protein 
expression is an already well characterised pathway (Dedmon et al., 2005, Bukau et al., 
2006).  However, as this system lies at the foundation of our proposed drug screening 
strategy in the C9orf72 model zebrafish, we deemed it necessary to examine the role of the 
heat shock protein system in C9orf72-ALS patients.  To assess whether the heat shock 
response is activated in human C9orf72-ALS, cerebellum grey matter from C9orf72-ALS 
patients or healthy controls was lysed and western blotted for HSP70 protein (the most 
ubiquitous and abundant heat shock protein).  Indeed, HSP70 protein expression was 
significantly higher in C9orf72-ALS patients as compared to healthy controls (1.1 vs. 0.58 
HSP70/tubulin for C9orf72 patients and controls respectively; Figure 4.17d+e).  Activation of 
the heat shock response in human ALS cases validates that identification of compounds 
which are able to alleviate heat shock activation may have neuroprotective effects in 
C9orf72-ALS.  To further validate the heat shock activation drug screening system, we next 
planned to identify a positive control compound which can reduce DsRed production in the 










Figure 4.17: Heat shock stress response activation is increased by C9orf72 
expansions 
(a) In end-stage 2.2-7 zebrafish brains, levels of GFP tagged DPR and DsRed proteins 
are increased compared with pre-symptomatic 2.2-7 and NTG.  (b) Quantification of GFP 
tagged DPR protein normalised to tubulin in adult zebrafish brains.  N=3 adult brains per 
condition. Statistical comparison was carried out using a one-way ANOVA with Tukey’s 
post hoc test. (c) Quantification of DsRed protein normalised to tubulin in adult zebrafish 
brains. N=3 adult brains per condition. Statistical comparison was carried out using a one-
way ANOVA with Tukey’s post hoc test. (d) In human cerebellum samples, HSP70 protein 
levels are higher in C9-ALS patients as compared to controls.  N=5 samples per group.  
The patient code is listed above each sample (see table 2.2 for full patient information).  
(e) Quantification of HSP70 protein levels normalised to tubulin in human cerebellum. 
Statistical comparison was carried out using an unpaired t-test.  All data are shown as 





4.15. Riluzole treatment reduces DsRed production in 2.2-7 zebrafish 
The first choice to use as a positive control compound in order to test the validity of the 
DsRed drug screening system in zebrafish was riluzole.  The reason for this, is that riluzole 
is known to have neuroprotective effects and is currently the only disease modifying 
treatment prescribed for ALS patients in the UK.  In order to test the efficacy of riluzole in our 
DsRed drug screening paradigm, 2.2-7 zebrafish were treated with either 10µM riluzole or 
vehicle control (DMSO) from 2-5 dpf.  At 5 dpf, zebrafish were lysed and their individual 
DsRed florescence levels were measured using a plate reader.  Riluzole treatment resulted 
in a significant reduction in hsp70 promoter driven production of DsRed protein, as 
compared with DMSO treatment (0.87 vs. 1.0 fold change in DsRed for riluzole and DMSO 
treatments respectively; Figure 4.18a).  As the DsRed readout had now been validated by 
demonstrating that it could identify riluzole as a hit, two compounds named ivermectin and 
selamectin were also tested using the same treatment paradigm.  The reason for selecting 
ivermectin and selamectin was that they had both previously been identified as hits in a 
SOD1-ALS drug screening zebrafish model (Ramesh lab, unpublished data).  Interestingly, 
10µM riluzole, 1µM ivermectin and 10µM selamectin treatments all significantly reduced 
DsRed production in 2.2-7 zebrafish, as compared to DMSO treatment (0.68, 0.73, 0.62 and 
1.0 fold change in DsRed for riluzole, ivermectin, selamectin and DMSO treatments 
respectively; Figure 4.18b).  Elucidating the mechanism by which drugs are reducing the 
heat shock response activation is an important step in targeting future therapies.  Ivermectin 
has previously been shown to inhibit α and β nuclear importins (Wagstaff et al., 2012).  This 
led us to hypothesise that ivermectin may reduce cellular stress by blocking nuclear import 
of poly(PR) DPR species.  To test this hypothesis, we treated zebrafish with the β-importin 
specific blocker importazole.  However, neither 1µM or 5µM importazole treatments 
significantly changed DsRed production in 2.2-7 zebrafish, as compared to untreated 2.2-7 
zebrafish (Figure 4.18c).  Further, work is required to elucidate the mechanism by which 
ivermectin or any of the other compounds tested are reducing activation of the heat shock 
stress response.    Andrographolide is a potent nuclear factor E2-related factor 2 (nfr2) 
activator (Mead et al., 2013), which reduces motor neuron toxicity mediated by co-culture 
with astrocytes derived from C9orf72 patients (Ferraiuolo lab, unpublished data).  However, 
treatment of 2.2-7 zebrafish with 10µM or 40µM andrographolide did not result in a 
significant change in DsRed production, as compared to untreated 2.2-7 zebrafish (Figure 
4.18d).  As the ALS/FTD and drug screening capability of the 2.2-7 zebrafish was now 
established, we next set out to identify a drug with known neuroprotective properties which 






Figure 4.18: Riluzole, selamectin and ivermectin can all alleviate stress response 
activation in 2.2-7 zebrafish 
(a) Treatment with 10µM riluzole from 2-5dpf significantly reduced the DsRed fluorescence 
in 2.2-7 zebrafish.  N=36 DMSO treated and 27 riluzole treated individual zebrafish.  This 
dataset was not normally distributed according to the Shapiro-Wilk test for normality and 
was therefore statistically compared using the Mann-Whitney U test.  (b) Treatment with 
10µM riluzole, 10µM selamectin or 1µM ivermectin from 2-5 dpf significantly reduced the 
DsRed fluorescence in 2.2-7 zebrafish.  N=33 DMSO treated, 34 riluzole treated, 34 
selamectin treated and 34 ivermectin treated individual zebrafish.  Statistical comparison 
was carried out using a one-way ANOVA with Tukey’s post hoc test.  (c) Treatment with 
either 1µM or 5µM importazole from 2-5 dpf did not significantly change DsRed production 
in 2.2-7 zebrafish, as compared to untreated 2.2-7     (legend continues on next page) 
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zebrafish.  N=8 untreated, 3 importazole 1µM treated and 5 importazole 5µM treated, 
these zebrafish were derived from a single clutch.  Statistical comparison was carried out 
using a one-way ANOVA with Dunnett’s post hoc test.  (d) Treatment with either 10µM or 
40µM andrographolide from 2-5 dpf did not significantly change 2.2-7 DsRed production 
as compared to untreated 2.2-7 zebrafish.  N=10 untreated, 10 andrographolide 10µM 
treated and 8 andrographolide 40µM treated individual zebrafish, these zebrafish were 
derived from a single clutch. Statistical comparison was carried out using a one-way 
ANOVA with Dunnett’s post hoc test. All data are shown as mean +/- standard deviation; 
ns: not significant, **P < 0.01, ***P < 0.001 and ****P < 0.0001. 
 
 
4.16. Over activation of PARP1 does not drive toxicity in 2.2-7 zebrafish 
In a subset of patients with cerebellar ataxia caused by XRCC1 mutations, 
neurodegeneration was discovered to be driven by over-activation of the DNA damage 
sensing protein PARP1 (Hoch et al., 2017).  Additionally, deletion of the PARP1 gene in 
XRCC1 mutant mice ameliorated the loss of cerebellar neurons (Hoch et al., 2017).  Given 
the current evidence suggesting chronic DNA damage as a mechanism of C9orf72 
expansion mediated toxicity (Lopez-Gonzalez et al., 2016, Farg et al., 2017, Walker et al., 
2017), we hypothesised that PARP1 over-activation may also contribute to C9orf72-ALS.  In 
order to test this hypothesis, we treated zebrafish with the PARP1 specific inhibitor olaparib.  
To assess olaparib target engagement, we treated 2.2-7 zebrafish from 2-5 dpf with 10µM 
and 1µM olaparib.  These zebrafish were then lysed and immunoblotted for PAR chains (the 
product of PARP1 enzymatic activity).  Both 10µM and 1µM olaparib treatments reduced the 
amount of PAR chains produced in 2.2-7 zebrafish, however the 10µM treatment was 
markedly more effective (Figure 4.19a).     
Next, to assess whether inhibiting PARP1 activity could ameliorate C9orf72 expansion 
driven toxicity, we treated zebrafish with olaparib from 2-15 dpf and assessed whether this 
would rescue the reduced survival observed in 2.2-7 zebrafish at 15 dpf.  Unexpectedly, 
10µM olaparib treatment caused clear toxic effects on both 2.2-7 and NTG zebrafish.  At 
around 10 dpf the zebrafish became lethargic, and over the next three days of treatment the 
condition of the zebrafish worsened, with many zebrafish appearing morphologically 
abnormal.  The 10µM olaparib treatment was stopped at 13 dpf and all zebrafish were 
culled.  The 10µM olaparib treatment resulted in a significant reduction in survival in both 
2.2-7 and NTG groups (28% vs 17% 2.2-7 survival and 85% vs 67% NTG survival, for 
DMSO and 10µM olaparib treatments respectively; Figure 4.19b+f).  The dose of olaparib 
was then lowered to 1µM and the water change protocol was altered in attempt to reduce 
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water quality stress on the zebrafish, as even the DMSO treated 2.2-7 zebrafish showed 
poor survival in the previous experiment.  However, at 10 dpf the same signs of toxicity were 
observed in the 2.2-7 zebrafish, and zebrafish were culled at 12 dpf.  With 1µM olaparib 
treatment a significant reduction in the survival of 2.2-7 zebrafish was observed, however the 
reduction in the survival of NTG zebrafish was not significant (80% vs 62% 2.2-7 survival 
and 95% vs 90% NTG survival, for DMSO and 1µM olaparib treatments respectively; Figure 
4.19c+f).  The dose of olaparib was again lowered to 0.1µM, and the same water change 
protocol as previously described was used.  However, at 10 dpf the same signs of toxicity 
were observed in the 2.2-7 zebrafish, and zebrafish were culled at 11 dpf.  With 0.1µM 
olaparib treatment there was a strong trend towards a reduction in the survival of 2.2-7 
zebrafish (P = 0.0504), however there was no change in survival of NTG zebrafish (90% vs 
76% 2.2-7 survival and 95% vs 95% NTG survival, for DMSO and olaparib treatments 
respectively; Figure 4.19d+f).  The effect of olaparib on the heat shock response was also 
assessed by treating 2.2-7 with 5µM olaparib from 2-5 dpf and then measuring DsRed 
production.  Treatment with 5µM olaparib did not significantly change the heat shock stress 
response activation as measured by DsRed florescence (Figure 4.19e). 
Heat shock response activation gives a general readout of cellular stress conditions.  For 
this reason we next aimed to compare the level of heat shock response activation in 5.3 























Figure 4.19: Olaparib treatment reduces PAR production but does not rescue 
reduced viability in 2.2-7 zebrafish 
(a) Treatment of 2.2-7 zebrafish from 2-5 dpf with the PARP1 specific inhibitor olaparib 
markedly reduced the production of PARylated proteins at 10µM, and to a lesser extent at 
1µM also.  (b) Treatment with 10µM olaparib from 2-13 dpf was toxic, and caused a 
significant reduction in survival of 2.2-7 zebrafish and their NTG clutchmates, as 
compared to DMSO treated zebrafish of the same genotype.  N=60 individual zebrafish 
per condition, zebrafish derived from 3 clutches.  Statistical comparison was carried out 
using the Log-rank test.  (c) Treatment with 1µM olaparib from 2-12dpf was also toxic and 
caused a significant reduction in survival in 2.2-7 zebrafish but not in NTG zebrafish, as 
compared with DMSO treated zebrafish of the same genotype. N=60 individual zebrafish 
per condition, zebrafish derived from 3 clutches. Statistical comparison was carried out 
using the Log-rank test. (d) Treatment with 0.1µM olaparib from 2-11 dpf caused a strong 
trend towards reduced survival in 2.2-7 zebrafish but did not have any effect on NTG 
survival, as compared to DMSO treated zebrafish of the same genotype.  N=60 individual 
zebrafish per condition, zebrafish derived from 3 clutches. Statistical comparison was 
carried out using the Log-rank test. (e) Treatment with 5µM olaparib from 2-5 dpf did not 
significantly change DsRed production in 2.2-7 zebrafish, as compared to DMSO treated 
2.2-7 zebrafish.  N=26 DMSO treated and 29 olaparib treated individual zebrafish, derived 
from 3 clutches.  Statistical comparison was carried out using an unpaired t-test.  (f) 
Summary of the olaparib treatment and water change protocols used in each of the 3 
survival experiments.  Olaparib treatment was planned for 2-15 dpf, but was ended early 
in every experiment to protect the welfare of the zebrafish after observing signs of early 
toxicity. DsRed fold change data is shown as mean +/- standard deviation; ns: not 
significant, *P < 0.05. 
 
4.17. Heat shock response activation is higher in 2.2 than 5.3 zebrafish lines 
In both 5.3 (RNA-only) and 2.2 (RNA+DPR) zebrafish, activation of the hsp70 promoter 
drives production of the DsRed protein.  Due to this, it is possible to compare the relative 
expressions of DsRed by each line of zebrafish and use this as a generic readout of the 
amount of cellular stress being exhibited.  Cell stress influences DsRed production by 
increasing the drive on the hsp70 promoter.  However, transgene copy number can also 
influence the amount of DsRed produced by each line of zebrafish.  For this reason, in order 
to compare the relative stress levels of each zebrafish line, we normalised DsRed to GFP 
production, thus controlling for transgene expression levels within each zebrafish line.  There 
was no significant difference in DsRed/GFP levels between any of the 5.3 zebrafish lines 




Figure 4.20: 2.2 (RNA+DPR) zebrafish lines exhibit higher heat shock response 
activation than 5.3 (RNA-only) zebrafish lines when normalised to GFP expression 
The ratio of DsRed:GFP does not differ between any zebrafish in the 5.3 lines.  
Additionally, Both 2.2 zebrafish lines exhibit a significantly higher DsRed:GFP ratio than 
every 5.3 zebrafish line.  Finally, 2.2-7 zebrafish also have a higher DsRed:GFP ratio than 
2.2-2 zebrafish. N=76 x 2.2-7, 75 x 2.2-2, 9 x 5.3-9, 10 x 5.3-5 and 9 x 5.3-6 individual 
zebrafish, zebrafish from 5.3 lines were derived from a single clutch. This dataset was not 
normally distributed according to the Shapiro-Wilk test for normality, therefore statistical 
comparisons were carried out using the Kruskal-Wallis test with Dunn’s post hoc test.  All 
data are shown as mean +/- standard deviation; ns: not significant, **P < 0.01 and ****P < 
0.0001. 
 
all three 5.3 zebrafish lines (2.0 vs 0.78, 0.23 and 0.12 A.U., for 2.2-2, 5.3-9, 5.3-5 and 5.3-6 
respectively; Figure 4.20).  Additionally, 2.2-7 zebrafish had significantly higher DsRed/GFP 
levels than 2.2-2 and all three 5.3 zebrafish lines (2.8 vs 2.0, 0.78, 0.23 and 0.12 A.U., for 
2.2-7, 2.2-2, 5.3-9, 5.3-5 and 5.3-6 respectively; Figure 4.20).  Therefore, DsRed/GFP levels 
correlate with phenotypic severity.  It is important to note however that the zebrafish from 
each of the 5.3 lines were all derived from a single clutch.  Therefore, figure 4.20 should be 






As previously mentioned in discussion of RNA-only zebrafish injections, the 
microinjection/pre-screening method used here allows for highly efficient rates of 
transgenesis without the additional effort and potential pitfalls when using transposable 
elements.  RNA+DPR zebrafish were generated with an even higher rate of transgenesis.  
Of the highly chimeric zebrafish grown to adulthood, 43% (3/7) gave rise to full transgenic 
offspring.  This further highlights the efficiency of this system for producing transgenic 
zebrafish.  One of the highly chimeric RNA+DPR zebrafish, the highest expresser as 
determined by eye, showed severely reduced fertility and produced offspring which died 
within the first few days of life.  This phenotype is identical to the phenotype observed in high 
expresser RNA-only chimeric zebrafish.  Thus, these data suggest that high enough 
expression of C9orf72 expansion RNA is sufficient to generate a toxic phenotype.  However, 
it would be difficult to prove that RNA-only zebrafish are not also producing DPR species 
due to a lack of sample tissue caused by the low fertility of their chimeric founder 
(approximately 1 in 200 eggs is fertilised, and only a maximum of 50% of these are expected 
to be transgenic).  Previous reports have also identified that high expression of C9orf72 RNA 
(with no detectable DPRs) is sufficient to generate an early lethal phenotype, albeit the 
phenotype was less severe and less frequently observed than the phenotype of zebrafish 
which expressed poly(GA) encoding DPR constructs under the same promoter (Ohki et al., 
2017).  These data clearly indicate that C9orf72 expansion RNA can contribute to early 
toxicity in stable transgenic animal models.   
Of the two RNA+DPR zebrafish which did not show early lethality, the GFP expression 
levels of both zebrafish were not significantly different at 5 dpf.  However, the DsRed level 
and DsRed:GFP ratio of the 2.2-7 zebrafish was significantly higher.  These data suggest 
that different DPR species may have a differential ability to activate the heat shock stress 
response.  This would be consistent with previous reports showing that different DPR 
species have variable levels of in vivo toxicity (Mizielinska et al., 2014, Tran et al., 2015).  
Interestingly, adult 2.2-7 zebrafish also show a more severe phenotype than 2.2-2 zebrafish, 
exhibiting reduced swimming endurance, reduction in body mass, motor neuron loss and 
advanced muscle atrophy.  This suggests that the level of heat shock activation is a good 
predictor of phenotypic severity in 2.2 zebrafish.  Furthermore, hsp70 promoter-mediated 
DsRed production was significantly higher in end-stage vs pre-symptomatic zebrafish, 
further demonstrating that within the same zebrafish line heat shock activation correlates 
with disease severity.  Zebrafish of the 2.2-7 line also exhibited centre avoidance behaviour, 
decreased early viability and an adult onset reduction in survival.  It will be important in the 
future to assess 2.2-2 zebrafish using these assays also so that it can be determined 
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whether the observed milder phenotype of the 2.2-2 zebrafish is present in all phenotypic 
readouts. 
Reduced body mass was observed in the 2.2-7 zebrafish at 30 dpf, however the reduction 
had recovered to normal levels by adulthood.  This suggests that the reduction in body mass 
was not caused by tissue degeneration, but rather by a developmental delay which can be 
compensated for given enough time.   
Interestingly, not only did DsRed production increase from pre-symptomatic to end-stage in 
zebrafish brains, but levels of GFP-tagged DPRs were also more abundant in end-stage 
tissue.  The reason for this increase in DPR abundance is not currently known.  One 
possibility is that a reduction in the efficiency of protein clearance mechanisms leads to DPR 
accumulation.  Certainly impairment of protein clearance pathways is a well characterised 
feature of ALS /FTD pathogenesis (Shahheydari et al., 2017).  Another potential explanation 
for the progressive increase in DPR abundance could be due to increased drive through the 
ubiquitin promoter with age.  DPR species have previously been shown to bind ubiquitin in 
intracellular inclusions (Mackenzie et al., 2014, May et al., 2014, Zhang et al., 2014).  This 
ubiquitin binding may cause increased transcriptional drive on the ubiquitin promoter thus 
producing more C9orf72-RNA and more DPR protein (C9orf72 expansion expression is 
driven by the ubiquitin promoter in 2.2 zebrafish), resulting in the formation of a positive 
feedback loop.  These possibilities deserve careful exploration in the future. 
DPR expression in the CNS, activation of the stress response in the CNS, centre avoidance 
behaviour and motor neuron loss all provide evidence of neurological dysfunction in 2.2-7 
zebrafish.  Muscle tissue in 2.2-7 zebrafish also expresses DPR species, and may therefore 
contribute to the adult onset motor neuron loss through cell to cell transmission of DPR 
species, or by loss of trophic support for motor neuron axon terminals due to muscle 
degeneration (Griesbeck et al., 1995, Westergard et al., 2016).  It is important to note that, 
contribution to motor neuron pathology from muscle tissues has also been suggested in 
human ALS, as muscle tissue from ALS patients frequently contains abnormal protein 
aggregates such as p62 positive inclusions (Al-Sarraj et al., 2014).  In contrast, centre 
avoidance is primarily a behavioural abnormality and as such is unlikely to be influenced by 
muscle expression of DPR species.  The reason why abnormal centre avoidance behaviour 
is detectable at 5dpf, while reduced swimming endurance and motor neuron loss are not 
observed until adulthood, is not fully understood.  It is possible that this may reflect the cell 
type specific toxicity which is frequently reported with DPR proteins (Mackenzie et al., 2013, 
Gendron et al., 2015, Schludi et al., 2015).  In the future, careful time course analysis of 
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muscle and motor neuron pathology in 2.2-7 zebrafish would help to distinguish myogenic 
from neurogenic pathologies.  
Overall, it is clear from the characterisation of the RNA+DPR zebrafish that the phenotype 
expressed is more severe than the phenotype observed in RNA-only zebrafish.  This is 
discussed further in chapter 6.
117 
 
5. Chapter 5:  C9orf72 expansions induce upregulation of TDP1 
and SOD1 proteinopathy 
5.1. Introduction 
Dysregulation of multiple seemingly unrelated pathways have now been reported in C9orf72-
ALS cases.  It is difficult to separate pathways which are driving ALS pathogenesis from 
those which are consequences of neurodegeneration, unrelated to disease progression.  
These problems are further complicated by a lack of translation of animal model data.  For 
example, it is now clear that in animal models DPR drive toxicity to a larger extent than RNA 
foci (Tran et al., 2015, Ohki et al., 2017).  However, in human pathological studies, DPR 
expression poorly correlates with disease severity (Mackenzie et al., 2013).  In particular, 
most human pathological studies seem to agree that in the motor cortex, DPR expression is 
low and disease severity is high, whereas in the cerebellum the reverse is true (Mackenzie 
et al., 2013, Gendron et al., 2015, Mackenzie et al., 2015, Schludi et al., 2015).  In order to 
further test the argument that DPRs do not correlate with clinical phenotype, it is important to 
carefully quantify DPR levels in disease affected areas using robust techniques, and 
investigate whether early toxicity can be observed in the cerebellum. 
 
5.2. Aims 
We aimed to first assess whether DPR proteins can be reliably detected in disease relevant 
areas of human post-mortem samples using a quantitative immunoblotting technique.  
Following this, we aimed to characterise in detail whether the cerebellum shows any early 
signs of toxicity. Finally, we aimed to further interrogate the types of pathology induced by 
C9orf72 expansions in human post-mortem tissue. 
 
5.3. Multiple DPR species are detectable in cerebellum but only poly(GA) is 
detectable in motor cortex 
Post-mortem grey matter samples from the cerebellum and white matter samples from the 
motor cortex (white matter motor cortex was selected due to lack of grey matter motor cortex 
patient tissue availability at the time of the experiment) were lysed and drawn through a 
vacuum onto a PVDF membrane which was then immunoblotted.  To obtain loading 
controls, each lysed sample was divided into two tubes immediately before being vacuum 
drawn onto the PVDF membrane.  Thus, two duplicate membranes were obtained, one 
membrane was immuno blotted with tubulin (raised in mouse) followed by poly(PR) (raised 
in rabbit), while the other membrane was immunoblotted with poly(GA) (raised in mouse) 
followed by poly(GP) (raised in rabbit).  Tubulin images were used as a loading control for all 
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DPR antibodies, as both membranes contained duplicates of the same samples.  For more 
details see methods section 2.2.16.   
Poly(GA) protein levels were significantly higher in motor cortex and cerebellum samples 
from C9orf72 patients as compared with equivalent samples from non-neurological disease 
controls (1.1 vs 0.022 poly(GA)/tubulin for motor cortex samples from C9orf72 and control 
patients respectively; Figure 5.1a-c; 5.1 vs 0.0043 poly(GA)/tubulin for cerebellum samples 
from C9orf72 and control patients respectively; Figure 5.1d-f).  In both motor cortex and 
cerebellum samples, poly(GA) protein levels in sALS patients were not significantly different 
compared to those in non-neurological disease controls (Figure 5.1a-f). 
Poly(GP) protein levels were not significantly different in white matter motor cortex samples 
from C9orf72 patients or sALS patients when compared with non-neurological disease 
controls (Figure 5.2a-c).  However, poly(GP) protein levels in grey matter cerebellum 
samples from C9orf72 patients were significantly higher compared with non-neurological 
controls (4.3 vs 0.043 for C9orf72 and control samples respectively; Figure 5.2d-f).  No 
difference in poly(GP) levels was observed in grey matter samples from sALS patients as 
compared to non-neurological controls.   
No significant difference was observed in poly(PR) protein levels in white matter motor 
cortex samples from C9orf72 patients as compared with non-neurological controls (Figure 
5.3a-c).  Unexpectedly, poly(PR) protein levels from motor cortex were higher in sALS 
samples as compared to non-neurological disease controls (0.44 vs 0.10 poly(PR)/tubulin for 
sALS and control samples respectively; Figure 5.3a-c).  This difference was primarily driven 
by a single sample suggesting that this patient could potentially harbour a poly(PR) encoding 
expansion in another genetic locus.  Finally, poly(PR) protein levels were significantly higher 
in grey matter cerebellum samples from C9orf72 patients as compared to non-neurological 
disease controls (8.7 vs 0.15 poly(PR)/tubulin for cerebellum samples from C9orf72 patients 
and controls respectively; Figure 5.3d-f).   
There are some limitations to the dot blots described above.  As the same tubulin image was 
used as a loading control for both duplicate membranes used, this assumes that protein 
levels bound to each membrane were equal.  Additionally, only one protein concentration of 
each sample was used, rather than a dilution series.  Furthermore, unlike western blots, dot 
blots do not allow for the separation of specific and non-specific immunoreactive protein 
species by molecular weight.  Therefore, the precise proportion of signal which is contributed 









Figure 5.1: Poly(GA) DPR proteins are produced in both motor cortex and 
cerebellum of C9orf72 ALS patients 
(a) Dot blots of motor cortex white matter protein show similar loading in all groups, as 
measured by tubulin signal.  (b) Dot blots of motor cortex white matter proteins show a 
markedly higher poly(GA) signal in samples from C9-ALS patients.  (c) Quantification 
showing that in motor cortex white matter, significantly higher poly(GA) signal is detected 
in C9-ALS samples in comparison to control samples, when normalised to tubulin.  As this 
dataset was not normally distributed according to the Shapiro-Wilk test for normality, 
statistical comparison was carried out using the Kruskal-Wallis test with Dunn’s post hoc 
test.  (d) Dot blots of cerebellum grey matter protein show similar loading in all groups, as 
measured by tubulin signal.  (e) Dot blots of cerebellum grey matter proteins show a 
markedly higher poly(GA) signal in samples from C9-ALS patients.  (f) Quantification 
showing that in cerebellum grey matter, significantly higher poly(GA) signal is detected in 
C9-ALS samples in comparison to control samples, when normalised to tubulin. As this 
dataset was not normally distributed according to the Shapiro-Wilk test for normality, 
statistical comparison was carried out using the Kruskal-Wallis test with Dunn’s post hoc 
test. For all samples, the patient code is listed above each sample (see table 2.2 for full 
patient information). Con: Control, sALS: sporadic-ALS, C9: C9-ALS. All data are shown 










Figure 5.2 : Poly(GP) DPR proteins are produced in cerebellum but not white matter 
motor cortex of C9orf72 ALS patients 
(a) Dot blots of motor cortex white matter protein show similar loading in all groups, as 
measured by tubulin signal.  (b) Dot blots of motor cortex white matter protein show similar 
levels of poly(GP) signal in all groups. (c) Quantification showing that in motor cortex white 
matter, no significant difference in poly(GP) is observed between any group, when 
normalised to tubulin.  Statistical comparisons were carried out using a one-way ANOVA 
with Dunnett’s post hoc test. (d) Dot blots of cerebellum grey matter protein show similar 
loading in all groups, as measured by tubulin signal. (e) Dot blots of cerebellum grey 
matter proteins show a markedly higher poly(GP) signal in samples from C9-ALS patients. 
(f) Quantification showing that in cerebellum grey matter, significantly higher poly(GP) 
signal is detected in C9-ALS samples in comparison to control samples, when normalised 
to tubulin. As this dataset was not normally distributed according to the Shapiro-Wilk test 
for normality, statistical comparison was carried out using the Kruskal-Wallis test with 
Dunn’s post hoc test. For all samples, the patient code is listed above each sample (see 
table 2.2 for full patient information). Con: Control, sALS: sporadic-ALS, C9: C9-ALS. All 









Figure 5.3: Poly(PR) DPR proteins are produced in cerebellum but not white matter 
motor cortex of C9orf72 ALS patients 
(a) Dot blots of motor cortex white matter protein show similar loading in all groups, as 
measured by tubulin signal.  (b) Dot blots of motor cortex white matter proteins show a 
markedly higher poly(PR) signal in samples from sALS patients, but not C9-ALS patients. 
(c) Quantification showing that in motor cortex white matter, a significantly higher poly(PR) 
signal is observed in the sALS samples in comparison to control samples, when 
normalised to tubulin. As this dataset was not normally distributed according to the 
Shapiro-Wilk test for normality, statistical comparison was carried out using the Kruskal-
Wallis test with Dunn’s post hoc test. (d) Dot blots of cerebellum grey matter protein show 
similar loading in all groups, as measured by tubulin signal.  (e) Dot blots of cerebellum 
grey matter proteins show a markedly higher poly(PR) signal in samples from C9-ALS 
patients. (f) Quantification showing that in cerebellum grey matter, significantly higher 
poly(PR) signal is detected in C9-ALS samples in comparison to control samples, when 
normalised to tubulin. As this dataset was not normally distributed according to the 
Shapiro-Wilk test for normality, statistical comparison was carried out using the Kruskal-
Wallis test with Dunn’s post hoc test. For all samples, the patient code is listed above each 
sample (see table 2.2 for full patient information). Con: Control, sALS: sporadic-ALS, C9: 
C9-ALS. All data are shown as mean +/- standard deviation; ns: not significant, *P < 0.05 
and **P < 0.01. 
 
These data show that a diverse range of DPR proteins are readily detectable in cerebellum 
tissue samples from C9orf72 patients.  Given the reported toxicity of DPR proteins, we next 
aimed to assess whether sub-clinical neurodegeneration may be detected in C9orf72 
cerebellum samples. 
5.4. Purkinje cell loss is not a feature of C9orf72-ALS 
In order to assess whether DPR load in the cerebellum of C9orf72-ALS patients is capable 
of causing sub-clinical neurodegeneration, we counted Purkinje neurons from sections of the 
cerebellum adjacent to the dentate gyrus.  Beginning at the bottom of each slide, the contour 
of the Purkinje cell layer was followed until 200 Purkinje cells had been counted or the top of 
the slide had been reached (Figure 5.4a).  To control for the effect of any potential cell 
shrinkage, only Purkinje neurons in which the nucleolus was visible were counted during the 
blinded quantification (Figure 5.4b).  Surprisingly, despite the presence of DPR proteins in 
C9orf72 patient cerebellum samples, there was no significant difference between Purkinje 
cell counts of C9orf72 patients and those from non-neurological disease controls (Figure 
5.4c).  As there was no detectable neurodegeneration of Purkinje cells, we next focussed on 







5.5. The DNA repair factor TDP1 is upregulated in C9orf72-ALS and sALS 
Previous reports indicate that C9orf72 expansions cause DNA damage and inhibit DNA 
repair pathways (Lopez-Gonzalez et al., 2016, Farg et al., 2017, Walker et al., 2017).  Loss 
of function of the DNA repair factor Tyrosyl-DNA phosphodiesterase 1 (TDP1) has been 
identified as a cause of neurodegeneration in patients suffering from SCAN-1 (El-Khamisy et 
al., 2005).  We set out to assess whether TDP1 is among the multitude of DNA repair factors 
inhibited by C9orf72 expansions and may therefore contribute to C9orf72 expansion driven 
neurodegeneration.  We lysed post-mortem tissue samples from the grey and white matter 
of the motor cortex and the grey matter of the cerebellum, separated the proteins by SDS-
PAGE and then immuno blotted for TDP1.  In the grey matter of the cerebellum, TDP1 
protein levels were significantly higher in C9orf72 patients samples as compared to non-
neurological disease control samples (0.45 vs 0.017 TDP1/tubulin for C9orf72 patient and 
control samples respectively; Figure 5.5a+d).  TDP1 protein levels in grey matter 
cerebellum samples from sALS patients were not significantly different compared to non-
neurological control samples.   
Interestingly, in the white matter of the motor cortex TDP1 levels in sALS patients were 
significantly higher than in non-neurological controls (0.71 vs 0.27 TDP1/GAPDH, for sALS 
and controls samples respectively; Figure 5.5b+e).  However, in white matter of the motor 
cortex TDP1 levels in C9orf72 patient samples were not significantly different than in non- 
Figure 5.4: C9orf72 ALS patients have normal cerebellar Purkinje cell counts 
(a)  Representative image of cerebellar folia adjacent to the dentate gyrus.  The red 
dashed line indicates the Purkinje cell layer, from which Purkinje cells were counted.  
Scale bar = 2mm.  (b) Representative image showing three Purkinje cells in the Purkinje 
cell layer (red dashed line).  The red circles indicate Purkinje cells that would not be 
counted in the analysis as the nucleolus is not visible.  Whereas, the green circle indicates 
a Purkinje cell which would be included in the analysis as the nucleolus is visible.  Scale 
bar = 250µm.  (c) In the Purkinje cell layer adjacent to the dentate gyrus of the 
cerebellum, there is no significant difference in the number of Purkinje cells per mm in 
C9orf72 ALS patients as compared with non-ALS controls.  In order to control for potential 
cell shrinkage, only Purkinje neurons in which the nucleolus was visible were included in 
the analysis.  N=11 controls and 16 C9-ALS patients.  Statistical comparison was carried 






Figure 5.5: TDP1 protein is upregulated in sALS and C9-ALS patient brains 
(a) In cerebellum grey matter, TDP1 protein is markedly increased in C9-ALS patient 
samples.  (b) In motor cortex white matter, TDP1 protein is markedly increased in sALS 
patient samples.  (c) In motor cortex grey matter, TDP1 protein is markedly increased in 
C9-ALS samples.  (d) Quantification shows that cerebellar grey matter TDP1 levels are 
significantly higher in C9-ALS samples compared to controls, when normalised to tubulin. 
This dataset was not normally distributes according to the Shapiro-Wilk test for normality 
and was therefore statistically compared using the Kruskal-Wallis test followed by Dunn’s 
post hoc test.  (e) Quantification shows that motor cortex white matter TDP1 levels are 
significantly higher in sALS samples compared (Legend continues on next page)              
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to controls, when normalised to tubulin.  Statistical comparisons were carried out using a 
one-way ANOVA with Dunnett’s post hoc test.  (f) Quantification shows that motor cortex 
grey matter TDP1 levels are significantly higher in C9-ALS samples compared to controls, 
when normalised to tubulin.  This dataset was not normally distributes according to the 
Shapiro-Wilk test for normality and was therefore statistically compared using the Mann-
Whitney U test.  For all samples, the patient code is listed above each sample (see table 
2.2 for full patient information).  All data are shown as mean +/- standard deviation; ns: not 
significant and *P < 0.05. 
 
neurological controls.  Finally, in the grey matter from the motor cortex, TDP1 levels in 
C9orf72 patients were significantly higher than in non-neurological disease controls (0.17 vs 
0.019 TDP1/tubulin, for C9orf72 patient samples and control samples respectively; Figure 
5.5c+f). 
Taken together, these data indicate that protein expression of the DNA repair protein TDP1 
is not inhibited by C9orf72 expansions, but is actually upregulated in C9orf72-ALS and 
sALS, depending on tissue type.  As it seems that loss of TDP1 function does not drive 
neurodegeneration in C9orf72-ALS, we next set out to investigate whether wtSOD1 
proteinopathy may be implicated in C9orf72 expansion pathology. 
 
 
5.6. C9orf72 expansions induce wtSOD1 and TDP-43 proteinopathy in disease 
relevant areas 
To date, the role of wtSOD1 pathology in ALS has typically been studied using misfolded-
SOD1 specific antibodies in histological CNS sections, which thus far have suggested that 
misfolded-wtSOD1 is not a component of pathology (Da Cruz et al., 2017).  To examine 
wtSOD1 pathology in ALS patients, we probed total protein lysates from brain samples with 
a conventional SOD1 antibody (not misfolded-SOD1 specific) raised against amino acids 1-
100 of the wtSOD1 protein.  We identified that a high molecular weight (HMW) form of SOD1 
detected at just above 35KDa, was significantly more abundant in white matter from motor 
cortex of  ALS patients, as compared to comparable regions in non-neurological-disease 
control samples (Figure 5.6a+b).  Fragmentation of TDP-43 is a common feature observed 
in the majority of ALS cases, this primarily results in the formation of 35KDa and 25KDa 
TDP-43 fragments (Inukai et al., 2008, Tsuji et al., 2012, Kametani et al., 2016).  Here, we 
focussed on the 35KDa fragment of TDP-43 (TDP-35) as this was more abundant in our 
samples.  We identified that TDP-35 was also significantly more abundant in white matter 








Figure 5.6: HMW-SOD1 and TDP-35 are increased in C9-ALS motor cortex white 
matter 
(a) A marked increase in 35KDa SOD1 and 35KDa TDP-43 immunoreactive bands is 
observed in C9-ALS samples.  (b) Quantification shows that the signal of 35KDa SOD1 
immunoreactive bands is significantly higher in C9-ALS patient samples compared with 
controls, when normalised to tubulin.  Statistical comparisons were carried out using a 
one-way ANOVA with Dunnett’s post hoc test.  (c) Quantification shows that the signal of 
35KDa TDP-43 immunoreactive bands is significantly higher in C9-ALS patient samples 
compared with controls, when normalised to tubulin. Statistical comparisons were carried 
out using a one-way ANOVA with Dunnett’s post hoc test. (d)  There is a significant 
correlation between normalised TDP-35KDa and SOD1-35KDa irrespective of genotype.  
Correlation was analysed using the Pearson correlation coefficient. For all samples, the 
patient code is listed above each sample (see table 2.2 for full patient information).  
Western blot quantification data are shown as mean +/- standard deviation; ns: not 
significant, *P < 0.05 and ****P < 0.0001. 
 
neurological-disease control samples (Figure 5.6a+c).  Intriguingly, we also observed that 
those patients who showed abundant TDP-35 also showed abundant HMW-SOD1.  Indeed, 
there was a strong positive correlation between the abundance of TDP-35 and the 
abundance of HMW-SOD1 across all white matter motor cortex samples (Figure 5.6d).   
Furthermore, in grey matter samples from the motor cortex, HMW-SOD1 protein was again 
significantly more abundant in C9orf72 patient samples as compared with non-neurological 
disease control samples (Figure 5.7a+b).  Likewise, in grey matter samples from the motor 
cortex fragmented TDP-43 was also significantly more abundant in C9orf72 patient samples 
in comparison to non-neurological disease control samples (Figure 5.7a+c).  Similarly to 
findings from white matter, samples from grey matter of the motor cortex also showed a 
strong positive correlation between the abundance of TDP-35 and the abundance of HMW-
















In order to identify whether HMW-SOD1 and TDP-35 pathology is specific to disease 
affected areas, we also examined the abundance of these molecular species in cerebellum 
tissue.  The abundance of HMW-SOD1 was not significantly different between either sALS 
or C9orf72-ALS patients when compared to non-neurological-disease controls, in grey 
matter samples from the cerebellum (Figure 5.8a+b).  Similarly, the abundance of TDP-35 
was not significantly different between either sALS or C9orf72-ALS patients and non-
neurological-disease controls, when examined in grey matter samples from the cerebellum 
(Figure 5.8a+c).  Interestingly, despite no change in the abundance of HMW-SOD1 and 
TDP-35 in cerebellum samples, there was still a strong positive correlation between the two 
molecular species (Figure 5.8d).  This suggests that there may be a fundamental 
association between TDP-35 and HMW-SOD1, even under non-pathological conditions.  
This human pathological tissue data suggests that there may be a link between C9orf72 and 






Figure 5.7: HMW-SOD1 and TDP-35 are increased in C9-ALS motor cortex grey 
matter 
(a) A marked increase in 35KDa SOD1 and 35KDa TDP-43 immunoreactive bands is 
observed in C9-ALS samples.  (b) Quantification shows that the signal of 35KDa SOD1 
immunoreactive bands is significantly higher in C9-ALS patient samples compared with 
controls, when normalised to tubulin. This dataset was not normally distributed according 
to the Shapiro-Wilk test for normality and was therefore statistically compared using the 
Mann-Whitney U test.  (c) Quantification shows that the signal of 35KDa TDP-43 
immunoreactive bands is significantly higher in C9-ALS patient samples compared with 
controls, when normalised to tubulin. This dataset was not normally distributes according 
to the Shapiro-Wilk test for normality and was therefore statistically compared using the 
Mann-Whitney U test.  (d)  There is a significant correlation between normalised TDP-
35KDa and SOD1-35KDa irrespective of genotype.  Correlation was analysed using the 
Pearson correlation coefficient. For all samples, the patient code is listed above each 
sample (see table 2.2 for full patient information).  Western blot quantification data are 











Figure 5.8: No difference in HMW-SOD1 and TDP-35 in C9-ALS cerebellum grey 
matter 
(a) Similar levels of 35KDa SOD1 and 35KDa TDP-43 immunoreactive bands are 
observed across all three groups.  (b) Quantification shows that the signal of 35KDa 
SOD1 immunoreactive bands is not significantly different between all three groups, when 
normalised to tubulin.  Statistical comparison were carried out using a one-way ANOVA 
with Dunnett’s post hoc test.  (c) Quantification shows that the signal of 35KDa TDP-43 
immunoreactive bands is not significantly different between all three groups, when 
normalised to tubulin. Statistical comparison were carried out using a one-way ANOVA 
with Dunnett’s post hoc test. (d)  There is a significant correlation between normalised 
TDP-35KDa and SOD1-35KDa irrespective of genotype. Correlation was analysed using 
the Pearson correlation coefficient. For all samples, the patient code is listed above each 
sample (see table 2.2 for full patient information). Western blot quantification data are 




Unexpectedly, poly(PR) levels were significantly higher in sALS patient motor cortex white 
matter samples, although this increase was predominately driven by a single sample.  There 
are exactly 24 hexanucleotide sequences which could potentially encode poly(PR) proteins, 
G4C2 is only 1 of these.  Therefore it may be beneficial to screen sALS patients for additional 
DNA repeat expansions in other genetic loci which may also be causative of ALS/FTD.  It is 
noteworthy that the nature of DNA repeat expansions made C9orf72 hexanucleotides 
difficult for researchers to detect with traditional techniques and therefore allowed them to 
remain hidden for many years. 
A wider variety of DPR species were detectable in cerebellum grey matter samples from 
C9orf72 patients (poly(GA+GP+PR) detectable) vs motor cortex white matter samples from 
C9orf72 patients (only poly(GA) detectable).  Additionally, poly(GA) levels in cerebellum (300 
fold higher than sALS cerebellum samples) were markedly higher than levels in motor cortex 
(8 fold higher than sALS cerebellum samples).  This is consistent with other reports of higher 
DPR expression in the cerebellum compared with other brain regions (Mackenzie et al., 
2013, Mann et al., 2013, Baborie et al., 2015, Davidson et al., 2016).   
Despite substantial DPR load, the number of cerebellar Purkinje neurons was not decreased 
in C9orf72 patient brains.  Purkinje cells were originally selected as a readout of cerebellar 
neurodegeneration as they are the largest neurons in the cerebellum, and therefore may be 
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more susceptible to DPR mediated dysregulation.  The theory that large cell types may have 
increased susceptibility to certain pathologies has been suggested in an attempt to explain 
why motor neurons are selectively lost in ALS cases.  However, in the case of the C9orf72-
ALS patients studied presently, large Purkinje neurons suffered no decrease in cell number 
despite DPR loads in local regions.  Previous studies indicate that multiple DPR species are 
detectable in molecular, granular and Purkinje cells of the cerebellum of C9orf72 patients 
(Mackenzie et al., 2013, Mackenzie et al., 2015, Saberi et al., 2017).  This may suggest that 
resistance of cerebellar neurons to DPR mediated pathology may be conferred due to 
epigenetic differences in gene regulation in these types of neurons in comparison with 
ALS/FTD affected motor neurons and pyramidal neurons.  The precise gene expression 
profile which may confer DPR resistance to cerebellar neurons may be investigated in the 
future by using laser capture followed by single cell RNA sequencing to determine 
transcriptomic profile differences between Purkinje cells and motor neurons.  Additionally, 
counting of cerebellar granule or molecular cell layer neurons may be informative as to 
whether sub-populations of neurons in the cerebellum are differentially susceptible to 
C9orf72 expansion mediated toxicity. 
Upregulation of HMW-SOD1 and fragmented TDP-43 was also discovered in motor cortex 
grey and white matter from C9orf72-ALS patients.  The nature of these species is discussed 
at length in chapter 6.  Most interestingly, the abundance of HMW-SOD1 strongly correlated 
with levels of fragmented TDP-43 in all tissue types tested, including non-neurological 
control tissue and tissue from disease unaffected areas.  This correlation therefore appears 
to be fundamental and occurs regardless of other pathological features.  This suggests that 
fragmented TDP-43 may induce expression of HMW-SOD1 or vice versa (also discussed 
further in chapter 6).  However, it is important at this point not to rule out that there may be a 
third, currently unknown species, which drives expression of both fragmented TDP-43 and 
HMW-SOD1 simultaneously.    
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6. Chapter 6: Discussion 
6.1. RNA foci vs DPR toxicity 
We have generated two distinct types of C9orf72 zebrafish, these are RNA-only and 
RNA+DPR zebrafish models.  Our RNA-only zebrafish express RNA foci and GFP protein 
(GFP detectable in embryonic and adult tissues).  Despite sustained transgene expression, 
no DPRs could be detected in RNA-only zebrafish at adulthood.  In this respect, RNA-only 
zebrafish were successful in segregating RNA foci and DPR expression.  Additionally, the 
highest expressing RNA-only zebrafish did not show any reduction in survival or underlying 
reduction in swimming endurance at 26 months (although a mild hyper activity phenotype 
was detected at 5dpf).  These data are consistent with previous reports indicating that RNA 
foci expression alone is not sufficient to produce a toxic phenotype in drosophila models 
(Mizielinska et al., 2014, Tran et al., 2015).  Conversely, another report identified RNA foci 
mediated toxicity in zebrafish even when the absence of DPRs was confirmed (Swinnen et 
al., 2018).  These data suggest that C9orf72 expansion RNA may have to be expressed 
above a certain threshold for toxicity to be observed. 
The second type of zebrafish generated were RNA+DPR zebrafish.  These zebrafish 
showed RNA foci and RAN-translated DPR expression.  RNA+DPR zebrafish also exhibited 
increased average speed of movement and increased total distance moved at 5dpf in 
comparison to NTG zebrafish.  The identification of a hyperactivity phenotype in both RNA-
only and RNA+DPR zebrafish at 5dpf was unexpected.  The cause of this early hyperactivity 
phenotype remains unclear, although motor neuron hyperexcitability has been previously 
reported in the early stages of ALS and is thought to contribute to the fasciculations 
characteristic of ALS onset in many patients (Iwai et al., 2016).  RNA+DPR zebrafish also 
exhibited centre avoidance behaviour at 5dpf.  This suggests an unwillingness to explore the 
environment and is consistent with similar results from open field tests conducted in RNA 
foci and DPR expressing C9orf72 BAC transgenic mice (Liu et al., 2016).  These features 
then progressed to reduced body mass, reduced swimming endurance, motor neuron loss, 
muscle atrophy and early mortality.  These data are consistent with the motor neuron loss 
and early mortality reported in a BAC transgenic mouse model expressing RNA foci and 
DPR species (Liu et al., 2016), as well as the motor deficits reported in two independently 
generated virally transduced mouse models expressing RNA foci and DPR species (Chew et 
al., 2015, Herranz-Martin et al., 2017). 
It is important to highlight that RNA-only and RNA+DPR zebrafish have different C9orf72 
expansion orientations (G4C2 and C4G2 respectively) and different expansion lengths (99 
repeats and 89 confirmed repeats respectively).  The presence of uncontrolled variables 
makes direct comparison of RNA-only and RNA+DPR zebrafish more difficult.  For example, 
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comparison of RNA foci abundance and distribution between the two lines was not possible 
as two different in situ hybridisation RNA probes with potentially different 
affinities/specificities were required.  For these reasons it is difficult to make precise 
comparisons between the molecular pathologies of the RNA-only and RNA+DPR zebrafish 
reported here.  However, it is reasonable to conclude that within our zebrafish models, 
expression of RNA foci + DPR species cause a more severe phenotype than expression of 
RNA foci alone.   
Other in vivo model data supports the conclusion that RNA foci + DPR expression is more 
potently toxic than RNA foci alone (Mizielinska et al., 2014, Tran et al., 2015, Ohki et al., 
2017).  It is possible that RNA foci contribute towards toxicity to a lesser extent than DPRs, 
or that RNA foci and DPRs act additively/synergistically to generate toxicity (2 hits theory).  
Certainly, previous data in zebrafish models suggest that RNA foci and DPR may both 
contribute towards toxicity via independent mechanisms (Swinnen et al., 2018).  It is 
important to note that use of alternate codons have allowed DPR species to be encoded 
without use of G4C2 C9orf72 RNA (Mizielinska et al., 2014).  However, alternate codons 
encoding DPR species still require expression of repetitive exogenous RNA species, and 
therefore do not fully eliminate the potential of RNA mediated toxicity.  Therefore, data 
presented here and previously, indicate that DPR and RNA foci are both toxic in C9orf72 in 
vivo models, with DPR presence usually correlating with a more severe phenotype. 
 
6.2. Zebrafish DPR expression profiles 
Western blotting of RNA+DPR zebrafish lysates revealed that multiple DPR species were 
present, producing a laddered appearance.  Both sense and antisense DPRs were detected, 
and DPRs could be produced via both conventional ATG-driven translation and RAN-
translation.  Detection of species of varying MW has also been reported during RAN-
translation of CAG repeats (Zu et al., 2011), and during RAN-translation of GGGGCC in C9-
ALS patients (Zu et al., 2013).  In both previously mentioned cases the RAN-translation 
products formed a smear rather than distinct laddered protein bands as in our C9-zebrafish.  
The reason for this discrepancy may be due to the interruptions in the CCCCGG sequence 
used to generate our model causing the translation machinery to uncouple, thus consistently 
producing protein species of the same size.  It is also possible that due to instability of the 
repeat DNA, multiple concatemerised transgene copies may contain variable repeat lengths 
and could therefore be producing multiple RNA transcripts of variable length, and thus 
multiple DPRs of variable length.  Certainly, this reasoning may also explain why different 
DPR band expression profiles are observed between 2.2-2 and 2.2-7 zebrafish.   
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More RAN-translation mediated bands were detected in adult 2.2-7 zebrafish CNS 
compared to adult 2.2-2 zebrafish CNS.  Additionally, poly(GA) expression was only 
detected in 5dpf 2.2-7 zebrafish, suggesting that bidirectional transcription is only occurring 
in 2.2-7 zebrafish.  It is not currently known whether bi-directional transcription and 
increased formation of RAN-translation products during adulthood may be partially 
responsible for the increased toxicity observed in the 2.2-7 zebrafish line.  Activation of 
cellular stress pathways has been shown to potentiate RAN-translation, potentially forming a 
feedforward loop (Green et al., 2017, Cheng et al., 2018).  Given that heat shock stress 
activation is higher in 2.2-7 zebrafish, this may potentiate RAN-translation thus resulting in 
the observed increased number of bi-directionally transcribed and RAN-translated products, 
in comparison to 2.2-2 zebrafish.  Whether activation of the heat shock response influences 
RAN-translation efficiency in 2.2 zebrafish is an interesting line of investigation for the future.  
Interestingly, poly(PR) species were detected at higher MWs than other DPR species.  In the 
future, it may be important to investigate whether poly(PR)s tendency to form high MW 
species is related to its potent in vivo toxicity. 
 
6.3. Use of interrupted C9orf72 expansions 
Both RNA+DPR model zebrafish lines contained an interrupted C4G2 transgene construct.  
The advantages in using this construct are: 1) Only anti-sense RNA foci have been found to 
co-localise with TDP-43 mislocalisation (a common molecular hallmark of neurodegeneration 
in ALS) (Cooper-Knock et al., 2015b).  2) Anti-sense repeats will produce a greater 
proportion of the highly toxic proline-arginine repeat peptide (Mizielinska et al., 2014) and 3) 
Interruptions in the expansion allow for largely equal expression levels of all three anti-sense 
DPR proteins.   
There are also potential disadvantages of using interrupted C9orf72 expansions. 
Interruptions may increase the biochemical stability of DNA/RNA in comparison to pure 
repeat expansion DNA/RNA.  Although, interrupted C9orf72 expansions and pure repeat 
expansions are reported to produce similar levels of RNA foci, it has also been noted that 
larger expansions are more stable when interruptions are present (Mizielinska et al., 2014).  
This suggests that interruptions in C9orf72 expansions may alter DNA/RNA structure, which 
could potentially influence the affinity with which RNA foci sequester RNA-binding proteins.  
Additionally, there is conflicting evidence as to whether interrupted expansions increase or 
decrease genomic instability once incorporated into genomic DNA in a cellular setting,  
which further suggests that there are fundamental differences in the biochemical properties 
of interrupted and pure repeat expansions (Ananda et al., 2014, Landrian et al., 2017).  A 
further disadvantage of the use of interrupted repeats is that frameshifting interruptions will 
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result in all three DPR species (either 3 sense orientation or 3 antisense orientation DPRs) 
being encoded into a single protein.  DPR species have distinct biochemical properties.  In 
drosophila models where DPR proteins are individually expressed, poly(PR) localises to the 
nucleus, whereas poly(PA) and poly(GP) primarily localise to the cytoplasm (Mizielinska et 
al., 2013, Tran et al., 2015).  In contrast, in the 2.2 zebrafish reported in this thesis, all three 
antisense DPR species are expressed in a single protein, and all three antisense DPRs are 
primarily localised to the nucleus (likely due to the biochemical nature of the poly(PR) 
containing regions of this protein).  This is an example of how frameshifting interruptions can 
result in the production of protein species which have distinct characteristics from protein 
species encoded by pure repeat expansions. 
Due to the technical difficulty of sequencing large DNA repeat expansions, it is currently 
unknown whether C9orf72 expansion bearing patients possess interrupted repeats or pure 
repeats.  Notably, other repeat expansion disorders such as spinocerebellar ataxia are 
known to contain interruptions in some cases (Chung et al., 1993).  Ultimately, 
improvements in DNA expansion sequencing technologies which allow the presence or 
absence of interruptions in C9orf72 patient repeats to be confirmed will likely inform whether 
future C9orf72 expansion models should contain interrupted or pure C9orf72 expansions.   
 
6.4. Gain of function or loss of function mechanisms as drivers of C9orf72-
ALS/FTD 
Both RNA foci and DPR protein production are gain of function mechanisms of potential 
toxicity in C9orf72 expansion ALS.  However, an additional toxic mechanism proposed for 
C9orf72 expansion ALS/FTD, is loss of function of C9orf72 endogenous gene products 
leading to haploinsufficiency.  This mechanism was first proposed after the observation that 
mRNA encoding C9orf72 endogenous protein products was reduced in expansion bearing 
patients (DeJesus-Hernandez et al., 2011).  Furthermore, recent mass spectrometry 
analysis revealed decreased expression of the long isoform of the C9orf72 protein in the 
frontal cortex of C9orf72 expansion harbouring FTD patients (Viode et al., 2018).  Loss of 
C9orf72 protein function in two transient zebrafish models, and a stable C9orf72-knockout C. 
elegans model, all resulted in motor neuron pathologies (Ciura et al., 2013, Therrien et al., 
2013, Yeh et al., 2018).  Conversely, early data from stable C9orf72 knockout zebrafish 
suggest that no neurodegenerative or motor phenotype is observed (Stepto et al., 2014).  
Indeed, it has been reported that the transient knockdown phenotype observed in zebrafish 
is often not consistent with the phenotype exhibited upon stable knockout of the same gene 
(Kok et al., 2015).  Furthermore, multiple C9orf72 loss of function mouse models did not 
display any ALS/FTD phenotype (Koppers et al., 2015, Atanasio et al., 2016, Jiang et al., 
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2016, O'Rourke et al., 2016, Sudria-Lopez et al., 2016, Ji et al., 2017).  Moreover, multiple 
C9orf72 expansion gain of function mouse models have accurately recapitulated key 
disease features of ALS/FTD (O'Rourke et al., 2015, Liu et al., 2016, Herranz-Martin et al., 
2017, Walker et al., 2017).  Taken together, the conflicting data from in vivo models of 
C9orf72 loss of function, and the success of gain of function mouse models in recapitulating 
key features of ALS/FTD have caused haploinsufficiency of the C9orf72 protein to fall out of 
favour as a proposed driving mechanism of ALS/FTD.   
Some researchers argue that, although haploinsufficiency of the C9orf72 protein is unlikely 
to drive ALS/FTD progression, it may be a modifier of RNA/DPR toxicity (Webster et al., 
2016b, Nassif et al., 2017, Shi et al., 2018).  The C9orf72 protein itself has been identified as 
being crucial in the initiation of autophagy (Farg et al., 2014, Sellier et al., 2016, Webster et 
al., 2016a).  Importantly, C9orf72 knockout mice have been reported to show impaired 
autophagy functioning (Ji et al., 2017), and impaired autophagy has been associated with 
ALS causative genetic mutations in SQSTM1 and UBQLN2 genes (Goode et al., 2016, 
Osaka et al., 2016).  Taken together, these data form the basis of the argument that 
haploinsufficiency of the C9orf72 protein may cause defects in normal autophagy processing 
which can potentially augment RNA/DPR mediated toxicity.  In line with this, induced motor 
neurons from C9orf72 patients, exhibit reduced autophagy-mediated clearing of DPR 
aggregates, which has been identified as contributing toward neurodegeneration (Shi et al., 
2018).  Moreover, knockout of the mouse orthologue of the C9orf72 gene in the background 
of a previously described BAC transgenic mouse expressing human C9orf72 expansions 
with flanking regulatory regions (Liu et al., 2016), caused a more severe motor phenotype in 
these mice (Shao et al., 2019).  However, most C9orf72 patients are heterozygous for the 
hexanucleotide expansion, and therefore retain a single wildtype functional copy of the 
C9orf72 gene.  Therefore, patients homozygous for C9orf72 hexanucleotide expansions may 
be expected to show an even greater reduction of C9orf72 endogenous protein and 
therefore more severe autophagy defects, thus modifying RNA/DPR toxicity to produce more 
severe clinical outcomes.  However, a case report of a single patient with homozygous 
C9orf72 expansions displayed a clinical profile which was within the expected pattern of 
disease progression of heterozygous patients, thus suggesting that homozygous reduction 
of C9orf72 protein production did not further augment RNA/DPR toxicity in this case (Fratta 
et al., 2013).  A possible experiment to resolve this issue, would be to measure C9orf72 
protein/mRNA levels in disease affected areas of post-mortem ALS/FTD patient CNS tissue, 




6.5. Clinicopathological correlations of DPRs in ALS/FTD 
A significant obstacle in our understanding of the driving pathomechanisms of C9orf72-
ALS/FTD is the relative lack of DPR pathology in disease affected regions.  In vivo models of 
C9orf72-ALS/FTD, including the present study, have clearly identified that DPR species are 
more toxic than RNA foci alone (Mizielinska et al., 2014, Tran et al., 2015, Ohki et al., 2017).  
However, multiple neuropathological studies have identified that DPR burden in disease 
affected areas (spinal cord, motor cortex, frontal cortex and temporal cortex) is typically 
lower in comparison to disease unaffected areas (basal ganglia and cerebellum) of C9orf72-
ALS/FTD patients (Mackenzie et al., 2013, Mann et al., 2013, Baborie et al., 2015, Davidson 
et al., 2016).  A potential explanation is that neurons exhibiting substantial DPR burden in 
disease affected areas may have completely degenerated when end-stage ALS/FTD is 
reached, and are therefore not detectable in post-mortem tissues.  This argument however 
does not explain why areas such as the cerebellum have a substantial DPR load, yet in the 
present study and a previous study, cerebellar DPR load did not correlate with significant 
neurodegeneration (Mackenzie et al., 2013).  As discussed previously, this may indicate a 
difference in the ability of different neuronal sub-populations to resist DPR-mediated toxicity.  
Investigation of the transcriptomic and epigenetic differences between affected and 
unaffected CNS regions in ALS/FTD patients is an attractive option to highlight pathways for 
potential therapeutic modulation.  More recently, poly(GR) DPR species have been identified 
to correlate with neurodegeneration in C9-ALS patients (Saberi et al., 2017, Sakae et al., 
2018).  Additionally, the majority of poly(GR) DPR inclusions were also positive for TDP-43 
(Saberi et al., 2017).  TDP-43 positive inclusions have also previously been shown to 
correlate with the extent of neurodegeneration in C9orf72-ALS/FTD post-mortem tissue 
(Mackenzie et al., 2013).  Taken together, these data indicate that most DPR species show 
poor spatial correlation with neurodegeneration and TDP-43 proteinopathy, with the 
exception of poly(GR).  This suggests that further studies should be directed towards 
studying poly(GR) specific mechanisms of toxicity.   
In order to compare the spatial distribution of various DPR species, most neuropathological 
studies rely heavily on immunohistochemical staining and occasionally western blotting 
using standard protocols (Mackenzie et al., 2013, Mann et al., 2013, Baborie et al., 2015, 
Mackenzie et al., 2015, Davidson et al., 2016, Saberi et al., 2017).  Whilst analysing CNS 
DPR levels in the present study, both immunohistochemical staining and western blotting 
were attempted, but both techniques resulted in difficult to interpret results in which control 
samples showed apparently high levels of DPR-like inclusions and multiple protein bands.  
Eventually, dot blotting tissue lysates under a vacuum was utilised as this method was able 
to detect significantly higher signal in C9orf72 patient cerebellum samples compared to 
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sALS or non-neurological control samples.  This may be because dot blotting removes the 
opportunity for DPR species to become trapped in western blot gels during electrophoresis.  
However, dot blotting of samples also has limitations due to an inability to separate specific 
and non-specific protein species bound by DPR antibodies (see section 5.7 for a full 
discussion of limitations of the dot blot technique).  The limitations of current DPR detection 
techniques highlights the need for the development of more sensitive DPR detection 
methods.  More sensitive detection methods will help reveal whether disease affected areas 
such as spinal cord may be expressing low levels of DPR species.  Additionally, multiple 
lysis buffers were tested when optimising DPR extraction from both zebrafish and human 
tissues.  Conventional RIPA or even high triton X-100 buffers were found to be inadequate 
when attempting to extract DPR species.  Furthermore, DPR species were found to readily 
pellet out during centrifugation.  For these reasons, tissue was lysed directly in loading buffer 
and no centrifugation step was used (see section 2.2.7 for lysis method details).  These 
techniques allowed much more sensitive detection of both zebrafish and human DPRs and 
may therefore be worthwhile to be adopted in future studies in replacement of standard lysis 
protocols.   
 
6.6. The heat shock response in ALS 
The heat shock response involves the up-regulation of heat shock proteins in response to 
the presence of aberrant cellular proteins in an attempt to refold, or target these aberrant 
proteins for degradation (Dedmon et al., 2005, Bukau et al., 2006).  Activation of the heat 
shock response was observed to some degree in both RNA-only and RNA+DPR zebrafish.  
Normalising for transgene expression levels by comparing ratios of DsRed:GFP between 
lines showed that both RNA+DPR zebrafish had significantly higher hsp70 promoter 
mediated production of DsRed, as compared with all RNA-only zebrafish lines.  These data 
suggest that DPRs drive heat shock activation more potently than RNA foci alone.  
Additionally, activation of the heat shock response was also detected in post-mortem 
cerebellum samples from C9orf72-ALS/FTD patients.  This is in line with previous reports, 
which identified activation of the heat shock response at the RNA level, in both cerebellum 
and frontal cortex of C9orf72-ALS/FTD patients (Prudencio et al., 2015, Mordes et al., 2018).  
Furthermore, the ALS causative G93R mutant SOD1 protein causes activation of the heat 
shock response in zebrafish (McGown et al., 2013). 
The G93R SOD1-ALS model zebrafish described previously also contained the same 
hsp70:DsRed drug screening construct used in the C9orf72 zebrafish reported in this thesis 
(Ramesh et al., 2010).  In the SOD1 zebrafish, treatment with riluzole (a disease modifying 
ALS treatment) ameliorated the extent of heat shock response activation (McGown et al., 
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2013).  Therefore, in SOD1 zebrafish, heat shock promoter mediated DsRed production was 
used as a disease biomarker against which to screen potentially therapeutic compounds.  
Approximately 2000 compounds have now been screened using these SOD1-ALS zebrafish 
models, and two of the top hits identified were the compounds ivermectin and selamectin 
(Ramesh lab, unpublished data).  Taking this into consideration, riluzole, ivermectin and 
selamectin were also tested in C9orf72 model zebrafish, and were shown to ameliorate heat 
shock promoter mediated DsRed production.  Ivermectin has previously been administered 
to SOD1-ALS transgenic mouse models by an independent lab, and was found to increase 
survival in these mice (Andries et al., 2007).  These data further demonstrate that 
compounds identified by hsp70:DsRed screening in zebrafish show genuine potential as 
prospective ALS treatments.  Ivermectin has been demonstrated to both ameliorate 
excitotoxicity and block specific nuclear importers, although the precise mechanism of the 
therapeutic properties of ivermectin in ALS models is not currently known (Andries et al., 
2007, Wagstaff et al., 2012).  Determining the mechanism of action of both selamectin and 
ivermectin in ALS models will be an important next step, which would allow additional 
compounds acting via similar mechanisms to be assessed in ALS models. 
However, there are also limitations to the use of the heat shock response as a drug 
screening readout for ALS.  As the drug screening readout relies upon hsp70 promoter 
mediated production of DsRed, it is possible that hits identified in each drug screen may 
mediate their effect by directly blocking heat shock response activation (through blocking 
transcription factor binding at the hsp70 promoter or by other means), rather than by 
reducing cellular stress.  Similarly, it is also possible that increased heat shock activation in 
ALS models and patient tissue is caused by disease associated mechanisms which are not 
directly related to disease progression.  In this case, drugs which reduce heat shock 
response activation would be unlikely to have significant therapeutic benefit to ALS patients.  
Both of the above mentioned limitations of the hsp70:DsRed drug screening system may be 
addressed by secondary validation of identified drugs using a phenotypic readout.  A simple 
paradigm which may address the limitations of the hsp70:DsRed system, would be to 
conduct higher throughput screening of compounds using the hsp70:DsRed system in 
zebrafish, and then to validate the top hits from these screens using survival, or time until 
onset of motor symptoms in ALS model zebrafish or mice as a phenotypic readout. 
In summary, activation of the heat shock response in C9orf72-ALS patient post-mortem 
tissue has been reported by two independent sources, and amelioration of heat shock 
activation by treatment with riluzole, ivermectin or selamectin can be achieved in in vivo 
models of two distinct genetic sub-types of ALS.  These data suggest that heat shock 
response activation may be a robust readout for identifying hits from compound libraries in 
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C9orf72 and SOD1-ALS zebrafish, before secondary validation of identified hits by 
phenotypic readouts. 
 
6.7. DNA damage and neurodegeneration in ALS 
The DNA damage response associated proteins PARP1 and TDP1 were identified as 
potential targets for investigation in C9orf72-ALS/FTD pathology due to their known role in 
other neurodegenerative disorders (El-Khamisy et al., 2005, Hoch et al., 2017), and the 
known involvement of DNA damage in C9orf72-ALS/FTD (Lopez-Gonzalez et al., 2016, Farg 
et al., 2017, Walker et al., 2017).  We did not find any evidence for over-activation of PARP1 
driving C9orf72-ALS/FTD pathogenesis.  Unexpectedly, PARP1 inhibition with olaparib had 
a detrimental effect on the survival of 2.2-7 C9orf72 zebrafish, and seemed to be selectively 
toxic to 2.2-7 zebrafish and not NTG zebrafish at lower doses.  These data indicate that 
PARP1’s crucial role in recruiting DNA repair factors to local DNA lesions was likely 
protective in C9orf72 zebrafish rather than detrimental as previously thought (Ciccia and 
Elledge, 2010).  Moreover, we did not find evidence of loss of TDP1 function, the reported 
cause of neurodegeneration in SCAN-1 patients (El-Khamisy et al., 2005).  Rather, TDP1 
protein was found to be upregulated in grey matter samples of cerebellum and motor cortex 
in C9orf72 patients and in white matter samples from motor cortex of sALS patients.  Taken 
together, these data support the notion that C9orf72 expansions cause DNA damage, and 
also suggest that a component of DNA damage may be present in sALS patient tissue.  
Finally, over activation of PARP1 or loss of TDP1 function are not likely candidates as 
drivers of ALS/FTD pathogenesis. 
 
6.8. Relationship between C9orf72 expansions, TDP-43 and SOD1 
A contentious question that is raised within ALS research, is whether a common mechanism 
exists which accounts for the pathogenesis of multiple ALS-subtypes.  Nearly all sporadic 
and familial (except SOD1-ALS and FUS-ALS) ALS cases show ubiquitinated cytoplasmic 
TDP-43 positive aggregates which co-localise with disease affected areas (Arai et al., 2006, 
Neumann et al., 2006, Mackenzie et al., 2007, King et al., 2015).  However, the role of SOD1 
in non-SOD1 ALS is more controversial, with multiple studies reporting 
misfolded/aggregated SOD1 in spinal cord tissue from sALS patients (Bosco et al., 2010, 
Forsberg et al., 2010, Pokrishevsky et al., 2012, Grad et al., 2014), and multiple other 
studies refuting this finding (Kerman et al., 2010, Brotherton et al., 2012, Liu et al., 2012, 
Ayers et al., 2014, Da Cruz et al., 2017).   
In the present study, HMW-SOD1 protein was found to be significantly more abundant in 
post-mortem white and grey matter motor cortex of C9orf72-ALS patients.  This is in line with 
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a recent study which identified misfolded SOD1 staining in the CNS of 15 C9orf72-ALS/FTD 
cases (10/15 of these cases showed positive misfolded SOD1 staining in the motor cortex) 
(Forsberg et al., 2019).  The reason why SOD1 forms HMW species in C9orf72 patient 
motor cortex is not known.  Although, formation of high molecular weight species has also 
been reported in cell models expressing multiple variants of mutant SOD1 protein (Brown 
and Borchelt, 2014).  HMW-SOD1 species also showed a non-significant increase in sALS 
patient samples from motor cortex white matter.  Given that the increase in HMW-SOD1 in 
C9orf72 patient samples was much clearer in grey matter motor cortex, it will be vital to 
examine HMW-SOD1 expression in this region of sALS patients also.  Additionally, we 
confirmed a previous report of increased abundance of fragmented TDP-43 in the frontal 
cortex of C9orf72-ALS patients (Tsuji et al., 2012).  Unexpectedly, fragmented TDP-43 was 
not increased in white matter motor cortex samples from sALS patients, and future 
investigation of grey matter samples from these patients will be of vital importance.  
Importantly, both HMW-SOD1 and fragmented TDP-43 pathology were only more abundant 
in the motor cortex of C9orf72 patients, and not in the cerebellum, indicating that both 
proteinopathies were specific to disease affected areas of C9orf72-ALS patients.   
Interestingly, in all analysed post-mortem tissues, there was a strong positive correlation 
between fragmented TDP-43 and HMW-SOD1, thus suggesting that there may be a 
fundamental association between the two species.  It has previously been reported that 
TDP-43 proteinopathy can induce wtSOD1 pathology in cultured cells (Pokrishevsky et al., 
2012, Pokrishevsky et al., 2016).  Certainly, this mechanism may explain why TDP-43 
pathology is rarely observed in fALS patients harbouring a mutation in the SOD1 gene 
(Mackenzie et al., 2007).  As a SOD1 mutation may be sufficient to alter SOD1 protein 
conformation, TDP-43 proteinopathy may no longer be a prerequisite for the initiation of 
SOD1 proteinopathy.  It is important to note that, the presence of wtSOD1 pathology in ALS 
remains highly controversial, and whether TDP-43 proteinopathy may induce wtSOD1 
pathology in ALS patients would require much further investigation of the temporal 
relationship between the two proteinopathies.  Furthermore, correlation of fragmented TDP-
43 and HMW SOD1 protein levels does not prove that one species induces the expression 
of the other, as it is also possible that another currently unknown process may drive 
expression of both fragmented TDP-43 and HMW SOD1 simultaneously.  The finding of 
SOD1 pathology in C9orf72 patients is of particular importance, due to the ongoing SOD1 
antisense oligonucleotide clinical trials being conducted in ALS patients with SOD1 
mutations (clinical trial identifier: NCT03070119).  It remains to be seen whether 




A final note on SOD1 and TDP-43 proteinopathies in ALS, is that previous studies have 
relied very heavily upon the use of immunohistochemical staining and misfolded SOD1 
specific antibodies.  In the present study we used a conventional SOD1 antibody (not 
misfolded-SOD1 specific) raised against amino acids 1-100 of the wtSOD1 protein to detect 
pathological HMW-SOD1.  Previous studies have indicated that use of misfolded SOD1 
specific antibodies would be unlikely to detect these HMW-SOD1 species, even when native 
gels are utilised to maintain endogenous protein structure (Brown and Borchelt, 2014).  
Additionally, western blotting of protein samples is a much more efficient and quantitative 
method to use when analysing the extent of TDP-43 proteinopathy.  Furthermore, use of 
misfolded SOD1 specific antibodies has led to the publication of conflicting data.  For these 
reasons, future studies could also include western blotting with conventional antibodies as a 
potentially more quantitative method of assessing both SOD1 and TDP-43 proteinopathy. 
 
6.9. Conclusions 
The body of in vivo and in vitro evidence from various C9orf72 expansion models is now 
clearly pointing toward DPRs being the most toxic species in C9orf72-ALS/FTD.  RNA foci 
formation almost certainly contribute to toxicity in C9orf72 models also, but the presence of 
DPR species are often required for toxicity to be observed, suggesting a second hit may be 
required in order to overwhelm the cells compensatory mechanisms.  Future therapies such 
as antisense oligonucleotides against RNA foci are a very attractive option, as they would 
allow for the simultaneous reduction of both RNA and DPR burden.  Haploinsufficiency of 
the C9orf72 protein seems unlikely as a disease driving mechanism and does not represent 
an easily druggable target.  As such therapies addressing loss of function of the C9orf72 
protein may be a less valuable prospect.  The obstacle of DPR protein expression not 
correlating with disease affected CNS regions is slowly being overcome, as careful analysis 
of poly(GR) has highlighted its correlation with disease affected regions and TDP-43 
proteinopathy.  The development of more sensitive detection methods for DPR species will 
be required before low level expression of DPRs in disease affected areas can be entirely 
ruled out. 
Activation of the heat shock response is a feature of both SOD1 and C9orf72-ALS.  
Additionally, heat shock activation has successfully been used to identify riluzole as a hit in 
both SOD1 and C9orf72 zebrafish models, thus validating heat shock activation as a good 
quality readout against which potential therapeutic compounds can be screened. 
C9orf72 expansions drive fragmentation of TDP-43 and SOD1 proteinopathy, and increased 
abundance of these species was detected in motor cortex, but not in cerebellum of C9orf72-
ALS patients.  Although the study of TDP-43 and SOD1 proteinopathy as a common ALS 
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mechanism seems to have fallen out of favour recently, future studies should carefully 
consider the roles of these pathological species.  If indeed it exists, finding a common 
mechanism for ALS pathogenesis may allow for the development of neuroprotective 
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Mouse Yes Yes Not tested No No Stable 
(Peters et al., 
2015) 
Exons 1-6 of human C9orf72 gene with 140.5 
Kb of upstream sequence was expressed.  
G4C2 repeats lengths of both ~300 and ~500 




Mouse Yes Yes Not tested No No Stable 
(O'Rourke et 
al., 2015) 
Full length human C9orf72 gene was 









(Liu et al., 
2016) 
Full length human C9orf72 gene was 
expressed with 52Kb upstream and 19 Kb 
downstream sequence.  Multiple lines of mice 
were generated with the following G4C2 
repeat sizes (500), (500 and 32), (36 and 29) 
and (37), all lines were phenotypic with the 
exception of (37).  Mice displayed anxiety like 
behaviour, paralysis and motor neuron loss.  





Mouse Yes Yes Not tested Cognitive Yes Stable 
(Jiang et al., 
2016) 
Exons 1-5 of the human C9orf72 gene with 
140Kb of upstream sequence was expressed.  
G4C2 repeat lengths of ~110 or ~450 were 
reported in different mouse lines.  Mice 
expressing ~450 repeats showed anxiety like 
behaviour and impaired working memory.   
Gain 
Viral overexpression 
of G4C2 expansion 






(Chew et al., 
2015) 
66 G4C2 repeats were virally overexpressed by 
intracerebroventricular injection of virus.  
Mice showed anxiety like behaviour and 
rotarod performance deficits.  Cortical neuron 





of poly(GA) encoding 
construct 






(Zhang et al., 
2016) 
50 poly(GA) encoding repeats were virally 
overexpressed by intracerebroventricular 
injection of virus.  Mice showed anxiety like 
behaviour and rotarod performance deficits. 
Gain 
Viral overexpression 
of G4C2 expansion 







Martin et al., 
2017) 
102 G4C2 repeats were virally overexpressed 
by cisterna magna injection of virus.  Mice 
showed defects in gait analysis and object 
recognition tests.  Increased cleaved-PARP1 
was reported in cerebellar regions but no cell 
loss was observed. 
Gain 
Viral overexpression 
of poly(GA) encoding 
construct 
Mouse NA Yes NA Motor Yes 
Viral 
expression 
(Walker et al., 
2017) 
69 poly(GA) encoding repeats were virally 
overexpressed by cisterna magna injection of 
virus.  Mice showed defects in gait analysis 




Mouse NA Yes NA Cognitive Yes Stable 
(Choi et al., 
2019) 
Mice stably expressing 80 poly(GR) encoding 
repeats in the forebrain.  Mice showed defects 
in tests of social interaction and increased 




Mouse NA NA NA No No Stable 
(Koppers et al., 
2015, Atanasio 
et al., 2016, 
Sudria-Lopez et 
al., 2016, Jiang 
et al., 2016, 
O’Rourke et al., 
2016, Ji et al., 
2017) 
6 independently generated models C9orf72 
knockout mice reported similar results 
Both 
Expansion containg 














(Shao et al., 
2019) 
Phenotypic BAC mice generated previously by 
Liu and other authors were crossed with 
C9orf72 knockout mice.  The precise BAC 
expansions size was not reported for these 
mice.  Knockout of one or both copies of  
mouse C9orf72 increased the severity of the 







Zebrafish Yes No Not tested Not tested No Stable 
(Ohki et al., 
2017) 
80 G4C2 repeats without an upstream ATG 




Zebrafish Yes Yes Not tested Not tested No Stable 
(Ohki et al., 
2017) 
80 G4C2 repeats with an upstream start codon 













(Lee et al., 
2013) 
72 G4C2 repeat containing constructs were 
injected into zebrafish at the one cell stage.  
An increase in apoptotic markers was reported 









(Swinnen et al., 
2018) 
0.844µM of 3, 4, 10, 35, 70 and 90 G4C2 
repeat RNA was injected at the 1-2 cell stage.  
Motor axonopathy was observed with 35 
repeats or more.  Poly(GR) was not detected in 
any condition.  Poly(GP) was present at just 
above the limit of detection in 90 repeat 









(Swinnen et al., 
2018) 
0.844µM of 35 and 70 C4G2 repeat RNA was 
injected at the 1-2 cell stage.  Motor axon 
abnormal branching was observed in both 
conditions.  Poly(PR) and poly(GP) were not 









(Swinnen et al., 
2018) 
0.844µM of 50 codon optimised repeats of 
poly(GR), poly(PR), poly(GP), poly (PA) and 
poly(GA) repeat RNA was injected at the 1-2 
cell stage.  Motoraxonopathy was observed in 
poly(GR) and poly(PR) injected conditions, but 










(Swinnen et al., 
2018) 
0.844µM of RNA-only RNA of repeat lengths 
70 (sense), 108 (sense), 70 (antisense) and 108 
(antisense) were injected at the 1-2 cell stage.  
Motor axonopathy was observed in all 
conditions.  Although RNA foci and DPR 
production was not investigated in the present 
study, the presence of RNA foci and absence 
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of DPR when expressing these constructs in 
drosophila has been reported previously 
(Mizielinska et al., 2014) 




(Ciura et al., 
2013) 
Morpholino mediated knockdown. Defects in 
spontaneous swimming and touch evoked 
escape responses were observed.  Defects in 




Zebrafish NA NA NA Motor Yes Transient 
(Yeh et al., 
2018) 
Injection of non-functional C9orf72 RNA 
(lacking various DENN domain segments).  Also 
confirmed with C9orf72 morpholino 
knockdown.  Defects in touch evoked escape 




Zebrafish NA NA NA No No Stable 
(Stepto et al., 
2014) 




Drosophila NA NA Yes Not tested Yes Stable 
(Wen et al., 
2014) 
50 poly(PR) encoding repeats resulted in 
neurodegeneration, however an equal number 





Drosophila Yes Yes Yes Not tested Yes Stable 
(Mizielinska et 
al., 2014) 
103 G4C2 repeats, produced poly(GP) and 




Drosophila Yes No No Not tested No Stable 
(Mizielinska et 
al., 2014) 
108 RNA-only G4C2 repeats.  RNA-only repeats 
were generated by inserting bi-directional 




Drosophila NA NA Yes Not tested Yes Stable 
(Mizielinska et 
al., 2014) 
100 poly(PR) encoding repeats.  The same 





Drosophila NA Yes NA Not tested No Stable 
(Mizielinska et 
al., 2014) 
100 poly(GA) encoding repeats.  A small 
reduction in lifespan was observed in this 
model.  The same results were obtained with 
100 poly(PA) encoding repeats, however no 




Drosophila Yes Yes Not tested No No Stable 
(Tran et al., 
2015) 
160 G4C2 intronic repeats expressed between 
exon 1 and exon 3 of the human C9orf72 gene.  
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A poly(A) tail was not present in this construct.  




Drosophila Yes Yes Not tested Not tested Yes Stable 
(Tran et al., 
2015) 
34 G4C2 repeats expressed in the context of a 





C. elegans NA NA NA Motor Yes Stable 
(Therrien et al., 
2013) 
Paralysis and motor neuron degeneration was 
observed 
Neurodegen: Presence of neurodegeneration.  Studies which utilised multiple distinct animal models have been separated into 
multiple table entries for clarity.
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Appendix B Sequence of 99 G4C2 containing transgene 
 
______      ISceI meganuclease restriction site 
______      Zebrafish ubiquitin promotor 
______      GFP 
______      Start codon 
______      Stop codon 
______      (G4C2)99 C9orf72 expansions 
______      Heat shock promotor 70 
______      DsRed 
 























































































































Appendix C Sequence of 89 C4G2 containing transgene 
 
______      ISceI meganuclease restriction site 
______      Zebrafish ubiquitin promotor 
______      GFP 
______      Start codon 
______      Stop codon 
______      (C4G2)89 C9orf72 expansions 
______      Heat shock promotor 70 
______      DsRed 
 
NB: Due to difficulties in sequencing GC rich DNA we were not able to obtain a 
sequencing read which spanned the entire C4G2 expansion, therefore 
expansion size is listed as 89 C4G2 repeats which is the minimum known size 
ascertained by comparing forward and reverse sequencing reads through the 
expansion.  Additionally, as sequencing reads could not span the C4G2 
expansion, the reading frame could not be determined and the precise location 
of the stop codon is not known. 
 
























































































































Appendix D PhD outputs 
The data described in this thesis have been presented at various stages of my PhD in the 
form of poster presentations at the University of Sheffield research day and in the form of 
oral presentations in the SITraN seminar series. 
Additionally, data generated during this thesis have been published in the journal Acta 
Neuropathologica Communications: 
Shaw MP, Higginbottom A, McGown A, Castelli LM, James E, Hauterbeurgue GM, 
Shaw PJ* and Ramesh TM*  Stable transgenic C9orf72 zebrafish model key aspects 
of the ALS/FTD phenotype and reveal novel pathological features.  Acta Neuropathol 
Commun. 6:125. (November 2018) 
* These authors contributed equally to this work 
 
A further manuscript including the data on ‘5.3’ RNA-only zebrafish models is currently in 
preparation. 
